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 Aptamers are unique sequences of single-stranded DNA or RNA that exhibit 
significant affinity toward a particular target of interest. They have a number of advantages 
over antibodies – ease of modification, cell-free synthesis, and spontaneous renaturation – 
yet the preference of most researchers for antibodies continues due to prevalence of 
commercial antibody sources, hesitance adjusting existing research protocols, and a 
subconscious association of binding behavior with proteins rather than nucleic acids. While 
aptamers have already shown their technical advantages in the literature, they will also 
need to demonstrate their practicality via a broader range of targets and useful applications 
in order for aptamers to become more widespread in bioanalytical research. 
 One challenge aptamers have faced is the inconsistency of SELEX, the 
combinatorial method by which new aptamers are identified, as well as a small pool of 
potential aptamer targets. This dissertation demonstrates the feasibility of aptamer 
selection against intact membrane proteins using a capillary electrophoresis-based SELEX 
technique, an achievement not yet demonstrated in the literature that opens SELEX to a 
much wider range of biologically significant potential targets. In addition to high affinity 
binding (Kd < 10 nM), these aptamers should undergo cellular internalization with their 
membrane receptor target, allowing hybrid aptamers to reach previously inaccessible 
intracellular targets as well.  
 Additionally, this dissertation serves to increase the body of work demonstrating 
the bioanalytical capabilities of aptamers and other oligonucleotide affinity reagents. First, 
progress is shown toward aptamers targeting mouse leptin for use in a real-time aptamer-
based microfluidic assay to quantify leptin secretion in cultured adipocytes. This proposed 
device would allow measurement of leptin, an important metabolic protein related to 
obesity, on a sub-minute time scale in response to metabolic stimuli. Quantification 
involves on-line separation of aptamers and aptamer-leptin complexes by electrophoresis, 
a technique that lends itself well to oligonucleotide affinity reagents due to their highly 
negative charge.  
 Finally, a heart model based on cardiomyocyte differentiation from induced stem 
cells is demonstrated in preparation for measurement of physiological effects of aptamer-
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like SPIDRs (small protein-interacting DNAs and RNAs) on cardiomyocyte beating. 
SPIDRs have been shown to bind to the calcium pump SERCA and its control protein 
phospholamban, increasing the calcium affinity of SERCA. The cardiomyocyte model will 
be used to evaluate the hypothesis that this increase in calcium affinity leads to measurable 
physiological changes in beating, namely the beat rate and fall time, demonstrating the 
therapeutic potential of SPIDRs. Herein, optimization of stem cell growth and 
differentiation to cardiomyocytes are shown, as well as preliminary quantitative data 
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 Affinity reagents, molecules designed to bind to a specific chemical or biological 
target, have become an integral part of our modern world. From monitoring metabolite 
levels in a patient’s blood, to identifying toxins in packaged foods, to neutralizing 
environmental contaminants, to purifying and extracting a new laboratory synthesis 
product, affinity reagents are needed on their own or as a part of a larger assembly to detect, 
capture, or modify a limitless assortment of molecular targets. While affinity reagents can 
take many forms, the most well-known and widespread are antibodies, large glycoproteins 
generated by, and invaluable to, the immune systems of many animals. The large, rigid 
framework of an antibody equipped with variable “sticky” ends to find a matching antigen 
provides an excellent system to generate affinity for any target desired, and the advent of 
the antibody-secreting hybridoma in 19751 brought antibody production to a significantly 
more scalable platform. This paved the way for a new era of antibody discovery and 
research, and elevated the potential and feasibility of commercial affinity reagents. To be 
sure, antibodies are a valuable resource in research, medical, and commercial applications 
that facilitate many processes and procedures that might not otherwise be possible, and it 
could be argued that they are responsible for the revolution of affinity reagents that has 
taken place. However, their decades-long reign as the first of their kind has led antibodies 
to be viewed as the consummate affinity reagent rather than one example of many, with 
strengths and weaknesses just like any other.  
 The fact that scientists could take advantage of a host animal’s immune response to 
generate large glycoproteins that were initially impossible to fully characterize, let alone 
synthesize on the benchtop, allowed antibody technology to proceed early and quickly. 
Now, however, it is this reliance on animals and cellular machinery that is the greatest 
weakness of antibodies. Because antibody production is carried out by the organism at the 
cellular level, there is little that researchers can do to control the process to reduce inherent 
batch-to-batch variation, and purification and characterization are much more complex and 
less efficient than for cell-free or recombinant synthesis. It is unsurprising, therefore, that 
antibody quality and variability is often cited as one of the chief causes of unreproducible, 
and therefore unreliable, biological research.2 One study found that less than half of the 
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thousands of commercial antibodies tested had specific affinity to the advertised target,3 
and poor quality and variation in antibodies are believed to be largely to blame for a study 
that was unable to reproduce 47 of 53 landmark preclinical oncology studies.4, 5 
 One promising alternative is aptamers, short sequences of RNA or single stranded 
DNA with high affinity and selectivity for a particular target. Aptamers already exist for a 
wide range of targets, and unlike antibodies, aptamers are produced by de novo solid-phase 
synthesis, which requires no cells or animals and yields batches that are essentially 
identical. While numerous other advantages, such as enhanced stability and ease of 
modification, have also contributed to a recent surge in aptamer research, antibodies are 
still the default affinity reagent in most research and commercial applications despite their 
relative unreliability. While part of this is surely due to antibodies’ legacy of ubiquity and 
researchers’ disinclination to introduce new variables unnecessarily, part of the blame also 
lies with the process of selecting aptamers for a new target, which can be more complex 
and more limiting than at first glance. The principles of aptamer selection (SELEX) are 
simple enough, but the procedure can be difficult in practice, varying from lab to lab and 
from target to target, with some common issues and limitations that can scare away 
potential aptamer converts. 
 Significant improvements to the SELEX process are sorely need, particularly those 
to decrease the limitations of SELEX and increase its accessibility. Significant SELEX 
optimizations could lead to an increase in aptamer usage in novel applications and give 
researchers and consumers a choice of affinity reagent where antibodies have in the past 
been uncontested. Therefore, this dissertation centers on improving methods for selection 
of new aptamers which could be accessible to non-specialized research groups, and filling 
current gaps in the aptamer technology toolbox. 
 
1.2 Aptamers 
 Though molecular biology’s central dogma portrays nucleic acids as chemically 
static molecules designed for storage and transmission of genetic information,6 the capacity 
of nucleic acids to carry out more varied processes in nature, such as catalysis, has been 
known since the 1970s.7 Following the logical progression, scientists built on nature’s 
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diverse usage of nucleic acids to develop sequences with new and useful functions. 
Aptamers, short sequences of single stranded DNA (ssDNA) or RNA with affinity for a 
particular target, were one such development that emerged from this work in the early 
1990s, and they have grown in prevalence and capability ever since.8-11 Aptamers have 
been selected for a huge range of targets including metal ions,12-14 small molecules,15-19 
lipids,20, 21 proteins and protein complexes,22-26 viruses,27-30 and even whole cells,31-34 
making them adaptable and appealing for a variety of uses. 
1.2.1 Current applications of aptamers 
 Due to their flexibility and wide applicability, nucleic acid aptamers have found 
numerous applications across a variety of fields. In the realm of analytical assays, aptamers 
have been applied to affinity chromatography and other biomolecule purification,35-37 
including separating enantiomers,38, 39 and many enzyme-linked immunosorbent assays 
(ELISAs) are switching from antibodies to aptamers as the affinity reagent.40-42 Aptamers 
also feature in numerous commercial assays and applications such as detection of specific 
mycotoxins or bacteria in food,43, 44 medical diagnosis based on blood biomarkers,45, 46 cell 
sorting and protein pulldown,47 and hot-start PCR.48  
 The medical field has been slower to embrace aptamers, but many aptamers are 
finding use as specific targeting agents for imaging contrast agents,49, 50 small interfering 
RNA (siRNA),51 and nanoparticles.52 Unfortunately, while many in the field view 
pharmaceutical aptamers as the potential pinnacle of aptamer technology, only one 
aptamer-based drug, Macugen, has been FDA approved and made it to market. However,  
at least ten aptamer-based drugs have reached clinical trials so far (Table 1.1) for 
indications ranging from diabetes to cancer, and countless more are in preclinical stages. 
1.2.2 Advantages of aptamers 
 Aptamers have a number of distinct advantages over other affinity reagents such as 
antibodies. Most notably, aptamers are generated by solid-phase synthesis, an inexpensive, 
scalable, and easily automated technique. In this way, aptamers can be generated (and 
adjusted) with nothing more than knowledge of the sequence. This stands in contrast to 
antibody production, which is primarily through expression in specific hybridoma cell lines  
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for each antibody. Thus, production not only inherits all of the batch-to-batch variation 
inherent in cell expression, but it requires access the specific hybridoma line itself, not to 
mention the associated time and expertise necessary for cell expression and maintenance. 
Additionally, aptamers are highly stable over a wide range of pH, temperature, and ionic 
strength, and they can refold spontaneously after denaturation.74 This makes aptamers 
particularly well suited to platforms requiring repeated usage since they can be used to 
capture a target, selectively denatured by heat or pH to release the target, then renatured to 
allow tests to begin anew.75 Finally, aptamers are easy to chemically link or modify during 
the synthesis process at virtually any position for customized applications. Aptamers’ 
physical and synthetic flexibility gives them the added potential to function as both affinity 
probe and signaling entity with the addition of a fluorophore or fluorophore-quencher 
pair;76 antibodies are far too large and rigid for this behavior to be accessible.77  
 
1.3 SELEX 
1.3.1 The SELEX method 
 First demonstrated independently by Ellington and Szostak8 and by Tuerk and 
Gold11 in 1990, the process of in vitro aptamer selection has come to be known as 
Systematic Evolution of Ligands by Exponential Enrichment (SELEX). The process starts 
with a randomized library of oligonucleotide sequences (oligos), either RNA or ssDNA. 
Clinical name (aptamer name) Primary indication or usage Status 
Macugen (Pegaptanib)53, 54 Age-related macular degeneration Approved 
Zimura (ARC1905)55, 56 Age-related macular degeneration II (C) 
AGRO100 (AS1411)57 Myeloid leukemia II (C) 
Olaptesed pegol (NOX-A12)58, 59 Colorectal, pancreatic cancer II (C) 
Emapticap pegol (NOX-E36)60, 61 Type II diabetes, albuminuria II (C) 
Lexaptepid pegol (NOX-H94)62, 63 Anemia of chronic inflammation II (C) 
Egaptivon pegol (ARC1779)64, 65 Thrombosis, von Willebrand disease II (C) 
REG1 (rb006/rb007) 66-68 Reversible anticoagulant III (T) 
Fovista (E10030)69, 70 Age-related macular degeneration III (T) 
ARC19499 (BAX499)71, 72 Hemophilia I (T) 
(NU172)73 Short-term anticoagulant I (U) 
Table 1.1: Therapeutic aptamers in clinical trial. In cases of aptamers in clinical trial for multiple 
indications, only the indication or usage (and corresponding trial status) for which the aptamer has 
completed the highest clinical trial phase is listed. Trial status lists the highest trial phase for the aptamer 
has reached along with whether this phase was completed (“C”), was terminated (“T”), or is unknown.  
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Each sequence is composed of a static primer region of roughly 20 bases on each end 
sandwiching a random region – commonly 40 bases, but sometimes ranging from 20 to 60 
bases. The ends serve as a primer region for PCR and may be labeled with a fluorophore, 
affinity tag, or other modification, particularly on the 5’ end (Figure 1.1). 
 To begin, a small amount of the target of interest is incubated with the concentrated 
random oligo pool. The massive number of sequences (around 1013) creates sufficient 
structural diversity for numerous sequences to compete for binding with the limited amount 
of target. The in vitro nature of this incubation allows parameters such as temperature and 
ionic strength to be adjusted for optimized binding under the specified conditions. Next, 
the unbound sequences are separated from target-oligo complexes and removed to waste. 
Selective partitioning is key, as either losing a large portion of complexes or collecting a 
large number of the unwanted unbound oligos can severely diminish the efficiency of the 
selection. This separation can be achieved by many different methods and will be addressed 
below and in Chapter 2. The complexed sequences are then amplified by PCR, which not 
only copies sequences with affinity but also provides an opportunity for sequence 
mutations, which may enhance binding. For RNA aptamers, transcription and reverse 
transcription steps are also required. Both DNA and RNA require that the double-stranded 
PCR product be separated and the complement strand removed in a purification step.78 This 
purified product becomes the starting pool for the next round, and another cycle of 
incubation, separation, and amplification is performed. The generic process is outlined in 
Figure 1.2. The affinity of the pool for the target is measured periodically to estimate the 
Figure 1.1: Schematic of the general oligonucleotide structure used in SELEX. Each oligonucleotide 
contains a random region, flanking primers, and possible modifications. 
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progress of the selection, and the 
cycle is repeated until affinity 
reaches a plateau. The high-affinity 
pool is then sequenced to determine 
the specific aptamer sequences, of 
which a handful are chosen, 
randomly or systematically, for 
synthesis and characterization.  
 While there is typically some 
variation within the field concerning 
the specifics of the incubation, 
amplification, and purification 
steps, the source of by far the most 
variability between labs is the 
method of separation of bound complexes from non-binding or weakly binding sequences. 
SELEX was originally performed using a nitrocellulose membrane to filter the incubated 
sample, in theory allowing free oligos to pass through while catching any large proteins 
(and associated oligo sequences), but this step has evolved significantly since then to 
techniques with increased speed, efficiency, and flexibility. While a large number of 
alternate SELEX partitioning techniques are covered in depth in Chapter 2, with an 
emphasis on microfluidic techniques, all of the SELEX research presented herein used 
capillary electrophoresis as the separation mechanism. 
1.3.2 Capillary electrophoresis 
 Capillary electrophoresis (CE) is a powerful technique that separates species in 
solution based on differences in their mobility in an applied electric field. CE typically uses 
a fused-silica capillary of 10-100 μm inner diameter and 10-60 cm in length. The capillary 
is filled with an electrolyte solution and a small plug of sample mixture is injected at the 
inlet. Then a high voltage is applied between the inlet and outlet, and species are separated 
based on their different rates of migration along the capillary. A small window is present 
Figure 1.2: Outline of SELEX process for isolating 
aptamers. The oligonucleotide library undergoes incubation 
with the target of interest, separation to remove sequences 
not bound to the target, amplification of binding sequences, 
and purification to remove complementary nucleotide 
strands. RNA selections require additional transcription and 
reverse transcription steps (not shown). 
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near the outlet for detection by laser-induced fluorescence (LIF) or ultraviolet-visible 
spectroscopy (UV-Vis), and the signal is plotted over time on an electropherogram.  
 Sample molecules or particles move through the capillary under the effect of 
multiple forces. The electrophoretic force stems from the electrostatic interaction between 
a molecule’s net charge and the longitudinal electric field, and it is counteracted by the 
viscous force of the medium. A molecule’s electrophoretic mobility (μEP), which is its 






	 Equation 1.1 
where VEP is the electrophoretic velocity, E is the applied electric field, Q is the net charge 
of the molecule, η is the viscosity of the medium, and R is the molecule’s hydrodynamic 
radius. Viscosity is generally quite consistent among all analytes in a particular sample, so 
a molecule’s electrophoretic mobility essentially varies with its charge-to-size ratio. 
 In addition to an electrophoretic force on charged species, the bulk solution 
experiences a net flow known as electroosmotic flow (EOF). For uncoated silica 
capillaries, the silanol groups on the interior surface ionize to negatively charged silanoates 
at neutral or basic pH, which causes cations in solution to collect against the surface wall 
to counteract the charge imbalance. The innermost layer of counterions is called the Stern 
layer and remains largely fixed to the capillary wall. The region just beyond marks the 
beginning of the diffuse layer, also called the mobile layer. The diffuse layer is still rich in 
cations due to incomplete shielding of the silanoates, but it is able to slide along the Stern 
layer. The Stern layer and diffuse layer together are referred to as electrical double layer, 
which is summarized in Figure 1.3.  
 When a voltage is applied along the capillary, the diffuse layer, which has a net 
positive charge due to excess solvated cations, moves toward the negatively charged 
cathode and pulls the bulk fluid with it. Because this force is generated primarily through 
the diffuse layer, the radial flow profile is flat except extremely close to the capillary wall, 
reducing band broadening compared to pressure-driven chromatographic separations. The 






  Equation 1.2 
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where VEOF is the electroosmotic velocity, ε is the solution dielectric constant near the 
capillary wall, and ζ is the zeta potential. The zeta potential is the radial electrical potential 
at the slip plane, the interface between the Stern and diffuse layers (Figure 1.3), and is 
affected by surface charge, ionic strength, and the presence of surfactants. 
 The apparent mobility (or net mobility)	of an analyte is the vector sum of these two 
mobilities, μEOF and μEP. Apparent mobility (μapp) can be determined experimentally and 
related to Equations 1.1 and 1.2 by 
 𝜇/00 =	𝜇!" + 𝜇!*+ =	
1%
2$
	 Equation 1.3 
where Ld is the length from the 
capillary inlet to the detector 
window, and t is the analyte peak 
time. Most analytes in this work 
have a net negative charge, meaning 
μEOF is toward the negative cathode 
and μEP is toward the positive 
anode. CE is typically run with the 
cathode at the outlet (referred to as 
normal polarity) so that EOF pushes 
all analytes toward the detector, 
though polarity may need to be 
reversed if the EOF is significantly 
reduced. 
1.3.3 CE-SELEX separation 
 As with any SELEX 
method, capillary electrophoresis-
SELEX (CE-SELEX) begins with 
incubation of random library DNA 
sequences with the target of interest 
to allow sequences with the best 
















































































Figure 1.3: Cross-section of the electrical double layer at 
the capillary surface. (Top) The capillary wall is negatively 
charged at most pH, generating a double layer of solution 
cations. The Stern layer adheres strongly to the surface 
while the diffuse layer is net positive but largely mobile. 
(Bottom) The boundary between the layers (the slip plane) 
marks the effective edge of the solution, and the potential 
at this point (ζ) is proportional to EOF strength. 
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target molecule. Once complexation occurs, a plug of the sample is injected and separated 
by CE. The separation in CE-SELEX is a specific case of affinity capillary electrophoresis 
(ACE), a CE separation based on noncovalent interactions between analytes and the 
resulting change in mobility. DNA is an excellent candidate for ACE because it has a 
charge-to-mass ratio of -3 kDa-1 (-1 charge per 330 Da), more negative than virtually any 
potential aptamer target. For reference, bovine serum albumin (BSA) at pH 7 has a charge-
to-mass ratio less than one tenth of that.79 As a result, any DNA-target complex experiences 
a significant reduction in magnitude of its electrophoretic mobility compared to free DNA. 
 In the majority of CE-SELEX cases, the separation is run with normal polarity. In 
this mode, EOF pulls all molecules to the outlet, but the electrophoretic mobility of 
negative analytes like DNA acts toward the inlet, so DNA elutes after most analytes. 
Because complexation causes a reduction in magnitude of the electrophoretic mobility, the 
complex with bound DNA emerges from the capillary before any free DNA (Figure 1.4A). 
The separation is run into a collection vial until just before free DNA begins to emerge 
from the outlet (calculated by capillary dimensions and the free DNA peak time), then the 
Figure 1.4: Schematic of CE-SELEX separation and electropherogram collection window. (A) In uncoated 
silica, net movement is dominated by μEOF toward the cathode, so CE is run in normal polarity and 
complexes are collected before free DNA. (B) When EOF is suppressed, net movement is dominated by μEP 
toward the anode, so CE is run in reverse polarity and complexes are collected after free DNA. 
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free DNA in the capillary is rinsed to waste. In order to increase the number of sequences 
collected, the CE run can be performed multiple times from the initial incubated sample. 
 Occasionally changes to conditions, such as high ionic strength or the presence 
some surfactants, can decrease the EOF significantly to the point where the magnitude of 
DNA’s electrophoretic mobility exceeds that of the capillary’s electroosmotic mobility. If 
this occurs, it is necessary to perform separations in reverse polarity, with the anode at the 
outlet, so that the electrophoretic force carries DNA toward the detector. In this case, free 
DNA elutes before any complex (Figure 1.4b). Therefore, the collection scheme is 
reversed: the separation is performed into a waste vial until the end of the free DNA peak 
has left the capillary, then the outlet is moved to a sample collection vial and the remaining 
complexes are eluted by voltage or pressure. To prevent free DNA that has already eluted 
from adhering to the outside of the capillary and transferring to the collection vial, the 
capillary outlet may be dipped into clean water or buffer before final elution. 
 
1.4 Affinity measurement 
 An important part of the SELEX process is measuring the affinity of the aptamer 
pools for the target in question during selection, frequently in comparison to the baseline 
affinity for the randomized oligonucleotide library. This allows researchers to make 
qualitative and quantitative assessments of the selection progress and make changes to the 
selection if necessary. Additionally, specific sequences isolated from the completed 
SELEX process often undergo a battery of characterizations, such as structural modeling 
or kinetic studies, but assessment of affinity for the target is always the first step because 
of the amount of fundamental information it provides in relation to how simple the assay 
tends to be. 
 Numerous assays exist to quantify aptamer affinity for a target, each with its own 
advantages and disadvantages. For this research, emphasis was placed on techniques that 
do not require large samples, that were quick or easily automatable, and that could be 
performed under the relevant selection conditions. To the last point, many affinity 
techniques require immobilization of the target on a microbead or solid surface in order to 
facilitate physical separation of bound species. This makes a great deal of sense if the target 
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has already been immobilized during the selection process, as the conditions are 
representative and the method of immobilization has been optimized. However, a key 
advantage of CE-SELEX is that it requires no immobilization or labeling of the target, 
which might limit target choice or select aptamers for side targets (discussed in more detail 
in Chapters 2 and 3). Therefore, affinity assays were chosen which also required no target 
immobilization or labeling in order to maintain those advantages of CE-SELEX. CE and 
fluorescence polarization (FP) were chosen and are discussed after a general explanation 
of affinity calculation below. 
1.4.1 Calculating the dissociation constant 
 For binding interactions between one aptamer (A) and one target (T) to form the 
aptamer-target complex (C),* all binding equations employed proceed from the generalized 
equilibrium 
	 A	+	T	⇌	C	 Equation 1.4	




	 Equation 1.5 
where Kd is referred to as the dissociation constant, the most frequently used quantity to 
express ligand affinity. The dissociation constant is the concentration of target at which 
50% of the ligand is bound and is generally in the low micromolar to high picomolar range 
for aptamers, with lower values representing a higher affinity. 
 The dissociation constant is not measured directly but is related to the fraction of 






	 Equation 1.6 
where [A]t is the total amount of aptamer in a free or complexed state. By combining 
Equations 1.4 and 1.5, the equation  
 
* Aptamer binding interactions typically have a 1:1 stoichiometry with the target except in rare cases. A 
different stoichiometry is often (but not always) visible via deviation in the data from Equations 1.6 or 1.7. 
This can be verified with the generalized Hill equation (with accurate enough data). Alternatively, 
analytical assays that provide kinetic data (such as surface plasmon resonance) or fundamental 






is obtained, relating Kd and the fraction bound. Bmax is a scaling parameter that corresponds 
to the calculated values for fully bound aptamer (more details below and in Chapters 3 and 
4). The fraction bound can be determined experimentally by multiple techniques and is 
typically measured for 6-10 values of [T].  Equation 1.7 takes the form of a rectangular 
hyperbola in the first quadrant, so a hyperbolic fit of the graph fa vs [T] yields the values 
of Kd and Bmax. 
 While the value of [T]t, the total concentration of free and complexed target, is 
known from sample preparation, the free target concentration [T] cannot be calculated 
without the Kd, technically leaving Equation 1.7 with too many unknowns. However, in 
cases where Kd is high and the total aptamer concentration [A]t is low, very little target 
becomes bound and [T] ≈ [T]t. Therefore, Equation 1.7 can be plotted versus [T]t to find a 
preliminary value of Kd. This value has little relative error in cases where Kd >> [A]tot. 
However, this estimation breaks down when Kd ≤ [A]tot and leads to significant error. In 
anticipation of low Kd aptamers, a more complete equation80, 81 is used throughout which 
properly accounts for the change in [T] due to complexation, 
 	𝑓9 = 𝐵=9>(1 +	
<*
([7]&@	B.D([5]&:	[7]&:<*@(([5]&:	[7]&:<*)+@.[5]&[7]&),..
)@F Equation 1.8 
where the denominator represents [T]. Equation 1.8 provides an accurate Kd determination 
regardless of the relationship between Kd and [A]t. 
1.4.2 Fluorescence polarization 
 When plane polarized light illuminates a sample of organic fluorophores, only 
fluorophores with their transition dipole aligned parallel to the electric field of the incoming 
radiation are excited. Additionally, fluoresced photons are consistently emitted with that 
same orientation of polarization relative to the fluorophore structure. As a result, any 
deviation in polarization angle between the excitation and emission radiation 
(“depolarization”) must be due to rotation of the fluorophore during the fluorescence 
lifetime, with a faster rotation giving rise to greater average depolarization in the emitted 
photons. The sample polarization (P) can be quantified with the equation 
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	 𝑃 = 	 G||@G0
G||:G0
	 Equation 1.9 
where F|| and F⊥ are the fluorescence intensity parallel to and perpendicular to the incident 
light, respectively. Thus, P = 1 represents no deviation from the incident plane (F⊥ = 0) 
while a P = 0 represents full depolarization of the light (F|| = F⊥). Because a molecule’s 
rate of rotation is proportional to its size, a fluorescent molecule will rotate much more 
slowly, and therefore yield emission with higher polarization, when bound to a large 
molecule than when free in solution (Figure 1.5).  
 Fluorescence polarization (FP), or fluorescence anisotropy, is an analytical 
technique which takes advantage of this phenomenon and provides information about the 






where P is the sample polarization, P0 is the average polarization of free fluorophore, and 
PB is the polarization value for fully bound aptamer. Unfortunately, PB is not calculable a 
priori and can’t always be found experimentally depending on the system. However, the 
value of PB does not impact Kd, so the maximum change in polarization (PB – P0) is set to 
100, approximately the highest polarization change seen in our aptamer FP experiments. If 
the target is sufficiently large to affect the rate of rotation of the fluorescent aptamer, 
incubating a fixed concentration of fluorescent aptamer with increasing amounts of target 
allows the fraction bound to be plotted against target concentration in order to extract Kd 
by applying Equation 1.8.  
 Beyond the theory, FP is particularly 
useful because it is simple and quick to set 
up, and it uses small volumes of sample. 
Using a microplate reader, 80-100 μL of 
sample can generate an entire binding 
isotherm, and all measurements can be done 
in parallel in less than a minute. And because 






Figure 1.5: Fluorescence polarization scheme. 
Upon binding, the fluorescent aptamer rotates more 
slowly due to increased effective hydrodynamic 
radius, and therefore retains greater emission 
polarization. 
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on parallel and perpendicular fluorescence intensities, FP is essentially insensitive to small 
changes in the total fluorophore concentration, which removes a substantial portion of the 
error inherent in sample preparation. 
 In practice, a number of factors can disrupt accurate FP measurement. Any change 
in viscosity can affect the rotational speed of species in solution, so temperature and 
surfactant concentration are tightly regulated during the assay. Control of the temperature 
and buffer composition also help to reduce fluctuation in fluorescence lifetime, which has 
a dramatic effect on measured polarization. One factor that can’t be tightly controlled is 
the choice of probe molecule. FP experiments are typically designed to result in the largest 
possible change in polarization between the free and bound state, meaning that probes 
should be as small as possible while still exhibiting affinity, typically 1-2 kDa or less. 
However, because the intent of the assay is to measure aptamer affinity for the target, the 
probe used is the oligo strand itself, roughly 25 kDa for an 80mer. With such a large probe 
molecule, the observed depolarization is due less to rotation of the oligo in space and more 
to rotation of the dye moiety around single bonds and other local motion, referred to as 
propeller motion. This has benefits and disadvantages. Because the propeller motion is 
relatively fast, binding that constricts the motion mimics the large change in polarization 
seen from much smaller probes. Unfortunately, binding that does not cover the fluorophore, 
or oligos in which the fluorophore is internal but still mobile, are unlikely to give rise to 
significant changes in polarization. For this reason, positive binding results are typically 
quite accurate in aptamer FP assays (especially with large target molecules), but results 
showing no affinity should be considered carefully and verified by another method. 
1.4.3 Capillary electrophoresis 
 Much has already been said about the ability of CE to efficiently separate free DNA 
from bound complexes, which also makes CE an excellent technique to calculate the bound 
aptamer fraction. CE shares with FP the ability to perform measurements on unlabeled 
targets in solution, which makes sample prep faster and more reproducible than for many 
other techniques. Though CE samples cannot be measured in parallel (except on specific 
multiplex instruments), commercial systems are equipped with an auto-sampler which can 
generally run the full assay without supervision. Unfortunately, CE affinity measurements 
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rely on comparison between baseline free DNA runs and sample runs that may occur hours 
later with many samples in between, so preventing sample degradation and instrumental 
drift during the assay is very important. As with FP, multiple samples are prepared and 
analyzed which contain a consistent amount of DNA and increasing amounts of the target. 
The method of affinity calculation varies depending on the stability and visibility of the 
complex band. 
 Subtractive Kd calculation (no dissociation, no complex peak). As soon as the 
sample is injected and begins to be separated, the complex is no longer in equilibrium with 
free DNA and target. This tends not to be an issue in many cases as the complex typically 
has a low rate of dissociation and remains bound long enough to fully separate from the 
free DNA band. There is frequently no visible peak containing the DNA-target complex 
due to low abundance, structural heterogeneity, or early dissociation. However, the free 
DNA peak is easily visible, and its size is proportional to the amount of unbound DNA in 
the sample. The increase in the bound fraction can be monitored by a corresponding 




			 Equation 1.11 
where I is the sample peak intensity (height or area) and I0 is the average peak intensity in 
the absence of target. Note that the free DNA peak intensity of the fully bound aptamer is 
theoretically zero, hence its absence from the equation. Again, fitting based on Equation 
1.8 allows extraction of the Kd. Frequently, peak area is preferred to height if the peak time 
varies more than 5-10%, whereas peak height may be preferred when a broad peak or noisy 
baseline makes determination of the area more difficult. In cases where height and area are 
both suitable, they can be analyzed independently. This analysis relies on an absolute 
fluorescence comparison rather than a ratiometric one, so sample preparation, injection, 
and detector sensitivity become more significant sources of error. These are generally still 
small compared to error in the data fitting, but an internal standard can be implemented to 
lessen these errors if necessary. 
 Ratiometric Kd calculation (complex peak or fast dissociation). In a small 
number of cases, the complex will be visible in the electropherogram, either as a fully 
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resolved peak or as a distinctive tail* of the free DNA peak. The latter occurs when the rate 
of dissociation is high and the DNA in the complex detaches from the target protein before 
it is fully resolved from the free DNA peak. (This population will continue to be referred 
to as “bound DNA” or “complex” even though it may not still be complexed at the time of 
detection.) In either case, the analysis uses the size of the free DNA signal (A1) and the 
complex signal (A2) to calculate the fraction of complex signal (C) by 
 𝐶 = 	 5+
52:5+
   Equation 1.12 
for each sample. For a tailed peak, the peak is split consistently into the areas of the main 
peak (A1) and the tail (A2), as shown in Figure 1.6. Peak height cannot be used in these 
cases. From here, the increase in the fraction bound can be seen from the corresponding 
increase in the sample complex fraction according to 
  𝑓9 =	
8	@	8,
F	@	8,	
   Equation 1.13 
where C is the sample complex fraction and C0 is 
the complex fraction in the absence of target. 
Fitting the fraction bound compared to target 
concentration by Equation 1.8 yields the Kd. 
 
1.5 Scope of this dissertation 
 Aptamers and other functional 
oligonucleotides have enormous potential to  
influence the future landscape of analytical affinity 
reagents, clinical theranostics, and commercial 
tests and assays. To do so, however, they will have 
to demonstrate that they are superior to existing 
technologies, such as antibodies, in significant 
scientific and practical ways. Rather than focusing 
on a single train of scientific thought, this 
 
* Note that the complex DNA presents as a tail in reverse polarity CE (as in Chapter 3) but as a front in 
normal polarity CE. 
Figure 1.6: CE peak shape for aptamers that 
dissociate rapidly. (Top) A CE sample with 
low target concentration displays minimal 
tailing and has a larger free DNA peak (A1, 
hashed) and a smaller complex signal (A2, 
solid), resulting in a smaller complex 
fraction. (Bottom) With a high-affinity 
aptamer, a sample with higher target 
concentration displays significant tailing and 
has a smaller free DNA peak, larger complex 
signal, and higher complex fraction than in 





dissertation explores multiple threads of the aptamer story, working to improve tools for 
selection and characterization of functional oligonucleotides to add to their convincing case 
for more widespread adoption. Chapter 2 looks beyond CE-SELEX and provides an 
overview of recent advances in other microfluidic methods of aptamer selection and 
characterization, particularly with respect to efficiency and throughput. Chapter 3 describes 
the process of CE-SELEX against low-density lipoprotein receptor (LDLR), a membrane-
bound protein which undergoes receptor mediated endocytosis, to provide proof of concept 
for SELEX against intact membrane proteins as well as aptamer-mediated transmembrane 
transport. Chapter 4 explored the process of CE-SELEX targeting leptin, an important 
soluble protein  and adipokine involved in weight regulation and obesity, for use in future 
online microfluidic experiments measuring leptin secretion in real time. Chapter 5 looks at 
aptamer-like functional oligonucleotides which interact with the cardiac calcium cycling 
proteins SERCA and phospholamban, specifically exploring stem cell-derived 
cardiomyocytes as a system for characterizing the physiological effects of these oligos on 
cardiac contraction. Chapter 6 will serve as a summary of this body of work, with an eye 
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 Nucleic acid aptamers have enormous potential as molecular recognition elements 
in biomedical targeting, analytical arrays, self-signaling sensors, and more. Given the 
tremendous applicability and the advantages of aptamers, it is not surprising that the 
number of aptamer-related papers has increased dramatically – indeed, 2019 and 2020 
alone account for nearly a quarter of all aptamer publications to date.82 However, the 
selection of aptamers for novel targets is less well represented in the literature, no doubt 
because of the time, resources, and expertise required to combine the disparate steps in 
aptamer development. In addition, successful selection of useful and applicable aptamers 
is never a guarantee, even in the most careful and well-intentioned cases. These practical 
limitations and inefficiencies in the SELEX process have hampered more widespread 
adoption of aptamer technologies. One innovation that has dramatically lessened the time- 
and labor-intensiveness of aptamer technologies is the incorporation of novel microfluidic 
strategies; no single advancement has led to as much improvement in speed, throughput, 
and automation in aptamer selection and characterization. (Microfluidics has also led to 
notable advances in aptamer-based sensing (aptasensors), especially involving 
electrochemical detection83-86 and low-cost printed or paper-based devices;87-89 however, 
this chapter will focus only on microfluidic selection and characterization techniques.) This 
chapter provides a detailed overview of the different types of microfluidic aptamer 
selection schemes, highlighting key examples of these families and the major contributions 
of the work. Current work in aptamer microarrays for selection and characterization is also 
covered. 
 
2.2 Traditional SELEX techniques 
 New aptamers are selected by SELEX, an iterative combinatorial process described 
in Chapter 1. To recap briefly, a library of randomized RNA or ssDNA oligos is incubated 
with a small amount of the target of interest, where specific sequences in the library have 
affinity for, and bind to, the target. Next, unbound oligos are separated by one of a variety 
of partitioning techniques and discarded while those sequences complexed with the target 
are amplified by PCR. (In the case of RNA aptamers, sequences are reverse transcribed 
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prior to PCR and transcribed back to RNA afterward.) Finally, the PCR products are 
purified and complementary strands are removed. This results in a new single-stranded 
pool which has been enriched with sequences that display affinity for the target. At the end 
of each cycle, the average affinity of the pool for the target of interest is measured, and the 
cycle is repeated until optimal binding affinity is reached. Finally, the nucleotide pool is 
sequenced and analyzed, and a subset of those sequences is synthesized and characterized 
in terms of their affinity, selectivity, and physical properties.  
 Nitrocellulose filtration was the first major partitioning technique employed 
because of its ability to allow through nucleic acid strands while stopping larger proteins.11 
While the technique is simple in that it requires no immobilization of the target and little 
adjustment from protein to protein, filtration is relatively inefficient and time-consuming, 
requiring a dozen rounds of SELEX or more and weeks to months to achieve suitable 
affinity. Filtration is also only effective for large proteins, making it unsuitable for many 
proposed targets. Affinity chromatography-based techniques, which rely on immobilizing 
the target of interest on a solid support, were introduced to fill the gaps in nitrocellulose 
SELEX and are now the technique of choice for many. The most frequently used supports 
are microbeads,90-92 which are easily retained by a microcolumn filter during selection, but 
other surfaces such as microplates are also used.93, 94 In both cases, the target can be 
attached covalently with linker chemistry,95 adsorbed non-specifically,93 or linked with 
biotin to a streptavidin-coated surface.96 While this technique enhances flexibility and the 
number of allowable targets, macroscale affinity chromatography on the whole does not 
significantly increase the efficiency of the selection and often uses relatively large amounts 
of material. Additionally, the solid supports, and any linker or capping molecules used, 
present potential surfaces with which aptamers may develop unwanted affinity, requiring 
extra negative selections to obtain target-specific aptamers. 
 
2.3 Microfluidic SELEX techniques  
 While different SELEX techniques offer certain pros and cons, there are a number 
of advantages that hold true of most or all microfluidic SELEX methods. First, because 
most separation techniques typically only operate at a surface interface, shrinking the 
 22 
system to yield a larger surface-to-volume ratio increases separation efficiency while 
reducing material consumption. In the case of affinity chromatography, this decrease in 
size also reduces the potential for non-specific and off-target binding, in many cases 
allowing negative selections to be removed altogether. Second, it has been shown that 
reducing the amount of target (thereby increasing the stringency of the selection) results in 
faster convergence of the aptamer pool to a small number of sequences.97 Microfluidic 
methods excel at handling small amounts of reagents, both increasing stringency and 
cutting material costs. Finally, a major drawback to SELEX in general is that each phase 
of the cycle can be labor-intensive, time-consuming, and require special expertise. 
Microfluidic techniques have a much higher potential for automation and multiplexing of 
this process, which will reduce the time and energy invested into each new aptamer and 
streamline the SELEX process. This has led to the development of many microfluidic 
SELEX separation techniques, including those based on electrophoresis, microfluidic 
bead-based separations, and sol-gel encapsulation. 
2.3.1 Electrophoresis-based SELEX 
 The first microfluidic technique introduced to enhance SELEX partitioning was 
capillary electrophoresis, introduced in Chapter 1. CE separates components of a mixture 
based on their electrophoretic mobility. Unbound DNA or RNA migrates together while 
oligo-target complexes, because of their altered size and charge, separate from the unbound 
sequences and are collected (Figure 2.1). Because DNA and RNA have a higher negative 
charge density than virtually any target molecule of interest, complexation results in a 
significant and predictable decrease in electrophoretic mobility. This, together with the 
Figure 2.1: Example electropherogram of a CE-SELEX separation using normal polarity. Target and 
unbound oligos have very different electrophoretic mobilities and separate during CE. Target-oligo 
complexes migrate between the two component peaks. Target and complexes are collected for amplification 
while unbound oligos are not. 
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dramatic increase in the performance and prevalence of CE technology during the 1990s 
in response to the Human Genome Project, made CE the natural choice for SELEX’s 
stringent nucleic acid separation requirements. 
 CE-SELEX was first implemented by Mendonsa and Bowser seeking a DNA 
aptamer for human immunoglobulin E (IgE).98 Because of the high partitioning efficiency 
of CE, only four rounds of SELEX were required to obtain multiple aptamer sequences 
with Kds below 30 nM, drastically shortening the overall selection time. Additionally, the 
entire incubation and separation process can be performed in free solution, which allows 
the process to be done without tagging or immobilizing either molecule. Similar CE-
SELEX techniques have been used to select aptamers for a variety of proteins, including 
human immunodeficiency virus-reverse transcriptase (HIV-RT),99  human vascular 
endothelial growth factor 165 (hVEGF165),100 α-fetoprotein,101 and human epididymis 
protein 4 (HE4).102 Although the separation between bound and unbound sequences is more 
substantial with larger targets, CE-SELEX has also been used successfully on smaller 
targets including the 4.3-kDa neuropeptide-Y103 and the 580-Da N-methyl mesoporphyrin 
(NMM),15 demonstrating the flexibility and robust nature of the technique. 
 An additional advantage of CE-SELEX is that CE provides an excellent technique 
for determining the binding affinity of both the mixed selection pool and individual 
aptamer sequences. However, this is typically done in an additional post-selection step. 
The Krylov group developed a variant of CE-SELEX, deemed Non-Equilibrium Capillary 
Electrophoresis of Equilibrium Mixtures (NECEEM), which applied a novel analysis to 
extract kinetic and thermodynamic parameters of the nucleic acid pool without additional 
affinity measurements.104 By supplying target-free buffer at the capillary inlet, the 
migrating complexes slowly unbound depending on the aptamer dissociation equilibrium 
and rate constants (Kd and koff, respectively), which were analyzed in the separation 
electropherogram. Krylov further reduced the required time by removing the intermediate 
amplification and purification steps altogether. This “non-SELEX” method facilitated three 
successive NECEEM separation steps in one hour and improved the affinity of the DNA 
pool for the HRas protein by over four orders of magnitude.105 While the selection 
stringency of this technique may be limited by the need to collect sufficient DNA for 
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subsequent partitioning steps, the utility of non-SELEX has been further demonstrated in 
identifying aptamers for three signal transduction proteins, each with at least three orders 
of magnitude improvement in affinity.106 
 One major concern over CE-SELEX is the small sample volume that CE can 
handle. Injections are often less than 10 nL,100 so even when very high DNA concentrations 
are used, only about 1012-1013 oligos are sampled per run. One way around this has been 
utilizing bulk separation techniques like nitrocellulose filtration prior to CE to remove a 
large portion of non-binding sequences before CE-SELEX.107 This effectively samples 
more relevant sequences by removing a large fraction of non-binders before the CE step, 
although it does so at the cost of additional time and complexity.  
 Another approach to increase the number of sequences assessed is to move from 
discrete separations to continuous partitioning techniques. One example of this is micro-
free flow electrophoresis (μFFE). In this technique, buffer and sample are pressure-driven 
through a planar channel while an electric field is applied across the channel, perpendicular 
to the direction of flow (Figure 2.2). Because species are deflected laterally based on their 
mobility, sample can be streamed continuously through the device rather than injected in 
discrete plugs.  Binding sequences are collected through a separate exit port than non-
binders. This continuous approach eliminates the complicated manual timing required in 
CE to obtain reproducible sample collections. A μFFE-SELEX technique was 
demonstrated that sampled nearly 2x1014 DNA sequences in a 30-minute separation, a 300-
fold improvement over CE-SELEX.108 Aptamers for human IgE with a Kd of 20-30 nM 
were selected in only two rounds, indicating no loss in performance versus CE-based 
techniques.  
2.3.2 Bead–based microfluidic 
SELEX 
 Magnetic methods. 
Implementing microbeads as a solid 
support allows even small volume 
systems to benefit from a large 
surface area, increasing the physical 
Figure 2.2: Schematic of μFFE-SELEX device. Buffer 
pressure at the inlet drives sample along the channel at a 
constant rate. A voltage is applied to the electrodes to create 
an electric field across the channel, deflecting non-binding 
sequences to waste while oligo-target complexes are 
collected from a separate outlet. 
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selection space. SELEX on microparticles was first implemented using magnetic beads 
almost 20 years ago and is still widely used today.109, 110 Briefly, the target molecule is 
covalently attached to the surface of a magnetic (usually superparamagnetic) microparticle 
or nanoparticle and incubated with the nucleic acid library. Binding oligos complex with 
the target and become bound to the magnetic particles as well. A strong external magnet or 
magnetic field is then applied, which either isolates the particles from the suspension or 
holds them immobile while they are rinsed. While the theory is simple, the efficiency and 
practicality of bulk magnetic separation are limited compared to other techniques. 
However, combining a microfluidic approach with traditional microbead separation 
enhances the effectiveness of the technique drastically.  
 The Soh group was the first to implement magnetic microparticle SELEX on the 
microfluidic scale. Their first device, a continuous-flow magnetic activated chip separation 
device (CMACS), used a multi-stream laminar flow architecture to keep the bulk sample 
at the edges of the channel and a fresh buffer stream along the center (Figure 2.3). This 
layout had less lateral diffusion across the interface than in a single-stream flow, which 
enhanced separation efficiency.111 Tiny ferromagnetic structures created strong, precise 
magnetic fields to guide the beads into the central buffer stream for collection. This 
microfluidic addition enhanced recovery of beads to over 99.5% under optimal conditions 
and achieved a bulk Kd of 33 nM in just one round.112 Despite the excellent results, CMACS 
suffered from a number of difficulties in practice. Ideal flow conditions were only reached 
Figure 2.3: Schematic of CMACS device. Laminar flow architecture keeps the sample stream near the 
channel walls and flows to waste. Angled magnetized Ni strips guide the magnetic beads containing bound 
oligos into the central buffer stream which is collected through a separate outlet. Optical micrographs show 
the device during operation at (A) the channel wall, (B) the buffer stream, and (C) the outlet. The large 
distance m prevents diffusion of unwanted sequences into the central stream. Adapted from Lou et al.111 
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with careful adjustment under microscopic monitoring, undermining the robustness of the 
technique. Microbubbles and blockages also occurred frequently, which disrupted the flow 
streams and had a detrimental impact on aptamer separation. 
 To combat these issues, a new design was developed: the micromagnetic separation 
chip (MMS). The MMS relied on grids of patterned titanium and nickel, which were 
magnetized externally, to catch target-coated magnetic beads as they flowed through the 
channel. Once enough sample had passed through the chip, the channel was rinsed 
thoroughly to remove non-specifically adhered oligos. The external magnets were then 
removed, releasing the microbeads and target-binding sequences into solution for 
collection (Figure 2.4).112 The MMS chip demonstrated recovery and partition efficiency 
as good as or better than those of CMACS (roughly 99.5% and 106, respectively) while 
offering significantly more robust and reproducible operation. MMS was first demon-
strated using the protein streptavidin as the target, and later applied to platelet-derived 
growth factor-BB to obtain three aptamers with Kd’s below 3 nM.113 The process has also 
been incorporated into special selections, such as obtaining orthogonal aptamer pairs for 
sandwich assays,114 aptamers with a long binding lifetime,115 and self-reporting aptamer 
biosensors.116  
 Magnetic microbead SELEX continues to be perhaps the most popular microfluidic 
SELEX mechanism, with constant tweaking and adjustment pushing the boundaries of the 
technique. Recently, a device by Hong et al.117 incorporated both a positive and negative 
selection chamber into the chip separated by a microvalve, reducing the time and hassle of 
negative selection. This work also 
performed quantitative fluorescence 
binding analysis on a separate 
microfluidic chip using magnetic 
target immobilization, demonstrat-
ing a trend towards miniaturization 
of other steps of aptamer selection 
as well.  
Figure 2.4: Schematic of MMS device. A (A) top view and 
(B) side view of the device are shown. Sequential buffer and 
sample inlets flow sample towards the outlet. The patterned 
Ti/Ni grids become magnetized by external rare-earth 
magnets and traps magnetic beads containing bound oligos. 
Adapted from Qian et al.112 
 27 
 Non-magnetic methods. Non-magnetic beads have also transitioned from bulk 
affinity chromatography-based separations to microfluidic SELEX. These beads, generally 
made of silica derivatives or organic polymers like agarose and acrylate, supply the same 
increased surface area with lower cost and without the challenges associated with magnetic 
separation. Recently, the Zhao group demonstrated a simple custom chip that used two 
sequential pinches to trap acrylate beads in the channel, the first beads containing multiple 
non-target proteins (negative selection) and the second beads functionalized with 
myoglobin (positive selection).118 The chip is shown schematically in Figure 2.5. DNA was 
introduced continually at the top of the channel and flowed first through the negative 
selection zone to remove unwanted non-specific binders and then through the positive 
selection zone to retain sequences with affinity for myoglobin. The second pinch was then 
rinsed to remove weak binders before aptamers were eluted with DTT. This technique 
exemplifies the ease of performing simultaneous positive and negative selection that 
microfluidic SELEX offers.  A peak Kd of 5 nM was obtained with exquisite specificity. 
 Since these beads do not move throughout the separation, similar strategies have 
been employed that forego the microbeads altogether, instead immobilizing the target 
directly on the device surface with similar effect. Liu et al. constructed a circuitous 
microfluidic path over a protein 
microarray so that oligos passed 
over four different negative selection 
proteins before reaching the region 
displaying the target, lactoferrin.119 
Then only those sequences bound to 
lactoferrin were eluted, achieving 
multiple sequences with Kds below 
10 nM. 
 In some cases though, the 
microbeads don’t just provide a 
static surface but are actually a 
dynamic part of the device as with 
Figure 2.5: Schematic of dual positive-negative selection 
chip. Beads in the first pinch are coated with multiple non-
target proteins for negative selection, while beads in the 
second pinch are coated with the target of interest. The 
oligos are flowed through inlet 1, and only sequences with 
affinity for the target but not for any of the negative 
proteins will bind in the second pinch. These oligos are 
then eluted by the addition of DDT to inlet 2. Adapted from 
Wang et al.118 
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many magnetic systems. Recently, a completely continuous separation device was 
developed using migration by acoustic waves (acoustophoresis) for aptamer selection.120 
Similarly to the CMACS device, the incubated sample of target-coated beads and DNA 
was introduced at the edges of the channel with a central buffer stream holding the sample 
stream against the channel walls. As sample passed down the channel, an acoustic standing 
wave field focused the beads to the node in the central buffer stream for collection while 
leaving smaller species such as unbound DNA in the waste-bound edge streams. An 
aptamer was obtained with sub-nanomolar affinity for prostate-specific antigen (PSA) after 
eight rounds of SELEX. As with other techniques not requiring a separate elution step 
(μFFE, CMACS), this device can overcome a common weakness of microfluidic SELEX, 
the small number of sequences sampled, by simply extending the time of continuous 
operation.  
2.3.3 Sol-gel–based microfluidic SELEX 
 While SELEX techniques that rely on immobilizing the target have undoubtedly 
been successful in many cases, there has always been some concern over whether 
immobilization affects target conformation, occludes possible binding sites, or has other 
unintended consequences on the selection. One approach to circumvent covalent 
immobilization has been the use of sol-gel nanocomposites to trap proteins or other 
biomolecules.121, 122 Briefly, monomers or nanoparticles of the gel precursor (often one or 
more silica derivatives) are dissolved to create an aqueous sol. Chemical additives, along 
with the target, are then mixed into the sol, causing the silica to coalesce and solidify into 
a porous framework, trapping the target in the growing gel. Gels with pores of two different 
sizes are favored; the smaller pores trap the macromolecule in place while the larger pores 
allow easy diffusion of aptamers or other ligands throughout the network. It has been 
shown that enzymes in the gel not only maintain their function but can be more stable 
against chemical and thermal denaturation than in free solution.123, 124 
 Sol-gel encapsulation was first demonstrated as a SELEX technique by Park et 
al.125 The microfluidic device consisted of a narrow channel connecting five identical 
chambers, each constructed over an aluminum microheater. A droplet of the protein-
containing sol-gel was spotted into each chamber and allowed to gel overnight, then a 
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polydimethylsiloxane (PDMS) cover sealed the chip. Incubated oligos were observed to 
bind with high efficiency to the trapped target but not significantly to the gel matrix. 
Applying current through the heater electrodes yielded enough heat to denature and elute 
the oligo sequences. A strength of 
the technique is high target density, 
with each 300-μm droplet holding 
about 0.6 ng of protein. The device 
isolated RNA aptamers with affinity 
for a yeast transcription factor125 
and TATA binding protein126 with 
high affinity and in fewer rounds 
than with conventional SELEX. 
The high target density and heat-
triggered release lend themselves 
well to a multiplexed selection, but 
the first attempts at simultaneous 
selection were fraught with issues of 
contamination. However, the design 
was improved by independent 
sample and elution lines as well as 
pneumatic valves between the 
reaction chambers (Figure 2.6). The 
new device performed selections 
against five targets simultaneously 
in less time than the previous 
system without contamination.127 
The capabilities and applicability of 
sol-gel–based SELEX have 
continued to expand, as the 
technique has selected aptamers 
Figure 2.6: Schematic of multiplex sol-gel–based SELEX 
chip. (a) A schematic of the individual layers and (b) a 
picture of the assembled chip are shown. Electrode heaters 
(b, left inset) are patterned onto the bottom glass layer and 
spotted with the sol-gel. The pneumatic layer controls the 
valves between reaction chambers to prevent cross-
contamination during elution, while the remaining layers 
contain the main fluidic network. With valves open, 
sample is flowed through the reaction chambers to 
incubate with each sol-gel droplet, followed by washing 
to remove non-specific binders. Valves are closed and 
aptamers are eluted by running current through the 
electrode heaters and collecting at each elution outlet. 
Reproduced from Lee et al.127 
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against the small molecule xanthine, even when traditional SELEX could not,128 and 
against Bisphenol-A, which is too insoluble for other SELEX methods.129  
2.3.4 Integrated microfluidic SELEX systems 
 As discussed previously, the SELEX cycle consists of four main steps: incubation 
of oligos with the target to compete for binding; partitioning of free oligos from those 
bound to the target; amplification of the oligo pool by PCR; and purification, whereby the 
complementary strand is removed to achieve a single-stranded pool again. (Additional 
transcription and reverse transcription steps are necessary when RNA aptamers are sought.) 
The techniques discussed thus far have focused on incorporating the partitioning and 
sometimes the incubation steps into to microfluidic environment. However, one of the main 
draws of a microfluidic SELEX technique, the enhanced potential for automation, is 
significantly limited until all parts of this cycle can be linked in a single integrated system. 
For this reason, many groups have pursued not only the microfluidic partitioning methods 
described above but also miniaturization of the amplification, purification, and 
intermediate steps as well.  
 The first major step to this end was a prototype by Hybarger et al. that incorporated 
transcription, incubation, selection, reverse transcription, and amplification into a system 
of microlines, all controlled by valves actuated in LabView.130 The main achievement of 
the prototype was not just a seamless transition between the steps but also the use of 
pressurized reagent manifolds to fill, rinse, and clear sections of the system accordingly 
with no manual intervention. The full prototype still had a large footprint and its own share  
of practical difficulties, but it nonetheless set a high bar for future integrated SELEX 
systems. 
 The first integrated microfluidic SELEX chip, developed in the lab of Gwo-Bin 
Lee, was a three-layer, four-chamber PDMS and glass chip.131 The processes of incubation, 
separation, and amplification were performed in a central sample chamber connected to 
reagent and waste chambers by pneumatic microvalves (Figure 2.7). The system used 
typical magnetic bead SELEX, first demonstrated with C-reactive protein (CRP) as the 
target conjugated to superparamagnetic polystyrene beads. Efficient mixing of the sample 
chamber was achieved within three seconds by deflection of the PDMS membrane layer 
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with pressurized air. After incubation, the microbeads and any bound aptamers were held 
by an external magnetic field and rinsed thoroughly from the wash buffer chamber. PCR 
reagents were then introduced and the temperature was cycled in the sample chamber using 
microheaters and microsensors patterned on the glass substrate. The inherent automation 
coupled with the faster temperature cycling allowed by on-chip PCR achieved a round of 
incubation, selection and amplification in under 60 minutes.  
 The system was further enhanced to improve mixing and transport, and a 
competitive assay chip was designed to accompany the SELEX chip and further improve 
automation and speed of the overall process.132 Though the competitive assay chip was not 
a direct in-line addition and required intermediate manual processing, the increased 
efficiency of a chip-based assay provides a glimpse into the possible future of combined 
SELEX-aptamer characterization chips. The system has been continuously adapted and 
expanded to improve function and robustness. Example improvements include additional 
reagent and sample chambers, vacuum-driven pumps to accommodate live cells without 
lysis, and temperature-controlled regions of the device to speed cycling while avoiding 
reagent degradation.133-135 
 Purification of the PCR products to remove reagents and complementary nucleic 
acid strands has proven the most difficult piece to incorporate into microfluidic systems, 
either performed off-chip (reducing speed and automation) or absent altogether (reducing 
Figure 2.7: Schematic of integrated SELEX chip by Huang et al. (A) The bottom glass layer is patterned 
with microheaters and sensors (platinum) with associated electrodes (gold) for temperature control during 
PCR. The thin-film PDMS membrane and thick PDMS block facilitate all liquid handling, including 
pumping and mixing by pneumatic membrane deflection. (B) The assembled device contains a main 
incubation/PCR chamber connected to chambers for wash buffer, PCR reagents, and waste by low-volume 
microchannels to prevent dead space and bubble formation. Adapted from Huang et al.131 
 
 32 
efficiency) in the previous devices. 
A new design by the Lin group 
utilized a bead-based PCR system 
to isolate the active aptamer from 
its complement generated during 
PCR.136 The device consisted of 
two chambers, one for incubation 
and selection, the other for 
amplification and purification 
(Figure 2.8). The chambers were 
connected by a gel-filled channel 
to facilitate electrophoretic transfer 
of the DNA from one chamber to the other and back. Each chamber was surrounded by a 
weir to keep the beads in the appropriate chamber while allowing reagents and buffers to 
come and go freely. The key to purification was the use of reverse PCR primers 
immobilized onto microbeads in the amplification chamber. By performing PCR with 
immobilized reverse primers, only aptamer strands were transferred back to the selection 
chamber while the complementary strands remained bound to the PCR beads. The device 
performed three complete rounds of selection in under 10 hours with no off-chip activity, 
obtaining aptamers for both protein (IgE) and small molecule (bisboronic acid) targets. 
While this strategy provided an elegant solution to the purification problem, the 
electrophoretic transfer was not without practical issues, which led to a new design that 
incorporated both electrophoresis and pressure-driven flow into the system.137  
 
2.4 Microfluidic aptamer characterization 
2.4.1 Sequencing 
 The majority of microfluidic influence in SELEX has focused on optimizing the 
separation and partitioning methods used in the selection itself, with the goal of obtaining 
sequence pools with the highest average affinity and the most high-affinity binders in the 
least amount of time. However, even given highly efficient selection and enrichment, the 
Figure 2.8: Schematic of integrated SELEX chip by Kim et 
al. (A) A top view of the device, showing the selection and 
amplification chambers connected by a gel-filled channel. (B) 
A side view of each chamber, showing weirs to prevent bead 
movement and patterned microheater for elution or PCR. 
Adapted from Kim et al.136 
 33 
ability to identify the best aptamers from the pool depends heavily on the nucleotide 
sequencing and binding characterization methods used.  
 Traditionally, aptamer pools were cloned into bacterial vectors and sequenced by 
the Sanger method, which demanded labor-intensive handling of individual bacterial 
colonies and usually returned a few dozen to a hundred sequences at most, a tiny percent 
of the selected pool. A small number of those sequences were then synthesized and had 
their affinity tested individually. Though this technique is still commonplace in the field, 
finding the best aptamers by this method is largely governed by blind luck in picking the 
colonies. The introduction of high-throughput next-generation sequencing (NGS) 
techniques has allowed researchers to view a much larger fraction of the pool and to 
rationally choose sequences for further characterization.113, 138 While sequence-based 
criteria (usually the read count or enrichment-fold of a motif) are not always the best 
indicator of affinity,100, 113 this strategy of rational sequence selection by NGS is arguably 
more effective than picking colonies randomly. As commercial NGS services become 
quicker and cheaper, choosing aptamer candidates via NGS analysis is rapidly becoming 
the method of choice. 
2.4.2 Affinity measurement 
 Once individual sequences are chosen, some number of them, usually up to a few 
dozen, are synthesized in high purity, and the affinity of the individual sequence is 
determined for the target of interest as well as possibly for similar targets to determine 
selectivity. While NGS sequence analysis may hint at the best aptamers, it is no substitute 
for experimentally determining the affinity of a large number of sequences, as the true 
trends in affinity always deviate from those predicted by the informatics data. Even when 
using the microfluidic selection techniques above, affinity characterization has almost 
universally been done sequentially on large instrumentation. Microplate fluorescence 
assays, affinity capillary electrophoresis, and surface plasmon resonance are among the 
most common techniques for finding target affinity, in each case determining the amount 
of aptamer bound at many different concentrations of target to construct a binding curve 
and determine the aptamer dissociation constant. Because instrumental characterization 
techniques are robust and highly automated, it is unlikely that microfluidic characterization 
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methods outside microarrays will see widespread adoption until they display significant 
advances in performance, automation, or multiplexing. 
 Custom chip-based methods. DNA microarrays have largely cornered the market 
on microfluidic affinity assays, but custom characterization chips do still appear in the 
literature from time to time. For example, the magnetic microbead SELEX by Hong et 
al.117 was presented with a custom chip that measured the fluorescence intensity of each 
magnetically bound sample post-partitioning, performing a microfluidic version of the 
normal microplate fluorescence binding assay. There is the potential for future integration 
of this type of technique directly into the selection, particularly when the partitioning 
already makes use of magnetic beads as well. Rather than toward integration, the Afi-Chip 
developed by Song et al.139 has gone toward a universal, low-cost design for potential 
commercialization. The quantitative gas generation in a catalase-linked assay moves a dye 
bar for each sample, meaning little expertise and no expensive equipment is required to 
interpret the length-based results. These types of chip-based characterization platforms 
provide an interesting glimpse into the possible future of the microfluidic SELEX 
workflow; however, they don’t yet represent an improvement in speed or performance 
compared to instrumental techniques, which is the main reason most researchers still rely 
on workhorse analytical techniques or DNA microarrays for characterization. 
 DNA microarrays. DNA microarrays are the only method of microfluidic 
characterization that has been widely adopted. A DNA microarray consists of thousands or 
millions of “spots” on a flat surface, with each spot containing many copies of a known 
DNA sequence. DNA can either be synthesized in situ or generated first and deposited onto 
the surface. A sample containing the fluorescently labelled target(s) of interest is then 
flowed over the array, and fluorescence intensity (and color, in the case of multiple targets) 
is scanned across the array to indicate binding. The basics of DNA microarrays and their 
usage in microfluidics have been reviewed elsewhere.140, 141  
 For characterization of aptamers, arrays were first used to examine and improve 
existing sequences. For example, aptamers against IgE have been of particular interest 
because a long consensus region is highly conserved through many known aptamers. 
Microarrays with thousands of sequences systematically mutated from a few IgE aptamers 
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have been used to interrogate the roles of specific bases.142, 143 Mutations of certain bases 
or motifs completely eliminated binding behavior while other changes had no effect, 
allowing the original sequence to be truncated further.142 Similar work has been done using 
microarrays with over 10,000 mutants to analyze and improve existing aptamer sequences 
binding to green fluorescent protein (GFP) and Drosophila negative elongation factor E 
(NELF-E).144 Ever improving technology has continued to increase both the number of 
sequences that can be tested and the amount of sample space that can be interrogated by 
more complex rational algorithms to control mutation. Work by Kinghorn et al.145 tested 
nearly 200,000 mutants of previously selected aptamers against a malarial antigen. The 
mutants were determined using the public tool Resample, which not only recognized and 
generated preliminary mutants around motif families but also filtered out candidates based 
on predicted disadvantageous pairing and structural motifs. The process produced a 
truncated version of an existing sequences, as well as three novel sequences, all with Kds 
below 10 nM, substantially better than the starting aptamers. 
 Arrays are most commonly applied after SELEX in this manner, but their use as a 
part of the SELEX process is an interesting shortcut to condense the workflow and reduce 
backtracking. This was demonstrated by Cho et al. by combining the MMS device, NGS, 
and commercial microarrays into the quantitative parallel aptamer selection system 
(QPASS).146 Briefly, four rounds of SELEX were performed on the MMS against the 
protein angiopoietin-2 (Ang2). A small aliquot from each pool underwent NGS and 
returned ~107 sequences, and the sequences were ranked by read count. Eight identical 
arrays were then generated, each containing the 235 most common sequences from each 
pool, including different types of linkers and control sequences, with each spot in triplicate 
per array. By incubating each array with a different concentration of fluorescent target, an 
8-point binding isotherm (and the associated Kd) was determined simultaneously for each 
of the over 200 sequences. Characterizing that many sequences sequentially by standard 
methods would be totally unthinkable, demonstrating the power of array-based SELEX.  
 The researchers have since used this technique for rapid discovery of aptamer pairs 
that bind to different epitopes of the same target.147 Such pairs are necessary for some 
highly selective analytical assays or for development of bidentate aptamer binding 
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schemes, but isolation of these aptamer pairs was difficult and relied largely on luck before 
this technique. By first generating an array of the Ang2 aptamers found previously, then 
incubating the target protein with the array, Ang2 was now presented for potential binding 
but with the binding epitope of the first aptamer occluded. A new library was then flowed 
over this protein-bound array to identify new sequences that bound to an independent 
epitope. Screening of this huge number of sequences allowed identification of multiple 
pairs with the strongest original aptamer sequence. By connecting these two aptamer 
sequences with a poly-T linker, the resulting aptamer exhibited an astounding 62 pM Kd, 
300-fold stronger affinity than either sequence individually. There is still tremendous room 
for growth, as these examples can be scaled up to current commercially-available arrays of 
1-2 million features with almost no change in time or labor. As the scale, complexity, and 
economics of microfluidic DNA arrays continue to improve, it seems inevitable that 
microarrays will become inextricably linked with the SELEX process itself. 
 
2.5 Conclusions 
 Despite many advantages of aptamers over other affinity reagents such as 
antibodies, conventional SELEX methods for isolating new aptamers are labor-intensive 
and fickle at best, which has bottlenecked progress in the field. However, incorporating 
new microfluidic SELEX techniques, either by scaling down existing procedures or by 
inventing novel strategies only feasible at the microscale, has produced tremendous growth 
in all parts of the selection and characterization process. While it is likely that no single 
SELEX technique will emerge as the optimal method in all cases (given the variety of 
targets, selection requirements, and intended aptamer uses), these abundant new 
microfluidic SELEX methods all have improved efficiency and speed over the older bulk 
techniques they have begun to replace.  
 Based on the current state of the field, the author predicts two significant future 
directions. First, extensive work has already been done on specific selection techniques, 
and the author anticipates a continued shift toward integrated microfluidic methods 
combining selection with purification, characterization, negative selection, and/or 
multiplexing to take full advantage of the superb automation that microfluidics provides. 
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Second, the trend has thus far been towards increased complexity in prototype design to 
maximize speed and elegance, creating a divide between method-focused groups designing 
new selection techniques and those groups selecting aptamers for use in their research. The 
author anticipates a future movement toward simpler designs that are more cost-effective 
and accessible to these application-focused groups with less microfluidics expertise, such 
as 3D printed devices or commercially available disposable devices. In both cases, we 
eagerly await exciting future microfluidic developments to meet the growing aptamer 


























 The advantages of DNA aptamers as affinity reagents – their stability, flexibility, 
and reproducible in vitro synthesis, to name a few – have already been expounded on in 
this dissertation. Unfortunately, one major drawback of aptamers has been the limited 
number of biomedically relevant molecules that can be targeted, which has two main 
factors. First, most current SELEX methods are incompatible with intact membrane 
proteins, which make up the majority of pharmacological targets of interest. Second, 
aptamers are unable to cross the plasma membrane to reach intracellular targets due to their 
size and charge. Because CE-SELEX separates targets without the need for immobilization 
and is amenable to the use of lipids to mimic the cell membrane, it is the perfect technique 
to develop a robust and generalizable method for aptamer selection against membrane 
proteins. In addition, aptamers selected for endocytosing receptors would provide a method 
for delivery of drugs, nanoparticles, or even other aptamers in a cell-specific manner. The 
work here focuses on optimization of the CE-SELEX method to target an intact membrane 
protein (as-yet unseen in the literature) and on development of DNA aptamers targeting 
low-density lipoprotein receptor for future use in aptamer-mediated endocytosis. 
 
3.2 Background 
3.2.1 Limitations of current techniques 
 Many of the issues with SELEX separations have largely been solved through 
creative negative selections, new separation techniques, methods of reducing contaminants 
and non-selective binding, and fine-tuned rinsing and collection that increases bound 
sequence retention. But one of the most pressing issues yet to be addressed is finding ways 
to reliably select membrane protein-targeting aptamers. Membrane proteins  generally have 
significant non-polar regions to facilitate insertion into the plasma membrane, which can 
cause issues with structure and solubility when attempting to work with them in isolation. 
They constitute nearly a quarter of the human proteome and more than half of current drug 
targets,148, 149 making them far too prevalent and important for the aptamer community to 
continue to simply write them off as “untargetable.” A small number of aptamers have been 
selected for certain specific membrane proteins by cleaving the transmembrane region or 
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by using only a small, soluble portion of the protein.24, 150, 151 The most significant example 
of this is aptamers targeting prostate specific membrane antigen (PSMA), which are known 
to undergo efficient receptor-mediated endocytosis (RME) and have been used as prostate 
cancer drug targeting agents with immense success.152  
 Despite individual successes, extracellular domain cleavage is not a reliable 
strategy for SELEX against membrane proteins for two reasons. First, many important 
membrane targets cannot be easily truncated to yield a significant, representative soluble 
portion. Perhaps the most exciting drug target research today involves G-protein coupled 
receptors (GPCRs), which are the targets of more than one third of small molecule drugs.153 
Each GPCR relies heavily on its seven non-polar transmembrane helices to anchor the 
tertiary structure of its selective binding site.154 Cleavage of the transmembrane regions 
completely disrupts the loop interactions and any semblance of the previous structure. This 
is just one example superclass, but many important proteins fall into this category. The 
second problem is that, even for a protein with a large extracellular domain, truncating the 
domain may create a structure which is unrepresentative of the membrane-bound version. 
This may be because it exposes a region which is normally sterically inaccessible, because 
the end of a cleaved chain interacts with another domain, or because the transmembrane 
region (or the membrane itself) is necessary to maintain proper structure of the extracellular 
domains. For these reasons, it is unsurprising that many subsequent selections against 
truncated proteins have not produced aptamer sequences that perform well with intact, 
bound targets. 
 Other methods besides truncation have their merit. Cell-SELEX, in which the entire 
cell is targeted, or selections against vesicles prepared from cell membranes, are both 
techniques seen in the literature.155 However, the target molecule cannot be chosen with 
these methods, and it often cannot even be identified following the selection.156, 157 These 
methods represent an interesting strategy for certain types of selections but are not 
appropriate for obtaining aptamers for a specific membrane protein.  
3.2.2 CE-SELEX with membrane-bound proteins 
 Besides truncation, another strategy for preventing aggregation and conformational 
changes in membrane proteins is the use of a surfactant membrane model. This allows the 
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protein to adopt a physiological conformation by solubilizing any intra- or transmembrane 
region in the non-polar center of the membrane model. While many common SELEX 
techniques, such as filtration and affinity chromatography, are incompatible with such 
surfactant structures, CE is known to be amenable to a wide variety of surfactants. In fact 
an entire class of CE separations, micellar electrokinetic chromatography (MEKC), uses 
charged surfactant micelles to enhance separation of uncharged analytes. Therefore, CE is 
an ideal choice of analytical technique to separate membrane proteins which have been 
solubilized in a surfactant membrane model. It is believed that this method should be far 
more generalizable and more likely to produce applicable aptamers than truncation. 
 Several types of surfactant membrane models exist, the most common of which is 
the micelle. A micelle is a spherical assembly of a single type of amphiphilic molecule 
with no internal aqueous space. The polar or charged head group faces out to interact with 
the aqueous environment while the tails point inward to create a wholly non-polar interior. 
Depending on the specific protein’s structure and normal interaction with the membrane, 
the membrane-bound region can fully span the micelle or simply be inserted into it. While 
micelles have a high degree of curvature compared to the cell membrane, they were chosen 
for this work due to their implementation being simple and consistent. A nonionic micelle 
presented the best opportunity for separation between the solubilized protein and the highly 
negatively charged DNA, as well being the most forgiving on separation performance in 
the event of poor micelle size homogeneity. Octaethylene glycol monododecyl ether 
(C12E8) was used for this work, a micelle-forming nonionic surfactant frequently seen in 
both  biological and analytical research.158, 159 
3.2.3 Low-density lipoprotein receptor 
 Low-density lipoprotein receptor (LDLR) is a transport protein found on the surface 
of virtually all human cells. It is responsible for importing low-density lipoprotein (LDL) 
particles, a source of lipids for mechanical and metabolic purposes, into the cell by RME 
(Figure 3.1). LDLR was chosen as a SELEX target for this work for a number of reasons. 
First, the ultimate goal of this project was to select one or more aptamers that could not 
only bind to the target but also be endocytosed by the receptor. LDLRs are known to 
undergo RME on a short time scale (every 12-15 minutes) and in the absence of ligand,160 
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increasing the likelihood 
that internalization would 
take place and be 
observable. Second, 
LDLR has a large and 
chemically heterogeneous 
extracellular portion – 3 
domains incorporating 
767 amino acids – and 
only a small 50-residue 
cytosolic portion. 
Because successful 
SELEX depends on 
aptamers binding in 
higher numbers to the 
extracellular side than the cytosolic side (since the cytosolic side may be exposed when the 
protein is solubilized in the micelle), such a difference in size and chemistry of the two 
ends makes it overwhelmingly more likely that any selected aptamers are binding to one 
of the extracellular domains. Finally, LDLR is expressed ubiquitously in human cells, 
making it very easy to find sample cell lines for future testing which express (or 
overexpress) LDLR and exhibit spontaneous RME. 
3.2.4 Optimizing selection and buffer conditions for future applications 
 Aptamers use a variety of different types of interactions to maintain their structure 
and to bind to their target, including hydrogen bonding, ring stacking, and backbone 
interactions.161 For this reason, aptamer structure and binding can be sensitive to a variety 
of gross factors – such as temperature, pH, or ionic strength – as well as to specific ions 
like potassium for G quadruplex formation.162-166 Therefore, while aptamers are “stable” 
over a large range of conditions in that they are not easily permanently altered, changes in 
these interactions due to the environmental conditions mean that aptamers may not perform 
equally well in all conditions. This makes it advantageous to consider the intended 
Figure 3.1: LDLR endocytic cycle. 1) The LDLR is embedded in the 
cell membrane facing the extracellular space. LDL particles are trapped 
by the receptor and remain bound. 2) The surrounding membrane buds 
inward to form a vesicle containing the LDLR, along with any bound 
LDL. 3) Once the vesicle joins with the endosome, bound LDL is 
released into the endosomal lumen. 4) Free LDL is sorted and exits the 
endosome in a vesicle bound for the lysosome, where it will be degraded. 
5) LDLR exits the endosome in a vesicle to return to the cell membrane 












applications of the aptamers during the selection process and the corresponding conditions 
for these applications if at all possible. This is equally as important for the target molecule, 
as crucial co-factors or other environmental factors may be necessary to obtain a 
representative target molecule structure during selection. In this particular case, aptamers 
targeting intact membrane-bound proteins will clearly be of most utility in physiological 
settings, whether with cultured cells in vitro or used for in vivo applications. The specifics 
of “physiological” can vary from case to case, but a number of factors are generally 
consistent, such as an aqueous environment with neutral pH (7-8), elevated temperature 
(37˚C), and high ionic strength. 
 On the flip side, there can be no aptamers without a successful selection, so 
conditions that adversely affect the selection process need to be considered carefully. For 
example, the CE current increases significantly with ionic strength of the running buffer, 
which can lead to poor temperature control, unwanted changes in viscosity, and even 
potential issues with instrument electronics. Therefore, prior to commencing CE-SELEX 
with the micelle system, multiple CE and buffer conditions were optimized to determine 
what level of pseudo-physiological conditions the CE instrumentation could tolerate 




 Nuclease-free water (nfH2O) was obtained from Ambion (Austin, TX). A set of 
four deoxynucleoside triphosphates (dNTP, 100 mM) was obtained from Denville 
Scientific (Metuchen, NJ). Agarose powder and glacial acetic acid were obtained from 
Fisher Scientific (Waltham, MA). Molecular biology grade 3-(N-
morpholino)propanesulfonic acid (MOPS) was obtained from Fluka (St. Lous, MO). All 
DNA libraries and sequences were obtained from Integrated DNA Technologies 
(Coralville, IA). Sequences of the library and labeled primers used were: 5’-6FAM-AGC 
AGC ACA GAG GTC AGA TG-N40-CCT ATG CGT GCT ACC GTG AA-3’ (FAM-
labeled library), 5’-6FAM-AGC AGC ACA GAG GTC AGA TG-3’ (FAM-labeled sense 
primer), and 5’-Biotin-TTC ACG GTA GCA CGC ATA GG-3’ (biotin-labeled antisense 
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primer). NaOH powder was obtained from Macron Chemicals (Radnor, PA). Hyperladder 
DNA ladder (25-base) was obtained from Bioline Reagents (Cincinnati, OH). Boric acid 
powder, CaCl2, KCl, and MgCl2 were obtained from Mallinckrodt Pharmaceuticals (St. 
Louis, MO). Taq polymerase and accompanying ThermoPol buffer were obtained from 
New England Biolabs (Ipswitch, MA). Recombinant human low-density lipoprotein 
receptor (LDLR, TP300006) was obtained from OriGene (Rockville, MD). 
Tris(hydroxymethyl)aminomethane (Tris) was obtained from Roche Applied Science 
(Penzberg, Germany). Octaethylene glycol monododecyl ether (C12E8) powder, NaCl, 
glycerol (99.5%), ethidium bromide, disodium ethylenediaminetetraacetic acid (EDTA), 
and disodium fluorescein were obtained from Sigma-Aldrich (St. Louis, MO). MgCl2 
solution (25 mM) and streptavidin-coated agarose resin were obtained from Thermo 
Scientific (Waltham, MA). 
3.3.2 Buffers and solutions 
 (1) CE running buffer contained 20 mM MOPS, 0.1% w/v C12E8, 5 mM KCl, 20 
mM NaCl unless otherwise noted, and was adjusted to pH 7.5 with NaOH. (2) Sample 
buffer was prepared in nfH2O and contained 20 mM MOPS, 0.1% w/v C12E8, 5 mM KCl, 
1 mM CaCl2, 16 mM NaCl unless otherwise noted, and was adjusted to pH 7.5 with NaOH. 
(3) PCR master mix was prepared fresh for each use in nfH2O and contained 540 nM FAM-
labeled sense primer, 540 nM biotin-labeled antisense primer, 216 nM each dNTP, 8.1 mM 
MgCl2, and 1.08x ThermoPol buffer. (4) TBE buffer for gel electrophoresis contained 45 
mM tris, 45 mM boric acid, 50 mM EDTA. (5) Purification buffer was prepared in nfH2O 
and contained 10 mM tris, 50 mM NaCl, 1 mM EDTA. 
3.3.3 CE equipment and protocols 
 All CE work was performed on a P/ACE MDQ (Beckman-Coulter) or P/ACE 
MDQ-Plus (SCIEX) automated CE instrument using 32 Karat data collection software. 
Uncoated fused silica capillary of 50-μm inner diameter and 360-μm outer diameter was 
used throughout, cut to 39.7 cm total length with a detection window (2-5 mm wide) burned 
29.5 cm from the inlet. Unless otherwise specified, CE sample storage was set to 37˚C 
while capillary temperature was set to 25˚C. Rinses used 20 psi forward pressure and 
sample injections were made with 10 s of 0.5 psi forward pressure. Before first use, new 
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capillaries were rinsed with 0.15 M NaOH for 3 min, rinsed with nfH2O for 3 min, rinsed 
with running buffer for at least 30 minutes, and allowed to equilibrate with running buffer 
for 48 hours. The capillary was rinsed with running buffer for 5 min between runs and for 
15 minutes at the start and end of each day. LIF detection (488 nm excitation/520±10 nm 
emission) was used throughout, unless otherwise specified. 
3.3.4 SELEX separation 
 DNA was heated at 72˚C for 5 minutes and cooled before use. For each round of 
SELEX, a 20-μL sample containing DNA and 10 nM LDLR in sample buffer was 
incubated at 37˚C for 20 minutes before selection. The first round used 100 μM random 
library DNA while each subsequent round used purified DNA from the previous round to 
make the sample as concentrated as possible, generally 1-5 μM. The sample was separated 
by CE at -30 kV until the end of the free DNA had migrated off the capillary (calculated 
from the electropherogram and capillary dimensions). The separation was then stopped 
manually and the outlet was dipped into a clean vial of nfH2O and placed in a collection 
vial containing 50 μL of running buffer. The capillary was rinsed for 2 minutes to push 
bound DNA into the collection vial. The whole injection, separation, and collection process 
were repeated two to three additional times into the same collection vial. 
3.3.5 PCR and gel electrophoresis 
 PCR samples were prepared with 92.5 μL master mix, 7.0 μL of DNA sample, and 
0.5 μL (2.5 units) Taq polymerase, with Taq polymerase being added once the sample 
reached 94˚C. Each PCR experiment was run with at least one positive control (DNA 
sample = 50 pM random DNA library) and at least one negative control (DNA sample = 
nfH2O). The thermocycler performed 25 rounds of 94˚C (30 s), 53˚C (30 s), and 72˚C (20 
s) sequentially, followed by a final 10 minutes at 72˚C and storage at 4˚C.  
 Gel electrophoresis was performed on all non-identical PCR samples (including 
PCR controls) to verify amplification and check for contamination. A 1.5% or 2% w/v 
agarose gel  made with TBE and 100 μg of  ethidium bromide was run in TBE buffer at 
200 V for 40 min. Gels were imaged on an ultraviolet transluminator with a Canon 1300d 
DLSR. 
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3.3.6 DNA purification 
 In a 10-mL affinity chromatography column, 300 μL of streptavidin-coated agarose 
resin and 500 μL of purification buffer were vortexed and then flushed. PCR-amplified 
sample DNA and 100 μL of purification buffer were introduced to the column and 
incubated at room temperature, vortexing periodically. After flushing with 5 mL of 
purification buffer, the column was then incubated at 37˚C with 200 μL of 0.15 M NaOH, 
vortexing periodically, and eluted into equimolar acetic acid. This NaOH incubation and 
elution was repeated into the same collection. The collected sample was spun in a 10-kDa 
centrifugal filter, rinsed with nfH2O, spun again, and collected in two clean microcentrifuge 
tubes, which were vacuum centrifuged to dryness at 50˚C then stored frozen. 
3.3.7 Affinity measurement 
 DNA was heated at 72˚C for 5 minutes and cooled before use. Samples were 
prepared containing 20 nM random library or aptamer pool, or 10 nM aptamer sequence, 
along with 0-250 nM LDLR in sample buffer, unless otherwise specified. All samples were 
incubated at 37˚C for 20-30 minutes before measurement. 
 For CE measurement, samples were separated at -30 kV and the free DNA peak 
height and area(s) were recorded. Samples were measured in triplicate from lowest to 
highest protein concentration. The uncorrected fraction bound for each concentration was 
calculated by the subtractive method (Equation 1.11). If the tailing of the free DNA peak 
increased at higher protein concentration and poor fitting was achieved with Equation 1.11, 
then the ratiometric calculation (Equations 1.12 and 1.13) was employed. The capillary 
was changed after each affinity assay. 
 FP measurements were performed on a BioTek Synergy 2 (Agilent) plate reader 
using 20-μL samples in an opaque 384-well plate. Measurements were made at 37˚C using 
a tungsten lamp (485±10 nm excitation/528±10 nm emission). Polarization values were 
measured in triplicate for all samples simultaneously with a 5-second mix between each. 
The uncorrected fraction bound for each concentration was calculated by Equation 1.10.  
 The Kd for each aptamer or pool was calculated in Origin 9.6 by fitting the triplicate 
uncorrected fraction bound data to a custom fit equation (Equation 1.8) with the constraints 
Kd > 0 and Bmax > 0. 
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3.3.8 DNA sequencing and preliminary sequence analysis 
 Prior to sequencing, the ssDNA pool underwent PCR as above except that 
unlabeled primers were substituted for the FAM- and biotin-labeled primers. PCR product 
was then concentrated by centrifugal filtration and submitted to the University of 
Minnesota Genomics Center (UMGC) for Illumina sequencing library preparation (TruSeq 
Nano) and high-throughput sequencing (MiSeq Nano 2x150 PE). 
 Sequence data files were compiled using PEAR. The sense primer sequence and 
reverse complement sequence of the antisense primer were trimmed using Cutadapt, along 
with any bases outside of those sequences, to remove extraneous bases from sequencing 
library creation. Untrimmed reads (due to incomplete or incorrect primer sequences) were 
discarded. The read count of each sequence was determined using the collapser function of 
Fastx Toolkit and ranked for each sequence length between 35 and 45 bases. Sequences 
were manually removed which contained the complete sense primer or antisense primer 
reverse complement sequence, or which differed from one of these by one point mutation. 
The original primer sequences were added back to all remaining reads. 
 
3.4 Results and Discussion 
3.4.1 CE optimization 
 A base running buffer of 20 mM MOPS, 5 mM KCl, and 0.1% w/v C12E8 was 
initially used. MOPS was selected because of its near-physiological pKa (7.2) and because 
its zwitterionic nature would add to the effective ionic strength without contributing to 
capillary current. MOPS concentration was limited to 20 mM as recommended for work 
with mammalian cells167 in case the buffer was necessary in future cell work. Potassium is 
required for proper formation of the G-quadruplex, a common stabilizing DNA secondary 
structure.168 First attempts also used 1 mM CaCl2 in the base running buffer, as Ca2+ is 
required as a cofactor for proper LDLR folding.169 Unfortunately, divalent cations such as 
Ca2+ can cause significant inconsistencies in the EOF, even in small quantities.170 Initial 
use of calcium ion in the running buffer as well as the sample buffer gave rise to 
substantially less consistent peak times and shapes than in the absence of calcium, so 1 mM 
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CaCl2 was used in the sample buffer but not in the running buffer in preparation for SELEX 
against LDLR. 
 CE buffer salt concentrations. CE separations were performed on FAM-labeled 
library DNA with increasing amounts of NaCl added to the base running buffer to increase 
the ionic strength and determine the maximum tolerable salt concentrations that could be 
used for selections. For this experiment, the sample buffer contained CaCl2 but no NaCl. 
As seen in Figure 3.2A, the peak shape of library DNA changed minimally between 0 mM 
and 20 mM, but a substantial splitting and broadening was observed at 24 mM NaCl. The 
experiment was repeated and yielded similar results, indicating that concentrations of NaCl 
above 20 mM in the running buffer give rise to poor and unreproducible peak shape. 
Although performing a selection with such a peak might still be manageable, any future 
quantitative experiments such as affinity measurements would suffer greatly from this 
degraded peak shape, so 20 mM was determined to be the optimal NaCl concentration in 
the running buffer. 
 Because the addition of calcium ion increased the ionic strength of the sample 
buffer as compared to the running buffer, it was unknown whether the sample buffer NaCl 
concentration should be decreased to compensate. While high ionic strength would be 
preferable from an applications perspective, care must be taken when considering the 
Figure 3.2: Effects of NaCl concentration on CE peak shape. (A) Increasing [NaCl] in the base CE running 
buffer had little effect on the DNA peak shape at or below 20 mM NaCl, but significant broadening and 
splitting was observed above 20 mM. A concentration of 20 mM NaCl in the running buffer was determined 
to be optimal. (B) Using running buffer with 20 mM NaCl, [NaCl] in the sample buffer was adjusted to 
observe its effect on peak shape and time. The changes observed were gradual, but the most significant 
change was seen between 18 mM and 20 mM NaCl. Therefore, 18 mM NaCl in the sample buffer was 












































relative ionic strengths of the separation and injection buffers. In typical CE, the injection 
plug often has a lower ionic strength than the running buffer, which generates a greater 
electrophoretic velocity in the injection plug when the voltage is first applied. This causes 
a local increase in concentration and decrease in band width when the sample reaches the 
boundary between the injection plug and the running buffer and slows down, a long known 
phenomenon called stacking.171, 172 The reverse phenomenon occurs when the sample plug 
has a higher ionic strength than the running buffer: sample bands can be broadened and 
even split, depending on the difference in ionic concentrations. 
 While maintaining a constant NaCl concentration of 20 mM in the running buffer, 
sample incubation buffers containing 1 mM CaCl2 and differing amounts NaCl were tested, 
and the effects on peak shape were monitored. As seen in Figure 3.2B, the free DNA peak 
became somewhat later and much broader as the NaCl concentration was increased steadily 
from 16 mM to 24 mM. Although the change in peak shape was more gradual than for the 
running buffer NaCl concentration, making determining the optimum concentration more 
difficult, the change in peak time and width seemed to be most distinct between 18 mM 
and 20 mM. Therefore, 18 mM was selected as the optimal sample buffer NaCl 
concentration. 
 Capillary temperature. Sample incubation at physiologically-relevant 
temperatures (around 37˚C) poses no performance issue for CE, but it was unclear whether 
separation at 37˚ would be tolerated by the assay. Increased temperature in the capillary 
reduces solution viscosity, which leads to increased current and can result in broader peaks. 
While obtaining sharp peaks and high resolution are not normally necessary in CE-SELEX 
because there is generally a wide window between the free DNA peak and the target 
complex, sharper DNA peaks allow for more efficient separation (requiring fewer selection 
rounds to maximize affinity) as well as more reproducible CE-based Kd measurements. 
Therefore, current and peak shape were monitored as the temperature was increased to 
determine whether a 37˚C separation was feasible. 
 In previous work, it was noted that a capillary current above 90-100 μA introduced 
substantial current fluctuation and seemed to decrease peak time reproducibility.  
Therefore, 10-minute separations were performed on library DNA at capillary temperatures 
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varying between 25˚C and 37˚C while the maximum current was monitored. The maximum 
current observed, 80.5 μA at 37˚C, was well below the cutoff of 90-100 μA (Figure 3.3A). 
In addition, no non-linear relationship between current and temperature was observed, 
which would have indicated Joule heating that could not be compensated by the capillary  
coolant system. The resulting traces in Figure 3.3B demonstrate that the DNA peak shape 
did not deteriorate at increased temperatures. In fact, the peak became somewhat earlier 
and sharper at 37˚C, which were both desirable changes.  
 Glycerol. Glycerol is commonly added to commercially available membrane 
proteins, as it was to the LDLR in this work, in high concentrations in order to circumvent 
issues with protein aggregation. The presence of glycerol in these experiments raised 
several possible CE performance issues including affecting C12E8 micelles, affecting EOF 
through surface adhesion, and affecting electrophoresis through changes in viscosity. CE 
runs were performed with DNA library in sample buffer that also contained increasing 
amounts of glycerol in order to determine if the presence of glycerol would be deleterious. 
The glycerol concentration was taken up to 2.5% by volume, which would be the highest 
concentration anticipated during affinity measurements. The effects of glycerol were 
surprisingly significant, as seen in Figure 3.4. Even at low concentrations, the peak became 
substantially deformed, with the peak height decreasing more than 5-fold at 2.5%. 
Additionally, multiple runs at the same glycerol concentration saw the peak become later 
Figure 3.3: Impact of capillary temperature on CE current and peak shape. (A) The maximum current 
observed was plotted against the capillary set temperature. Even at 37˚C, the current was below the planned 
cutoff of 90-100 μA. Additionally, the linear relationship indicates no excessive Joule heating which would 








































and shorter, so there are also undoubtedly 
effects of cumulative runs beyond the 
glycerol concentration of the current 
sample. Although a similar experiment to 
determine the effect of glycerol on FP 
performance had initially been planned, the 
effect of glycerol on CE performance alone 
was substantial enough to necessitate a 
complete buffer swap of the LDLR to 
remove all glycerol before any CE was 
performed. 
3.4.2 CE-SELEX against LDLR and pool 
sequencing 
 Concurrent with optimization experiments, multiple preliminary CE-SELEX 
experiments were performed including any optimized conditions known at the time. The 
purpose of these selections was to confirm proper operation of the other components of the 
SELEX method – collection, amplification, affinity measurements, and the like – with the 
LDLR target and micelle-containing buffer. Unfortunately, technical instrumentation 
issues precluded subsequent selections after optimized conditions were finalized, so all 
further data presented extends from the final preliminary selection. The selection differed 
from the optimized conditions above only minimally, as outlined in Table 3.1. 
 Four complete rounds of CE-SELEX were carried out, consisting of incubation, CE 
separation, PCR amplification, and purification. During CE, the end of the free DNA peak 
was judged to be the point at which the fluorescence intensity crossed below 1% of the 
peak height above the baseline. This point is shown for rounds 1 and 2 in Figure 3.5. (A 
peak height of 100 RFU, the detector maximum, was used for round 1 even though the 
peak surely extends significantly above this.) Separation was stopped manually when this 
point reached the end of the capillary, calculated by multiplying the electropherogram time 
by the ratio of the full capillary length to the inlet-to-detector length (1.357). The complex 
DNA remaining in the capillary was then collected separately with a pressure rinse into a  
Figure 3.4: Effects of glycerol in sample buffer on 
CE peak shape. The DNA peak shifts later and 
becomes substantially smaller and broader in the 
presence of glycerol. The effect is concentration 




























small collection vial. Because the 
amount of DNA collected was 
unknown, preliminary PCR assays and 
agarose gel electrophoresis were 
performed on dilutions of the 
collection ranging from 1× to 0.001× to 
determine the ideal dilution for 
amplification. The remaining collected 
DNA was diluted appropriately and  
amplified, usually yielding 10-14 
sample tubes of PCR. Gel 
electrophoresis was performed on each 
amplified sample and any tubes with poor amplification or incorrectly sized sequences 
were excluded. This generated enough DNA to prepare a new incubation pool of 1-5 μM 
while saving enough for affinity measurements and sequencing.  
 Actual Optimized 
MOPS (RB/SB) 20 mM 20 mM 
KCl (RB/SB) 5 mM 5 mM 
C12E8 (RB/SB) 0.1% 0.1% 
NaCl (RB) 20 mM 20 mM 
NaCl (SB) 16 mM 18 mM 
CaCl2 (SB) 1 mM 1 mM 
Glycerol (SB) Removed Removed 
pH (RB/SB) 7.5 7.4 
Sample temperature 37˚C 37˚C 











































Figure 3.5: CE-SELEX sample traces for LDLR selection. (A) The LIF trace for round 1 of selection is 
shown, with the arrow indicating the start of the collection window. Note that the 100-μM DNA sample 
maxed the detector here. (B) The LIF trace for round 2 of selection shows a free DNA peak at a similar 
time but smaller than in round 1 (to be expected), so the collection window began earlier. Subsequent rounds 
of selection were visually similar to round 2. C) A UV trace (200 nm) of LDLR alone confirms that the 
main LDLR band passes the detector after the DNA, around 4-5 minutes. 
Table 3.1: LDLR CE-SELEX actual and optimized 
conditions. Elements of the CE running buffer (RB), 
sample buffer (SB), or CE conditions are shown, 
comparing the actual conditions used for the selection with 
the ideal conditions based on optimization experiments. 
The three deviations between actual and optimized 
conditions are shown in bold. 
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  The affinity of the starting library for LDLR was measured to be 303±64 nM by FP 
(Figure 3.6), and the affinity of each purified pool for LDLR was measured in turn to 
evaluate the trend in affinity over the course of the selection. As seen in figure 3.6B, the 
decrease in Kd to rounds 3 and 4 marks a 5-fold improvement over the starting library, 
indicating an apparently successful selection. 
 The round 4 aptamer pool was sequenced and reads were processed to yield a list 
of approximately 380,000 sequences. The most common sequences are shown in the 
Appendix (Table A.1). The highest read count among all sequences was 740, making up 
less than 1% of the sequencing pool, and only six sequences had a read count above 100.  
Though the lack of convergence is surprising, previous CE-SELEX research in our group 
has suggested that the technique leads to more heterogeneous aptamer pools than do other 
SELEX methods.100 About 97% of sequences with the proper primer structure had between 
79 and 81 bases, initially suggesting good performance of amplification phases. However, 
around 1000 sequences had sections of the random region identical to within one point 
mutation of the sense primer or the antisense primer reverse complement. It is statistically 
unlikely this would have happened once by chance let alone multiple times, so it is clear 
that primers were improperly inserted during PCR on multiple occasions. One possible 
Figure 3.6: LDLR aptamer pool affinity trend measured by FP. (A) Binding plots are shown for the starting 
library (triangle, dashed line) and round 2 aptamer pool (square, solid line), illustrating the increase in 
affinity during SELEX. Error bars are omitted for clarity. The hyperbolic fit line (Equation 1.8) for each 
pool is shown, from which the Kd was calculated. (B) The Kd shows a significant downward trend from one 
round to the next, indicating an apparently successful selection. Error bars indicate the standard error of the 
Kd based on the fit. Note that the value shown for “Library” indicates data for one affinity assay trial 
performed prior to sequencing, not an average of all library affinity data. 











































Kd = 303 nM
Round 2
Kd = 80 nM
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culprit for this unusual behavior is the use of an intentionally mutation-prone PCR method 
during selection to encourage substitutions during amplification to enlarge the sequence 
space sampled. Regardless of the cause, these sequences were clearly present in the pool 
due to biases in amplification rather than affinity selection, so they were removed before 
any further analysis. 
 Current high throughput methods of aptamer characterization like DNA 
microarrays are not amenable to the C12E8 system, so only a handful of sequences could be 
selected for further analysis (Table 3.2). First, all sequences with a read count greater than 
one (approximately 4200 sequences) were grouped into clusters with high base position 
similarity using AptaCluster. An example cluster is shown in the Appendix (Table A.2). 
AptaCluster identified 42 clusters, nine of which contained 10 or more sequences. These 
nine clusters were ranked by the sum of the read counts of all sequences in the cluster, and 
the most abundant sequence in each of the top three clusters was chosen for analysis. This 
was done in an attempt to select sequences that were representative of the pool while not 
being similar to each other. By this method, A1, A3, and A4 were selected. While these 
turned out to be the three highest abundance sequences in the pool, the more complex 



















 A0 (Poly-T control) 
 AGCAGCACAGAGGTCAGATGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCACGGTAGCACGCATAGG 
Table 3.2: LDLR aptamer sequences selected for further characterization. Sequences are shown with the 
random region in bold. A1, A3, and A4 were selected fully rationally. A178749 was selected completely 
randomly. A10 and A3492 were partly rational and partly random. A0 is a poly-T control sequence. 
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other very similar abundant sequences in the pool, adding confidence to the decision to 
select these. 
 While choosing sequences from the list rationally, such as by read count, would 
seem to improve the odds of finding high-affinity sequences, some sources indicate that 
using read count or other statistical metrics does not lead to better results than choosing 
sequences randomly from the sequence pool.100, 113 Therefore, increasing amounts of 
randomness were introduced while selecting the final three sequences. First, from the 
remaining clusters containing 10 or more sequences, one cluster was chosen randomly and 
the highest abundance sequence was selected for characterization (A10). Additionally, one 
sequence was chosen randomly from among the approximately 4,200 sequences with a 
read count of two or higher (A3492). Finally, one sequence was chosen randomly among 
all sequences in the aptamer pool of roughly 380,000 (A178749). An additional control 
sequence was synthesized with a poly-T random region (A0) intended to display little 
secondary structure or binding. 
3.4.3 Affinity of selected aptamers 
  The affinity of each of the selected aptamers, along with A0 and the initial random 
library, was evaluated by FP and CE (Table 3.3). For FP assays, the uncorrected fraction 
bound was calculated with Equation 1.10 using (PB – P0) = 100, since the theoretical 
polarization value of the fully bound condition was unknown. Hopes were high that FP 
would provide reliable data given the strength of the fit for the selection rounds. However, 
Aptamer (Kd, nM) FP CE (subtractive) CE (ratiometric) 
A1 15.7 ± 8.8 >250 5.5 ± 1.8 
A3 >250 132 ± 19 -- 
A4 >250 16.4 ± 1.9 -- 
A10 2.4 ± 8.7** 107 ± 39 -- 
A3492 160 ± 600** >250 >250 
A178749 >250 >250 -- 
A0 >250 >250 -- 
Library 266 ± 67 (n = 3) 108 ± 18 -- 
Table 3.3: Measured affinity of selected aptamers for LDLR by FP and CE. For each sequence, the Kd 
reported is calculated from a single assay (unless specified with “n=”) with samples measured in triplicate. 
The error reported is the standard error in Kd calculated from the fit, or the root mean square of each 
standard error for n>1. (**) indicates that the fit converged but was questionable due to poor fit (R2<0.5). 
“>250” indicates that the fit did not converge, or that the CE fit was rejected due to low absolute signal 
change (Bmax<0.3). (--) indicates that the ratiometric calculation was not performed. 
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the FP data for some of the aptamers showed no visual trend nor convergence of the fit 
(Figure 3.7A). Because 250 nM was the highest concentration of LDLR tested for many of 
the FP assays, the Kd for all of these cases is listed as “>250 nM.” Additionally, some of 
the cases that converged did so with a poor fit (low R2) that accounts for little of the 
observed variation. For sequences with R2<0.5, the Kd is listed in Table 3.3 but marked as 
questionable. While it is important to remember that FP commonly yields false negative 
binding data for aptamer systems due to propeller motion (section 1.4.2), there is no way 
to tell from FP data alone when this is the case. Only aptamers A1 and A10 showed possible 
high affinity by FP, though A10 binding is questionable due to low R2. A1 showed the 
highest Bmax of the aptamer sequences tested and displayed a Kd of 15.7±8.8 nM, nearly a 
17-fold improvement over the starting library. FP binding curves and fit parameters are 
shown in the Appendix (Figures A.1 and A.2). 
 For CE assays, the uncorrected fraction bound was calculated by Equation 1.11 
using the free DNA peak height. Evaluation of Equation 1.11 using total peak area did not 
converge for any aptamer, which is unusual. Closer inspection of the data showed that the 
total peak area unexpectedly increased with increasing [LDLR], either initially or 
throughout, even in cases where peak height decreased. However, free DNA peak height 
data provided a much better fit than total area and was used to calculate the Kd in the 
Figure 3.7: Example aptamer FP affinity assays with no convergence or questionable convergence. Error 
bars indicate standard deviation of at least three replicate measurements for each sample. (A) A3’s signal 
seems largely random and actually trends downward at high [LDLR], leading to non-convergence. (B) 
While the red fit line is shown for the A10 data, its low R2 (0.097) indicates a poor fit that accounts for 
little of the observed variation. Additionally, Bmax is barely over 0.15 while most of the individual points 
have standard deviations above 0.15.  
A) B)















































subtractive case. Compared to FP results, the relative standard error of replicate 
measurements of the CE data was significantly lower, leading to increased R2 and much 
more visually credible fit data. There was also a solid fit for more aptamers, though it is 
unclear if this is due to superior reproducibility or to physical differences in the techniques. 
For A1 and A3492, where the CE traces showed obvious changes in peak shape (Figure 
3.8), the data was also evaluated by the ratiometric calculation using Equations 1.12 and 
1.13. 
 Unfortunately, issues with the instrument led to unreproducible current at high 
protein concentrations, limiting our ability to increase the maximum LDLR concentration 
to more appropriate levels. Possibly because of this, some aptamers displayed a very small 
overall decrease in peak height, which frequently coincided with large relative error bars. 
While it is rare to see the peak completely disappear at high protein concentration, we 
would expect to see the free peak intensity decrease by 30-50% or more (corresponding to 
a Bmax of 0.3-0.5) in the event of binding. Therefore, CE fit data with Bmax<0.3, such as for 
A178749 with Bmax = 0.08, was deemed inconclusive and ignored. These aptamers were 
treated the same as data with no fit convergence and are listed as “>250 nM.” All CE 
binding curves and fit parameters are shown in the Appendix (Figures A.3 and A.4) 
 Aptamer A1 showed the best affinity by CE, 5.5±1.8 nM by ratiometric area percent 
(Figure 3.9A). This is a 20-fold 
improvement over the library CE data, 
which is in strong agreement with the 
high affinity measured by FP. A4 was 
close behind at 16±2 nM by height 
(Figure 3.9B). Interestingly, the 
measured Kd of the library was much 
lower by CE (108 nM) than by FP (266 
nM), though again it is unclear if this 
stems at all from the larger uncertainty 
























Figure 3.8: Example of CE peak shape change indicative 
of binding. CE traces are shown for A1 with no LDLR 
(solid) and 250 nM LDLR (dashed). The high-LDLR 
sample exhibits a distinct shoulder due to dissociated 
complex DNA not present in the LDLR-free sample, 
indicating that the ratiometric calculation should be used. 
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registered affinity by CE but had Kd values closer to that of the random library. Overall, 
some aptamers exhibited evidence of strong affinity, with A1 displaying around 15- to 
20-fold improvement by both assays. However, additional affinity data, through repeated 
trials, higher LDLR concentrations, or new affinity techniques, will be required in order to 
draw more specific conclusions. 
 
3.5 Conclusions 
 In summary, aptamers were selected by CE-SELEX against an untruncated 
membrane protein target in free solution, an accomplishment that has not been seen in the 
literature to our knowledge. The significance of this method lies in its ability to be 
generalized to any membrane protein target, even one that cannot be easily truncated or 
immobilized. Considerable time was devoted to optimization of the CE selection platform 
to create a representative LDLR target and to improve the likelihood of obtaining aptamers 
useful for a variety of applications. CE was found to be amenable to the uncharged C12E8 
micelle system for LDLR stabilization, as well as to elevated temperatures and somewhat 
increased NaCl concentrations to mimic physiological conditions, but the glycerol often 
used to stabilize commercial membrane proteins was highly deleterious to the CE 
separation. 
 High-throughput sequencing demonstrated that the aptamer pool was extremely 
heterogeneous, which has been documented before for CE-SELEX. Three sequences were 
chosen for further characterization based on read count ranking and sequence clustering, 
Figure 3.9: Plots of fraction bound by CE for (A) A1 and (B) A4. Error bars indicate standard deviation 
of at least three replicate measurements for each sample.  
A) B)








































Kd = 5.5 ± 1.8 nM
A4
Kd = 16.4 ± 1.9 nM
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while three were chosen from the pool more randomly. The aptamers, along with a control 
sequence and the starting library, were assayed by CE and FP to determine their Kd for 
LDLR. Two aptamers, A1 and A4, were found to have Kds below 20 nM, a significant 
improvement over the control and starting library. The data also suggest that, in this 
instance, the aptamers chosen rationally outperformed those chosen randomly. 
Unfortunately, a significant amount of the FP affinity data was difficult to interpret due to 
poor reproducibility of the instrument. On top of that, the many negative binding results by 
FP are inconclusive given that false negatives due to propeller motion are common with 
aptamers. More binding data, through further trials as well as new techniques like 
isothermal titration calorimetry (ITC), is needed to make more accurate and sweeping 
conclusions about the individual aptamers. In addition, cell studies are needed to evaluate 
transport of aptamers across the membrane. 
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 The prevalence of obesity worldwide continues to increase, even amid growing 
public health campaigns, expanded treatment options, and improved scientific 
understanding of the disease.173 This is a problematic trend given that obese individuals are 
at increased risk for a variety of other serious medical conditions including cardiovascular 
disease and cancer.174 One of the key molecular players in obesity is leptin, a protein 
generated by adipocytes (fat cells) that helps control hunger and balance energy 
expenditure in the body. While the long-term relationships between leptin and obesity have 
been explored, the main tools used to study leptin levels, such as ELISA assays, are not 
suited to deal with faster leptin variation in response to specific metabolic stimuli.  
 One way to measure these faster variations is a proposed microfluidic system able 
to quantify leptin secretion from cultured adipocytes in real time. The system combines a 
flow cell to perfuse adipocytes and collect cell secretions, online incubation with a 
fluorescent leptin-specific aptamer, and micro-free flow electrophoresis (μFFE) separation 
to partition and quantify free aptamer and leptin-bound aptamer, allowing for calculation 
of leptin concentration. Aptamers present the ideal affinity tag in this scenario due to their 
efficient separation by electrophoretic modes, though an aptamer with high and consistent 
affinity will allow more accurate quantification. The work herein describes evaluation of 
existing leptin-targeting aptamers and progress toward selection of new aptamer sequences 
for leptin for use in the proposed microfluidic system. 
 
4.2 Introduction 
4.2.1 Obesity and leptin 
 Obesity, taken simplistically, is caused by an imbalance between energy intake via 
food and energy expenditure via physical activity, leading to excess accumulation of 
adipose deposits (fat tissue) around the body. Far beyond the related cosmetic effects, 
obesity is a serious health condition associated with increased rates of type 2 diabetes, 
cardiovascular disease, stroke, severe symptoms of COVID-19, some types of cancer, 
depression, sexual health issues, digestive and pulmonary issues, and more.173-179 For such 
a serious issue with a seemingly simple solution – eat less and exercise more – it stands to 
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reason that overweight and obesity should be decreasing as public awareness of the disease 
and its impacts grows. However, nothing could be further from the truth. Since 1980, the 
rate of obesity has doubled among American adults and tripled among children.175 As of 
2018, 13% of the world adult population is obese, with the age-adjusted prevalence 
exceeding 40% in the United States (Figure 4.1).180-183 The disease’s continued growth is 
a clear illustration of the many hidden complexities of obesity. Adding to the complication 
of studying and treating obesity is the sheer number of factors that play a role in obesity: 
genetic factors, socioeconomic status, race, age, gender, mental health status, and 
numerous environmental factors show significant differences in rates and outcomes of 
obesity on a group level, not to mention differences in personal behavior and habits based 
on everything from family and regional differences to cultural and religious identity.173, 184-
186 Untangling these many factors is quite difficult, which means that observational and 
correlational research studies are relatively limited in their conclusions and 
recommendations for specific interventional strategies. For this reason, methods for 
studying obesity from a molecular and mechanistic approach are of increasing importance. 
 One molecule of particular interest to the study of obesity is leptin, a protein 
secreted by adipocytes. The discovery of leptin in 1994 is largely responsible for the 
realization that adipose tissue plays an active role in endocrine signaling rather than just 
Figure 4.1: Trends in age-adjusted obesity and severe obesity prevalence among U.S. adults aged 20 and 
over: 1999 through 2018. Obesity is defined as individuals with a body mass index (BMI) of 30 or higher. 
Severe obesity is defined as individuals with a BMI of 40 or higher. Adapted from Hales et al.183 
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passive energy storage.187 The most important role of leptin is to regulate energy balance 
by decreasing both food-seeking behaviors and feelings of hunger.188 Serum levels of leptin 
increase exponentially with body fat, normally causing the individual to decrease food 
intake when the body has sufficient fat stores.189, 190 However, most obese individuals 
continue to display normal eating habits despite exhibiting four-fold higher serum leptin 
levels than do those of healthy weight, suggesting a mechanism of leptin resistance that 
impairs normal leptin-based energy regulation.191-193 While long-term trends in leptin 
relative to body weight and obesity have been well established, and intermediate trends 
such as those in response to sleep or fasting have been explored, little is known about the 
short-term trends and effects of leptin levels at a sub-30 minute time scale.189, 191, 194-196 A 
more comprehensive temporal understanding of leptin secretion in response to specific 
metabolic stimuli, such as artificial sweetener consumption, is needed in order to provide 
a complete picture of leptin signaling and yield answers about leptin and obesity that have 
so far evaded elucidation.  
4.2.2 Leptin measurement by perfusion and online micro-free flow electrophoresis 
 In research and some clinical settings, leptin concentrations are most frequently 
measured using ELISA kits,197-204 radioimmunoassays,205-208 or mass spectrometry.209, 210 
These techniques are highly reproducible, and some are well suited to parallel detection of 
multiple analytes, but they are all time-consuming and labor-intensive. Because of this, 
they are not well suited to make the type of repeated or continuous measurement necessary 
to scrutinize immediate responses and short-term trends in leptin secretion. One method 
ideally suited to quick measurement is micro-free flow electrophoresis (μFFE), a technique 
which continuously streams sample through a wide channel and uses an electric field to 
deflect analytes based on their electrophoretic mobility.108, 211, 212 μFFE devices can be 3D 
printed for fast prototyping, and they are easily coupled to different sampling methods, 
detection schemes, and other online components to create a highly customized device for 
specific uses.213-218 
 In a device proposed by this research group, adipocyte-like cells are cultured in a 
small flow cell and perfused with buffer, which can be spiked with glucose, insulin, 
artificial sweeteners, or other metabolic stimuli. Analytes secreted by the cells (such as 
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leptin) are swept up in the continuous buffer flow and carried downstream where they are 
mixed with fluorescently labeled aptamer with a known affinity for leptin. A sufficiently 
long incubation tube or channel allows sample leptin and fluorescent aptamer to reach 
binding equilibrium before the sample flows into the μFFE separation channel. Free 
aptamer and the leptin-aptamer complex are pushed down the channel by the buffer flow 
and separated laterally in a continuous manner by electrodes on either side of the channel. 
The quantities of bound and free aptamer are measured by LIF, and the ratio is used to 
calculate the amount of leptin present using Equation 1.7 and the known aptamer affinity. 
The main parts of the proposed assay are shown in figure 4.2. 
4.2.3 Leptin aptamer characterization and selection 
 Research regarding the construction and optimization of the flow cell and μFFE 
device proceeded independently at the hands of other researchers. Instead, the work here 
Figure 4.2: Outline of proposed aptamer-based real-time leptin quantification system. Mixing: A basic 
buffer, with or without a metabolic stimulus (such as glucose or insulin), is perfused over adipocyte-like 
cells, stimulating cells and collecting secreted leptin. The outflow is mixed with a known concentration of 
leptin-targeting aptamer. Incubation: The sample travels through a sufficiently long incubation tube or 
channel to reach binding equilibrium. This region could be temperature controlled if needed. Separation: 
Sample is streamed continuously onto a μFFE chip. Buffer flow pushes the sample down the channel while 
electrodes on either side separate bound (B) and free (F) aptamer laterally. Detection: Once separated, the 
bound (B) and free (B) aptamer peaks are each quantified by LIF. Due to the continuous separation, the rate 
of collection is limited only by the detector. Calculation: For each time point, the peak intensity of bound 
and free DNA are used to determine the proportion of aptamer complexed, from which the leptin 





















focuses solely on progress toward a well-characterized, selective, high affinity aptamer for 
leptin required for successful functioning of the proposed microfluidic device. 
 Plans for the device center around the use of adipocyte-like cells differentiated from 
3T3-L1 cells, with which our group has extensive experience. While these cells are a 
commonplace in the study of obesity as it pertains to humans, 3T3-L1 cells are mouse-
derived cells rather than a human cell line. This made it clear, therefore, that preliminary 
work would require aptamers against mouse leptin rather than human leptin. Efforts were 
made to find aptamers in the literature that could fill our requirements, thereby saving the 
time and cost of independent aptamer selection. While aptamers against mouse leptin with 
a published sequence were absent from the literature, a publication by Ashley and Li219 
indicated the sequences of multiple aptamers against human leptin from their research. 
Aside from targeting human rather than mouse leptin, these aptamers seemed ideal for our 
uses: the aptamers were found by CE-SELEX, which reduced any fears of negative impact 
from the electric field in the μFFE chip; the selection used free rather than immobilized 
leptin, which matched the anticipated usage; and the sequences had already been selected 
with the appropriate 5’ fluorescent tag for this work. Given that some antibodies display 
affinity for both human and mouse leptin,220 coupled with a 93% sequence similarity 
between the two, it seemed worth further investigation of these literature aptamers despite 
their different initial target. 
 The work in this chapter begins with measurement of the affinity of two of the 
literature aptamers (Lep2 and Lep3) for mouse leptin in order to assess its feasibility in the 
proposed microfluidic assay. Next, progress is demonstrated toward a new CE-SELEX 




 Nuclease-free water (nfH2O) was obtained from Ambion (Austin, TX). A set of 
four deoxynucleoside triphosphates (dNTP, 100 mM) was obtained from Denville 
Scientific (Metuchen, NJ). Agarose powder, glacial acetic acid, and NaHCO3 were 
obtained from Fisher Scientific (Waltham, MA). Molecular biology grade 3-(N-
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morpholino)propanesulfonic acid (MOPS) was obtained from Fluka (St. Lous, MO). D-
glucose was obtained from Gibco (Waltham, MA). All DNA libraries and sequences were 
obtained from Integrated DNA Technologies (Coralville, IA). The DNA sequences were: 
5’-6FAM-AGC AGC ACA GAG GTC AGA TG-N40-CCT ATG CGT GCT ACC GTG 
AA-3’ (library), 5’-6FAM-AGC AGC ACA GAG GTC AGA TG-3’ (sense primer), 5’-
Biotin-TTC ACG GTA GCA CGC ATA GG-3’ (antisense primer), 5’-6FAM-CTT CTG 
CCC GCC TCC TTC CTG GGT GGC CTC CCG TTT ATT CGA GAT TTG GTT GAA 
TTT GTG GAG ACG AGA TAG GCG GAC ACT-3’ (FAM-labeled Lep2), and 5’-6FAM-
CTT CTG CCC GCC TCC TTC CGT TAA TGG GGG ATC TCG CGG CCG TTC TTG 
TTG CTT ATA CAG GAG ACG AGA TAG GCG GAC ACT-3’ (FAM-labeled Lep3). 
KH2PO4 was obtained from J.T. Baker Inc. (Phillipsburg, NJ). NaOH powder was obtained 
from Macron Chemicals (Radnor, PA). Hyperladder DNA ladder (25-base) was obtained 
from Bioline Reagents (Cincinnati, OH). Boric acid powder, CaCl2, KCl, and MgCl2 were 
obtained from Mallinckrodt Pharmaceuticals (St. Louis, MO). Taq polymerase and 
accompanying ThermoPol buffer were obtained from New England Biolabs (Ipswitch, 
MA). Tris(hydroxymethyl)aminomethane (Tris) was obtained from Roche Applied 
Science (Penzberg, Germany). Recombinant mouse leptin (≥98%), NaCl, glycine, 
rhodamine 110 (R110), ethidium bromide, disodium ethylenediaminetetraacetic acid 
(EDTA), disodium fluorescein, and Tris∙HCl were obtained from Sigma-Aldrich (St. 
Louis, MO). MgCl2 solution (25 mM) and streptavidin-coated agarose resin were obtained 
from Thermo Scientific (Waltham, MA). 
4.3.2 Buffers and solutions 
 (1) CE running buffer (pH 7.5) contained 3.6 mM Tris and 16.4 mM Tris∙HCl (20 
mM Tris total), 5 mM KCl, 10 mM NaCl unless otherwise specified, 5 mM glucose, and 
1.8 mM NaHCO3. (2) Sample buffer (pH 7.5) was prepared in nfH2O and contained 3.6 
mM Tris and 16.4 mM Tris∙HCl (20 mM Tris total), 5 mM KCl, 30 mM NaCl unless 
otherwise specified, 1 mM CaCl2, 5 mM glucose, and 1.8 mM NaHCO3. (3) PCR master 
mix was prepared fresh for each use in nfH2O and contained 540 nM FAM-labeled sense 
primer, 540 nM biotin-labeled antisense primer, 216 nM each dNTP, 8.1 mM MgCl2, and 
1.08× ThermoPol buffer. (4) TBE buffer for gel electrophoresis contained 45 mM tris, 45 
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mM boric acid, 50 mM EDTA. (5) Purification buffer was prepared in nfH2O and contained 
10 mM tris, 50 mM NaCl, 1 mM EDTA. (6) TGK (1×) for literature leptin aptamer 
experiments contained 25 mM Tris, 192 mM glycine, 5 mM KH2PO4, and was adjusted to 
pH 8.3 with HCl. 
4.3.3 CE equipment and protocols 
 All CE work was performed on a P/ACE MDQ (Beckman-Coulter) or P/ACE 
MDQ-Plus (SCIEX) automated CE instrument using 32 Karat data collection software. 
Uncoated fused silica capillary of 50-μm inner diameter and 360-μm outer diameter was 
used throughout, cut to 39.7 cm total length with a detection window (2-5 mm wide) burned 
29.5 cm from the inlet. CE sample storage and capillary temperature were set to 25˚C. 
Rinses used 20 psi forward pressure and sample injections were made with 10 s of 0.5 psi 
forward pressure. Before first use, unless otherwise specified, new capillaries were rinsed 
with 0.15 M NaOH for 3 min, rinsed with nfH2O for 3 min, rinsed with running buffer for 
at least 15 minutes, and allowed to equilibrate with running buffer for at least one hour. 
The capillary was rinsed with running buffer for 5 min between runs and for 10 minutes at 
the start and end of each day. LIF detection (488 nm excitation/520±10 nm emission) was 
used unless otherwise specified. 
4.3.4 SELEX separation 
 DNA was heated at 72˚C for 5 minutes and cooled before use. For each round of 
SELEX, a 20-μL sample containing 2 nM leptin and DNA in sample buffer was incubated 
at 25˚C for 20 minutes before selection. The first round used 100 μM random library DNA 
while each subsequent round used half of the purified DNA from the previous round to 
make the sample as concentrated as possible. The sample was separated by CE at 30 kV 
into a collection vial containing roughly 50 μL of sample buffer. Unless otherwise 
specified, the separation was manually stopped 10 seconds before the free DNA peak 
reached the end of the capillary (calculated from the electropherogram and the capillary 
dimensions). The separation was repeated 2-3 additional times into the same collection 
vial. 
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4.3.5 PCR and gel electrophoresis 
 PCR samples were prepared with 92.5 μL master mix, 7.0 μL of DNA sample, and 
0.5 μL (2.5 units) Taq polymerase, with Taq polymerase being added once the sample 
reached 94˚C. Each PCR experiment was run with at least one positive control (DNA 
sample = 50 pM random DNA library) and at least one negative control (DNA sample = 
nfH2O). The thermocycler performed 25 rounds of 94˚C (30 s), 53˚C (30 s), and 72˚C (20 s) 
sequentially, followed by a final 10 minutes at 72˚C and storage at 4˚C.  
 Gel electrophoresis was performed on all non-identical PCR samples (including 
PCR controls) to verify amplification and check for contamination. A 1.5% or 2% w/v 
agarose gel  made with TBE and 100 μg of  ethidium bromide was run in TBE buffer at 
200 V for 40 min. Gels were imaged on an ultraviolet transluminator with a Canon 1300d 
DLSR. 
4.3.6 DNA purification 
 In a 10-mL affinity chromatography column, 300 μL of streptavidin-coated agarose 
resin and 500 μL of purification buffer were vortexed and then flushed. PCR-amplified 
sample DNA and 100 μL of purification buffer were introduced to the column and 
incubated at room temperature, vortexing periodically. The column was then flushed with 
5 mL of purification buffer. The column was then incubated at 37˚C with 200 μL of 0.15 M 
NaOH, vortexing periodically, and eluted into equimolar acetic acid. This NaOH 
incubation and elution was repeated into the same collection. The collected sample was 
spun in a 10-kDa centrifugal filter, rinsed with nfH2O, spun again, and collected in two 
clean microcentrifuge tubes, which were vacuum centrifuged to dryness at 50˚C then stored 
frozen. 
4.3.7 Affinity measurement 
 DNA was heated at 72˚C for 5 minutes and cooled before use. CE and FP samples 
were prepared containing 20 nM random library or approximately 20 nM aptamer pool 
with 0-16 μM leptin in sample buffer, or 10 nM literature aptamer sequence with 0-40 μM 
leptin in 1× TGK. Samples were incubated at 25˚C for at least 20 minutes before 
measurement. 
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 For CE measurement, samples were separated using 30 kV and 0.3 psi of forward 
pressure, and the peak height and area the free DNA peak and complex peak (if present) 
were recorded. CE running buffer was used unless otherwise specified. The leptin-free 
sample was separated multiple times until the free DNA peak settled (see Figure 4.2) and 
three consecutive measurements with less than 5% RSD in height or area were obtained. 
Samples were measured in triplicate from lowest to highest protein concentration. The 
uncorrected fraction bound for each concentration was calculated subtractively (Equation 
1.11) for all assays and ratiometrically (Equations 1.12 and 1.13) where appropriate. 
 FP measurements were performed on a BioTek Synergy 2 (Agilent) plate reader 
using 20-μL samples in an opaque 384-well plate. Measurements were made at 25˚C using 
a tungsten lamp (485±10 nm excitation/528±10 nm emission). Polarization values were 
measured in triplicate for all samples simultaneously with a 5-second mix between each. 
The uncorrected fraction bound for each concentration was calculated by Equation 1.10. 
 For CE and FP experiments, the Kd for each aptamer or pool was calculated in 
Origin 9.6 by fitting the triplicate uncorrected fraction bound data to a custom fit equation 
(Equation 1.8) with the constraints Kd > 0 and Bmax > 0. 
 Isothermal titration calorimetry (ITC) measurements were performed on a TA 
Instruments Nano ITC. Solutions of 75 μM leptin aptamer and 10 μM mouse leptin, each 
in 1× TGK, were degassed under vacuum immediately prior to measurement. The leptin 
sample was stirred at 400 RPM and kept at 25˚C throughout, and 250 μL of aptamer 
solution was delivered over 16 injections, 30 seconds each and 5 minutes apart. A reference 
cell of degassed deionized water was used. Aptamer Kd was calculated automatically by 
the instrument software NanoAnalyze. 
 
4.4 Results and Discussion 
4.4.1 Affinity of literature leptin aptamers 
 At the time of writing, only a single paper by Ashley and Li219 indicated any leptin 
aptamers with a published sequence. The aptamers seemed like a possible fit for the project 
but had been selected against human leptin, which has only 85% identity with and is a 93% 
positive match for mouse leptin. Two literature aptamers with the strongest reported 
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binding (Lep2 and Lep3) were synthesized in order to assay their affinity for mouse leptin. 
While the intention was to eventually tailor the selection buffer to more closely match the 
conditions seen in the proposed device, in this case affinity measurements were made using 
1× TGK, the buffer used for selection of Lep2 and Lep3, in place of sample buffer and CE 
running buffer in order to maximize the chance of binding. 
   FP experiments were performed first due to ease and speed, but the fit data did not 
converge for either aptamer. As explained in section 1.4.2, false negative FP binding results 
can arise due to propeller motion of the fluorescent tag, which seems likely in this case due 
to leptin’s small relative size. However, both CE and ITC data (Table 4.1) demonstrate a 
significant difference from the literature data for human leptin, with CE showing over ten-
fold lower affinity. Additionally, non-equilibrium capillary electrophoresis of equilibrium 
mixtures (NECEEM) affinity analysis, though similar in some respects to ratiometric CE 
analysis, requires quantification of the complex peak. No complex peak was observed in 
our CE experiments, even at high leptin concentration, further corroborating the lower 
affinity we observed. Overall, Lep2 and Lep3 exhibited relatively poor affinity for mouse 
leptin, indicating they did not lend themselves well to the proposed assay. For this reason, 
we moved forward with the plan to perform CE-SELEX in house against mouse leptin 
under conditions optimized for the proposed assay. 
4.4.2 Optimization 
 Optimization of SELEX conditions is always a compromise between conditions 
similar to future applications (for the sake of representative conformation and binding) and 
conditions that simplify the 
selection and affinity measurement 
process. Unlike in Chapter 3, the 
future application for these 
aptamers is known quite 
specifically, meaning that the 
balancing act could be weighed 
much more precisely. Preliminary 
work with the 3T3-L1s in the flow 
 
Assay type Lep2 Kd (μM) Lep3 Kd (μM) 
FP >40 >40 
CE (height) 33 ± 10 22 ± 8 
ITC 5.3 ± 2.1 2.4 ± 1.2 
NECEEM* 0.41 ± 0.13 0.32 ± 0.50 
Fluorescence* 1.18 ± 0.39 1.50 ± 0.25 
Table 4.1: Measured affinity of Lep2 and Lep3 aptamers for 
mouse leptin by multiple techniques. FP data did not converge, 
suggesting either very low affinity or a false negative due to 
propeller motion. Both CE and ITC results demonstrate a lower 
than ideal affinity for use in this research. Techniques with (*) 
were performed by Ashley and Li219 using human leptin and are 
shown for comparison. 
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cell prototype indicated that they were tolerant of perfusion with a buffer based on Ringer’s 
solution, so the SELEX optimization was performed assuming this media for future 
perfusion. Ringer’s is designed to be isotonic for mammalian physiology, and our perfusion 
buffer contained the 120 mM NaCl, 5 mM KCl, and 1 mM CaCl2 typical of Ringer’s as 
well as 1.8 mM NaHCO3 for pH control and 5 mM glucose to maintain basal metabolic 
activity. Conveniently, these KCl and CaCl2 concentrations are similar to common SELEX 
buffers to facilitate G-quadruplex formation and backbone bridging, respectively (such as 
in Chapter 3). The bicarbonate and low glucose concentrations were not expected to 
negatively impact the sample buffer, though additional buffer capacity would be needed to 
maintain pH and avoid redox acidification. The main predicted issue was the 120 mM 
NaCl. As explained previously (section 3.4.1), ionic strength in the running buffer must be 
relatively low to avoid excessive instrument current, and the ionic strength of the sample 
buffer cannot significantly exceed that of the running buffer to avoid poor peak shape due 
to sample destacking. 
 Buffer compounds tris, HEPES, and MOPS (chosen for their pKa near 7.5) were 
tested in the initial stages to see if one was preferable, and tris was chosen due to good 
DNA signal and frequent use in SELEX buffers. Further CE optimization was performed 
with 20 nM random DNA using the sample and running buffers specified in section 4.3.2 
but both with 10 mM NaCl. Optimization proved more difficult than expected due to poor 
reproducibility of the free DNA peak, with peak time varying substantially from day to 
day, and peak height frequently changing both randomly and systematically over the course 
of several runs. An internal standard of 2 nM fluorescein or 4 nM R110 was added to the 
sample to see if this could correct for peak size (for better quantification during affinity 
measurements), but no significant changes were seen in the internal standard (Figure 4.3). 
Internal standards are typically used to correct for imprecision in sample preparation, 
injection volume, or detector sensitivity, but the impressive consistency of the fluorescein 
peak suggested that the primary cause of the DNA peak size inconsistency was none of 
these and in fact due to a DNA-specific (or at least small molecule-independent) effect. 
After a number of runs, the DNA peak height and time seemed to settle somewhat and the 
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large systematic changes lessened 
noticeably, although the uncertainty in DNA 
peak height was still significantly greater 
than those of fluorescein or R110. The 
number of runs required for the DNA peak 
to settle (determined by three consecutive 
peaks within 5% peak height or area) 
seemed to vary from a dozen or more for a 
new capillary to 2-5 for a well-worn one. 
Peculiarly, the peak did not always settle to 
a similar final value, and on occasion the 
peak height increased rather than decreased 
to settle on its final value. This effect 
seemed to depend on the number of injection runs and not on any time factor (though 
overall inconsistency made it difficult to determine for sure), so it was speculated that the 
systematic effect was somehow due to DNA or Ca2+ interaction with the capillary wall. 
 Ten millimolar NaCl was not expected to be the optimized concentration for the 
running buffer, but this buffer already gave a current of 60 μA, similar to that seen 
Chapter 3. Because these runs were over twice as long as the LDLR runs (redox changes 
are a product of current and separation time) and they already displayed significant 
run-to-run variation, the running buffer was left at 10 mM to avoid increasing uncertainty 
or separation time. Increasing amounts of NaCl were added to the sample buffer while 
using the running buffer with 10 mM NaCl, and 30 mM NaCl was selected as the maximum 
usable concentration due to disruption of the DNA peak shape at higher levels. 
 While 30 mM NaCl is significantly lower than the 120 mM present in the perfusion 
buffer, it was decided that the aptamer solution could be mixed into the proposed device in 
a NaCl-free version of the buffer at a 1:1 or 2:1 ratio. This would lead to a final incubation 
solution in the device of 60 mM or 40 mM NaCl, respectively, which is much closer to the 
30 mM NaCl to be used for selection. This also allowed the SELEX experiments to be 


















Figure 4.3: Shifting DNA peak height in CE over 
the course of multiple runs. Ten separations were 
performed from a sample containing random DNA 
(circle, solid) and an internal standard of 
fluorescein (triangle, dashed). The DNA signal 
changed significantly, particularly early on, while 
the fluorescein showed <1% RSD in peak height, 
suggesting a DNA-specific issue. The DNA peak 
does seem to settle into a relatively consistent 
height  after multiple runs but still displays much 
greater uncertainty than the fluorescein peak, 
which was representative of DNA peak behavior. 
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4.4.3 CE-SELEX against mouse leptin 
 For the first round of selection, concentrated library DNA and 2 nM leptin were 
incubated for 20 minutes and then separated by CE to examine the behavior of the peak 
(Figure 4.4A), and a number of small peaks were observed before the main free DNA peak. 
This is a common occurrence, as minimal purification is performed on the random DNA 
to avoid biasing the library before selection. Additionally these early peaks typically 
disappear after the first round of amplification, suggesting that the species that cause them 



















































































Figure 4.4: Peak times and collection windows for leptin CE-SELEX. (A) The LIF trace of the first round 
of selection displayed multiple early peaks, so different collection windows (C1-C3) were tried. Note that 
this sample has maxed the detector. (B) The round 2 selection trace did not display any early peaks, though 
the main peak was much later. The end of the collection window is shown (arrow). (C) A UV trace (200 
nM) of leptin shows an early detector time (as expected) of 1.6 minutes. All traces (A-C) are plotted on the 
x-axis shown here. (D) Agarose gel electrophoresis was performed on test PCR conditions using multiple 
dilutions of each different collected sample.  The gel shows that the DNA collected in C3 was sufficient 
for amplification (at full concentration) but substantially less than in C1 and C2. 
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the early peaks were somewhat larger and more spread out than usual, extending into the 
expected location of the complex peak (roughly 3-4 minutes). Because of this, additional 
flexibility was built into the first round by using three different time windows to collected 
during different runs and into different vials, each successively more stringent (Figure 
4.4A). Each collection window was picked to correspond roughly to a different local 
minimum, and separation was stopped manually when the end of the collection window 
reached the end of the capillary, calculated by multiplying the electropherogram time by 
the ratio of the full capillary length to the inlet-to-window length (1.357). The different 
collected samples were amplified by PCR at multiple dilutions to check for the presence of 
appropriate DNA (Figure 4.4D). As expected, the longer window (C1) collected a larger 
amount of amplifiable DNA than the stringent C3 window. However, C3 still collected 
enough DNA for maximal amplification at its highest concentration (Figure 4.4D, “C3 
(1×)”), and it was expected that more generous collection would only serve to increase the 
proportion of unwanted free DNA in the sample. Therefore, C3 was used for full 
amplification to generate the pool for the next round. 
 As expected, the early peaks were entirely absent from future rounds of selection, 
confirming that they were from species that were not efficiently amplified during PCR. 
Interestingly, the later rounds of SELEX seemed to have the free DNA peak somewhat 
later than in round 1 (Figure 4.4B), though there was still enough variation in peak time 
from day to day to make this determination less confident. In the second round of selection 
onward, the end of the collection window was 10 seconds before the beginning of the free 
DNA peak reached the detector. The start of the peak was defined as two consecutive time 
points more than 10% above the baseline intensity. Four rounds of selection were 
performed. 
 The Kd of each pool and the starting library were measured by FP, but as with Lep2 
and Lep3, there was no fit convergence for any of the samples measured. Even looking at 
the FP plots (Appendix, Figure A.5), there was no qualitative difference between the pools. 
The first CE affinity assay with random library showed the emergence of an apparent 
complex peak (Figure 4.5, A2), which was welcome since ratiometric quantitation with the 
free and complex peak would serve to reduce some of the error due to peak size uncertainty. 
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The fraction of signal in the complex peak was calculated ratiometrically using Equations 
1.12 and 1.13. While the complex peak grew in with increasing leptin concentration, the 
fraction bound increased quite linearly, which is indicative of a Kd higher than the largest 
ligand concentration used (16 μM). The affinity of the round 2 and round 4 pools were also 
evaluated by CE, but no complex peak greater than 1% was ever visible, and no trend was 
seen in the free DNA peak height or area (Appendix, Figure A.6). 
4.4.4 Estimation of complex mobility 
 In trying to understand the cause(s) of this unsuccessful selection, one possibility 
identified was that the collected sample from the CE separation did not contain a higher 
proportion of leptin-DNA complexes as intended. Indeed, the disappearance of the 
complex peak might suggest that these binding sequences were partially or completely 
excluded from the collected sample, accidentally selecting for sequences without affinity 
for leptin. A simple approximation of the electrophoretic mobilities of leptin and DNA in 
our system was performed in order to better estimate the location of the complex during 
selection, since it was not visible on the electropherogram. This would allow us to 
determine more clearly whether the complexes had been included in or excluded from the 
collected sample. New measurements of leptin, random DNA, and the neutral dye 
rhodamine 110 (R110) were taken on the same day to reduce the impact of day-to-day drift 
(Figure 4.6). 
Figure 4.5: Emergence of the complex peak in leptin-library affinity measurements. (Left) The free DNA 
peak (A1) remained relatively constant throughout, but a smaller peak (A2), assumed to be the complex 
peak became more prominent at higher leptin concentrations. (Right) The complex fraction, calculated 
from equation 1.12 using peak height, is shown. While the increase is expected, the linear rather than 
















































































 Calculation of leptin and DNA 
mobilities. As described in section 1.3.2, each 
analyte in CE experiences an apparent 
mobility (μapp, Equation 1.3)	that is the vector 
sum of its electrophoretic mobility (μEP) and 
its electroosmotic mobility (μEOF). μEOF acts 
through a bulk buffer flow and affects all 
analytes in the run equally, though its 
magnitude can drift because of its sensitivity 
to small variations in capillary surface 
chemistry and buffer conditions (Equation 
1.2). In CE, neutral compounds are unaffected by electrophoresis and migrate only under 
the effect of EOF, so R110 was used to measure the μEOF for these conditions. In the 
experiments shown in Figure 4.6, R110 took 67.5 s to reach the detector (295 mm from the 
inlet), yielding an electroosmotic velocity of 4.37 mm/s. All separations used 30 kV along 
a 397 mm capillary for an applied field (E) of 75.6 V/mm (Table 4.2). With the 
electroosmotic velocity and applied field known, the μEOF was calculated to be 
5.78×10-8 m2/V∙s by Equation 1.2 for the Figure 4.6 experiments. 
 In order the find the μEP for the free DNA, the net mobility was first calculated from 
Figure 4.6. DNA traversed the detector length of 295 mm in 168 s (2.80 min), 
corresponding to a net velocity 1.76 mm/s in the 75.6 6 V/mm electric field, or a net 
mobility of 2.32×10-8 m2/V∙s. Since net mobility is the sum of μEP and μEOF and the μEOF 
was found above, the μEP of the free DNA was calculated to be -3.46×10-8 m2/V∙s (Table 
4.2). The same strategy was applied for leptin, with its 70.2 s peak time (Figure 4.6), to 
find the μEP of -2.22×10-9 m2/V∙s. Note that both species have a negative μEP, indicating an 
electrophoretic force toward the inlet and opposite the EOF direction. 
 Estimation of hydrodynamic radii and complex mobility. The μEP for free DNA 
was used to estimate its hydrodynamic radius in our system using Equation 1.1.* For this 
 
* It should be noted that use of this equation makes a number of simplifying assumptions about the system. 
For example, Equation 1.1 is valid for a centralized point charge rather than a finite size particle with 
charge distribution. In addition, the equation considers only the nominal charge of the compound itself and 
Figure 4.6: CE comparison of R110, leptin, and 
free DNA. Neutral R110 was detected at 1.125 min 
(LIF), leptin at 1.171 min (UV), and the DNA at 
2.800 min (LIF). UV detection was performed at 
200 nm. 








approximation, the charge number of -82 (-1 per base and -2 for the carboxyfluorescein 
dye) was multiplied by the electron charge to find Q (1.31×10-17 C), and the viscosity of 
pure water at 25˚C (8.90×10-4 Pa∙s) was used for η since the solution was relatively dilute. 
This yielded an estimated hydrodynamic radius of 22.6 nm. The same strategy was 
employed for leptin using a charge number of -4.5. This value was calculated from the 
amino acid sequence221 for mature mouse leptin, including the disulfide bond, using Prot 
pi’s protein calculator at pH 7.5.222 This yielded a hydrodynamic radius of 19.3 nm for 
leptin.  
 	 Without specific a priori knowledge of the likely binding interaction, several 
assumptions were made about the hypothetical leptin-DNA complex to facilitate simple 
calculation. First, it was assumed that the net charge of the complex would be the sum of 
the net charge of free DNA and leptin, or a charge number of -86.5 at pH 7.5. Second, it 
was assumed that ssDNA, leptin, and the complex were roughly spherical, allowing their 
hydrodynamic volume to be calculated by 4/3πR3. This calculation yielded hydrodynamic 
volumes for free DNA and leptin of 4.86×10-23 m3 and 3.02×10-23 m3, respectively. Finally, 
it was estimated that the hydrodynamic volume of the complex would be the sum of the 
 
does not account for an excess of counterions within and surrounding the DNA structure. However, a 
number of factors justify the use of Equation 1.1. First, this analysis is performed in one direction (to 
predict species’ hydrodynamic radii) and then in the other (to predict complex mobility from its radius), 
suggesting that many inaccuracies from these assumptions will largely be nullified in the overall analysis. 
Second, a number of other assumptions are made throughout the estimation, such as the sphericality of the 
species or the additivity of volume on complexation, that are unavoidable and seem more significant in 
magnitude. Finally, more complex analyses that take more of these factors into account, such as the 
Smoluchowski expression or Manning electrophoresis equation, have more variables that are not known 
precisely and would therefore require additional assumptions or approximations in their use as well. Using 
the simplified equation increases the transparency and accessibility of this analysis. 
 
 μEP (m2/V·s) z R (nm) 
Free DNA -3.46×10-8 -82.0 22.6 
Leptin -2.22×10-9 -4.5 19.3 
Complex -3.11×10-8 -86.5 26.6 
 
E (electric field) = 75.6 V/mm Length = 295 mm η (viscosity) = 8.90×10-4 Pa·s 
Table 4.2: Summary of selected values for CE mobility calculations. Electrophoretic mobility (μEP), charge 
number (z), and calculated hydrodynamic radius (R) are shown for free DNA, leptin, and the theoretical 
DNA-leptin complex. The electric field strength (E), length of capillary to the detector, and solvent 
viscosity (η) used for calculation are also shown. 
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hydrodynamic volumes of free DNA and leptin.*  This led to a volume of 7.88×10-23 m3 
for the complex, corresponding to a hydrodynamic radius for the complex of 26.6 nm. 
Using the same calculations for Q and η	as above, the complex was calculated to have an	
μEP of -3.11×10-8 m2/V∙s by Equation 1.1. 
 Using the model to evaluate previous data. As mentioned previously, the drift in 
peak times is based almost entirely on variations in EOF resulting from slight changes in 
the capillary surface and/or buffer composition.223-225 Therefore, the value of μEOF was 
adjusted, keeping μEP values constant, to examine previous data. First, the library DNA 
affinity data collected by CE (Figure 4.5) had a free DNA peak time of 2.875 minutes, 
corresponding to a net mobility of 2.26×10-8 m2/V∙s. Keeping the free DNA μEP constant, 
the new μEOF was determined to be 5.72×10-8 m2/V∙s. Therefore, the net mobility of the 
complex for this run was the sum of its μEP and the run μEOF of 5.72×10-8 m2/V∙s, or 
2.62×10-8 m2/V∙s. This net mobility yielded a calculated peak time for the complex of 2.49 
minutes. This is somewhat close to the A2 peak (Figure 4.5) observed at 2.28 minutes which 
was believed to be the complex, but not as close as might be expected. There are two 
possibilities that could lead to this disparity. It could be that the A2 peak belonged to the 
complex but differed from the time calculated by the model. The small time difference 
between the R110 and leptin peaks in the initial calculation means that errors in peak time 
would be amplified through the calculation. Additionally, a number of assumptions and 
simplifications were made in the calculations (particularly of the complex radius). These 
factors could definitely have led to the 8% time difference observed. Alternatively, it could 
be that the A2 peak belonged to some fluorescent contaminant and not the complex. If the 
leptin sample was contaminated prior to sample preparation, the contaminant would be 
expected to increase linearly with leptin concentration, which matches with the trend 
observed (Figure 4.5). No fluorescent contaminant was observed previously or 
subsequently in the leptin stock, but this does not preclude a one-time contamination event 
leading to the results observed. 
 
* On one hand, this assumption overestimates the thickness of the hydration shell of the complex, leading to 
a calculated volume and radius that are too large. On the other hand, assuming that two roughly spherical 
molecules combine to form a larger sphere (rather than a more oblong shape) would underestimate the 
radius of the new complex. Without any knowledge of their magnitude or simple methods to correct them, 
these errors were considered to offset each other. 
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 Finally, the round 1 selection data (Figure 4.4) was examined to estimate the 
location of the complex band in order to determine whether the complexes were collected 
or not. Unfortunately, because the free DNA peak maxed the detector for this run, it is 
impossible to tell the exact peak time, but it was estimated visually to be in the range of 
5.6-6.1 minutes. Using the early end of the range, 5.6 minutes was equivalent to a net 
mobility of 1.16×10-8 m2/V∙s, necessitating a μEOF of 4.62×10-8 m2/V∙s. This μEOF 
combined with the complex μEP (-3.11×10-8 m2/V∙s) gave the complex a net mobility of 
1.52×10-8 m2/V∙s, corresponding to a peak time of 4.29 minutes. This is the earliest we 
would calculate the complex would reach the detector since using a higher estimate of the 
free DNA peak time (such as 6.1 minutes) would give rise to a lower μEOF and ultimately 
a later complex peak. The calculated 4.29 minutes is over one minute after the end of the 
collection window used in round 1 of selection (Figure 4.7), a significantly larger 
difference than observed in the library affinity data above. This essentially confirms that 
any DNA complexes were not collected in round 1. Even though the collection window 
was moved later in subsequent rounds, it is very likely that there were too few binding 
sequences at this point given their exclusion in round 1. This is consistent with the 
unsuccessful selection that occurred, as well as the possible complex peak observed in the  
affinity measurement of random library but not in subsequent SELEX rounds. 
 Fortunately, while the selection was unsuccessful, an incorrect collection window 
is a very easy problem to fix, highlighting the tunability of CE-SELEX. Additionally, the 
mobility model for this system developed above will allow more precise calculation of the 
Figure 4.7: Leptin SELEX round 1 collection window and calculated complex peak time. The 
collection window used (C3 in Figure 4.4) ends at 3.13 minutes, over one minute before the 
earliest expected complex peak time based on calculations. This is a clear indication that DNA-
leptin complexes were not collected during the round 1 selection as expected, likely the cause of 




































0 min – 3.13 min
Complex peak (calc)
4.29 min – 4.58 min
 80 
complex peak location regardless of daily changes in the EOF to avoid these issues in the 
future. However, if the collection window is moved later, the issue of collecting the 
unwanted early library peaks becomes more problematic. This can be solved by 
purification of the library before selection, such as by HPLC from the vendor or in-house 
pre-SELEX CE collection and amplification. Both introduce their own bias into the starting 
library, but cleaning up the peak and allowing much higher efficiency partitioning will 
likely outweigh this bias significantly. Another change that would help, with or without 
library cleanup, would be to increase the leptin concentration used in the first round of 
selection. The library unsurprisingly displays weaker affinity for leptin than for larger 
proteins like LDLR, so increasing the leptin concentration for the first partitioning would 
lead to collection of a much larger number of DNA complexes, hopefully overwhelming 
any unwanted DNA from the early peaks. 
 
4.5 Conclusions 
 To fill the need for near-real time measurement of leptin secretion in cultured cells, 
an aptamer-based microfluidic system was proposed combining cell perfusion, on-line 
aptamer incubation, and quantification by μFFE-LIF. However, a well characterized high 
affinity aptamer against mouse leptin is required before a prototype can be effectively 
tested. Due to the similarity between mouse leptin and human leptin sequences, two 
aptamer sequences against human leptin from the literature (Lep2 and Lep3) were ordered 
to test affinity against mouse leptin in preparation for use of 3T3-L1 cells in the proposed 
device, a common system for the study of obesity. Three techniques were used to quantify 
the affinity: FP, CE, and ITC. FP yielded no fit data whatsoever, though this is not 
surprising given the frequency of false negative results in studying aptamers due to 
propeller motion and large probe size.  CE and ITC both yielded results with high RSDs, 
but they suggested that our measured affinity for mouse leptin was significantly poorer 
than the affinity for human leptin that the authors demonstrated. 
 To begin CE-SELEX for new aptamers targeting mouse leptin, the sample buffer 
was adjusted only slightly from the Ringer’s-based buffer planned for cell perfusion. Out 
of necessity, the NaCl concentration was reduced about 4-fold, and the physiological buffer 
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tris was added to improve pH stability during running. Surprisingly, the DNA peak 
exhibited very poor time reproducibility from day to day and significant peak size variation 
even from one run to the next. Attempts were made to correct the peak size uncertainty 
with small molecule dyes, but the variation was not observed in either dye to the same 
extent, suggesting a DNA-dependent phenomenon. 
 The library DNA peak exhibited a number of early features preceding the main 
peak by several minutes, making determination of the collection window problematic. In 
the first round, three different collection windows were used in case insufficient DNA was 
collected early on, but the earliest collection window (C3) gave rise to successful 
amplification and was used for future rounds. After four rounds, no affinity was observed 
by CE or FP for the library, round 2, or round 4. Additionally, a possible complex peak 
was observed in the library affinity assay but not in the others, a confusing fact. It was 
feared that the unsuccessful selection was due to accidental exclusion of the complex DNA 
during selection. A simple model was developed for calculation of the component 
mobilities and prediction of the complex peak location, which examined multiple different 
sample sets. According the model, the complex band was significantly later than the 
collection window used, which accounts for the poor selection. Future selection using 
updated collection window timing and a purified library is expected to result in successful 





















Chapter 5: Optimization of a differentiated cardiomyocyte system for evaluating the 




 Heart muscle cells, or cardiomyocytes, engage in precisely timed transport of 
calcium ions within and around the cell to produce a healthy heart beat. Disorders in 
cardiomyocyte calcium management are frequently associated with cardiomyopathy and 
other cardiovascular diseases. The calcium pump sarco(endo)plasmic reticulum calcium 
ATPase (SERCA) and its control protein phospholamban (PLN) are largely responsible for 
regulating removal of calcium from the cytoplasm and initiating relaxation of the heart, 
making both proteins prime drug targets. It has been shown in recombinant systems that 
random sequence ssDNA, RNA, and some non-natural DNA analogues (XNAs) bind to 
one or both targets to increase apparent calcium affinity of SERCA. This interaction, which 
is dependent on oligonucleotide length and backbone, provides an excellent potential 
pharmacological mechanism for modulating heart relaxation. In order to investigate how 
this oligonucleotide interaction on a protein level translates to measurable changes in heart 
physiology, a more complex cardiac model system is needed. The work here aims to 
optimize a cardiomyocyte system differentiated from human induced pluripotent stem cells 
(iPSCs) as a suitable biological model to observe the physiological effects (and 
pharmacological potential) of oligos on the SERCA/PLN system. 
 
5.2 Introduction 
5.2.1 Cardiovascular disease and its impact 
 The human heart beats over 100,000 times per day, pumping 2,000 gallons of blood 
to every part of the body without a break.226 Even though it is absolutely vital to our 
survival, we often take it for granted, as it generally carries out its complex and coordinated 
cellular ballet without our notice. Unfortunately, diseases of the heart and blood vessels, 
collectively called cardiovascular disease (CVD), are very prevalent and very serious, 
responsible for over 650,000 American deaths per year.227 On top of this, healthcare costs 
of CVD are over $200 billion per year in the U.S.,228 much of which is spent on alleviating 
the most pressing symptoms rather than on treating the biochemical source of the disease. 
 At a cellular level, the heart beat is driven by changing levels of cytoplasmic 
calcium ion, which is responsible for both triggering the beat (excitation) and the 
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contraction itself. A major part of that cycling is SERCA and its regulatory protein PLN, 
which together are largely responsible for controlling evacuation of calcium ions from the 
cytoplasm, causing muscle relaxation. Disorders in cardiac calcium cycling due to SERCA 
and PLN expression and activity are frequently associated with abnormal heart rhythm 
(arrhythmia) and weak heart beats (cardiomyopathy), both of which can lead to heart 
failure if left unchecked.229, 230 Apparent causality can also be reversed, as it has been 
shown that reduced blood supply to the heart due to infarction (blockage) can lead to 
decreased SERCA expression in as little as four weeks.231 Because of this common link 
between SERCA and heart health, it is believed that elevating SERCA activity could be 
used as a method to mitigate failing heart function even in cases where SERCA is not the 
underlying cause. 
5.2.2 SERCA, PLN, and calcium cycling in cardiomyocytes 
 The finely tuned beating of individual cardiomyocytes (CMs) is achieved through 
spatial and temporal manipulation of calcium ions (Ca2+) within the CM cytoplasm to 
control both signaling and contraction. The majority of intracellular calcium is stored in a 
tubular structure called the sarcoplasmic reticulum (SR). The cytoplasmic Ca2+ 
concentration rests at approximately 100 nM,232 considerably lower than both the 
extracellular and SR concentrations. When triggered by an action potential, the cell 
membrane depolarizes and indirectly activates ryanodine receptors on the SR membrane. 
This allows a dramatic influx of calcium from the SR into the cytoplasm known as a 
calcium spark.233 Cytoplasmic calcium binds to troponin and causes a structural 
rearrangement, which allows actin and myosin fibers to interact, leading to muscle 
contraction.  
 In order for the fibers to relax, the calcium concentration in the cytoplasm must 
decrease to resting levels.232 This is achieved primarily by SERCA, a P-type ATPase in the 
SR membrane that transports calcium from the cytoplasm back into the SR lumen. Though 
some calcium is also expelled from the cell, at least 70% of calcium transfer out of the 
cytoplasm is performed by SERCA, giving SERCA the leading role in triggering relaxation 
of the heart muscle.234  
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 SERCA activity is controlled in part by phospholamban (PLN), a 52-residue protein 
in the SR membrane. While PLN can be found as a lone monomer or a homopentamer, it 
is typically found in an equilibrium of states interacting with SERCA; this equilibrium 
tends toward states which lower SERCA’s apparent calcium affinity, and therefore its 
activity.235 In healthy hearts, phosphorylation at Ser16 by protein kinase A shifts PLN’s 
equilibrium toward a non-inhibitory state, restoring SERCA activity and allowing control 
over calcium reuptake.236 
5.2.3 SPIDRs and interactions with cardiac proteins 
 It has been observed previously that random sequences of RNA, ssDNA, and some 
XNAs interact strongly with PLN (Kd ≤ 10 nM) and, more importantly, relieve PLN’s 
inhibition of SERCA activity.237 For a random sequence pool, this level of affinity towards 
a target other than a dedicated DNA- or RNA-binding protein is unprecedented. While 
these oligos undoubtedly share some similarity with aptamers, aptamers are defined by 
their specific sequence and structure, a specificity which is absent in this interaction. To 
differentiate from aptamers, an oligonucleotide which engages in high-affinity sequence-
independent binding has been labeled a small protein-interacting DNA or RNA (SPIDR). 
Even more interesting is that the extent of relief of SERCA inhibition is dependent upon 
both SPIDR backbone (e.g. RNA versus XNA) and oligonucleotide length. This makes a 
strong case for investigating SPIDRs as a therapeutic agent to enhance heart contractility, 
as having systematic parameters besides concentration to fine tune drug interactions would 
increase drug applicability and decrease the likelihood  of side effects. SPIDRs have shown 
significant affinity for PLN and a corresponding increase in SERCA calcium affinity, but 
these effects have primarily been observed in reconstituted vesicle systems using purified 
protein (Figure 5.1).237 In order to tell whether the increased affinity of SERCA in the 
presence of SPIDRs leads to the predicted increase in muscle contractility, similar 
experiments must be carried out in an appropriate cardiac model system. 
 5.2.4 Impedance measurement of differentiated CMs as a suitable cardiac model 
 In any type of biological work, picking the appropriate model system can have a 
huge impact on the research practicalities as well as the conclusions that can be drawn. On 
one hand, a simple system with a small number of constituents and variables (such as the 
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reconstituted lipid system) will be cheaper, more reproducible, and easier to learn and  
manipulate. However, simple systems lack many components and much of the underlying 
complexity present in the original system, which may render the model unrepresentative 
and the results moot. Ultimately we settled on in-house differentiation of human iPSCs for 
a number of reasons. First, iPSCs can be propagated essentially indefinitely, providing the 
large supply of CMs to test various SPIDRs, concentrations, and time courses. Use of 
animal models or primary cardiomyocytes (which do not proliferate) would be extremely 
limiting to the number of independent experiments that could be performed. Second, the 
cardiac systems of small animals (i.e. mice) are not the most representative of humans’, 
whether in simple matters like resting heart rate or complex issues like presentation of 
genetic disorders.238 Third, primary cardiomyocytes are very difficult to obtain in the 
quantities needed for these experiments (particularly cells with a specific disease 
phenotype for future work), and measuring their base beat rate is difficult since they do not 
beat spontaneously like iPSC-derived CMs. Fourth, the differentiation of iPSCs to CMs is 
well established in the literature by a number of different strategies,239-241 suggesting that 
the process will be easily optimizable for our uses without utilizing commercial CMs. 
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3.3.4 NA   PLN    ERCA    
We also performed coupled enzyme assays using the same lipid 
reconstituted system as in Fig. 2. For these experiments, the corresponding 
20mer XNA, random sequence library was added to the complex before 
beginning the assay. Previously we showed that different lengths of ssDNA have 
a graded effect on the SERCA/PLN complex 147, with the 20mer showing partial 
relief of inhibition. Fig. 6A depicts the pKCa values obtained from normalized 
SERCA/PLN activity curves upon addition of the different 20mer XNAs. Without 
addition of oligonucleotide, SERCA alone displays a higher Ca2+ affinity (Figure 
3-6, leftmost black curve and bar).  
PLN binding to SERCA results in inhibition or decreased SERCA Ca2+ 
affinity, (i.e. the lowest pKCa), as depicted with the red curve and bar (Figure 3-
6). Addition of an XNA to the PLN/SERCA complex shifts the pKCa higher, 
indicating that SERCA s apparent affinit  for Ca2+ ions is partially restored. While 
the affinity for all of the charged XNA molecules (DNA, RNA, L-DNA, and 2 -O-
methyl RNA) is essentially equal, their functional effect is distinct. All activity 
assays were performed at saturating concentrations of XNA well above observed 
Kd s with PLN. The observed differences in XNA effect on PLN inhibition are 
 
Figure 3-6  E ec   c e de a a   PLN  b   SERCA ac .  A) 
Normalized SERCA ATPase activity was measured at increasing Ca2+ concentrations using 
 
 58 
50mers), have high affinity for PLN if longer than a 5mer (Figure 3-1). The 20mer 
library, which is representative of the typical length of endogenous miRNAs, 
shows 9-19 nM binding affinity (Figure 3-1). RNA demonstrated no measurable 
affinity for SERCA (Kd > 4 µM).  Similarly, only weak affinity was observed for a 
group of cardiac proteins including actin, myosin and troponin suggesting that the 
observed RNA affinity is specific for PLN. 
We performed a competitive assay to determine the contribution of the 
FAM label to binding.  As shown in Figure 1B, unlabeled, random sequence, 
20mer RNA effectively competes with the FAM labeled RNA library at the PLN 
binding site.  The slope of the curve is 1.32 ± 0.07 suggesting that if anything, 
addi i  f he FAM abe  di i i he  RNA  affi i  f  PLN.  
Figure 3-2  Effec  f RNA  PLN  h b  f SERCA ac . A) Normalized SERCA 
ATPase activity was measured at increasing Ca2+ concentrations using a coupled enzyme 
assay in DOPC:DOPE lipid vesicles. The black line is the activity curve for SERCA alone; 
red is SERCA + PLN while the other colors represent addition of different lengths of 
random sequence RNA to the SERCA + PLN mixture. A regression analysis (equation 1) 
was used to estimate pKCa (i.e. pCa2+ at activity half maximum) from each curve.  Each 
data point is the average of n = 3 replicates.  Error bars were omitted for clarity.  B)  pKCa 
estimates from A) are plotted for different length random sequence RNAs.  Error bars are 
the standard errors from the regression analyses used to estimate pKCa (equation 1, n = 3 
replicates measured at 12 Ca2+ concentrations).  PLN inhibits SERCA by lowering 
SERCA  a a e  Ca2+ affinity resulting in a lower pKCa value. The addition of 50mer RNA 
fully restores SERCA activity (no statistical difference from SERCA alone, p > 0.05). All 
lengths other than the 5mer and 10mer are statistically different compared to WT PLN (p < 























































Fi ure 5.1: Eff cts of SPIDRs on PLN’s inhibition of SERCA activity in reconstituted vesicle system. For 
each condition, normalized SERCA activity was measured using a coupled enzyme assay at increasing 
calcium concentrations to generate an activity curve (not shown) and estimate pKCa (pCa2+ at activity half 
maximum). As expected, SERCA alone showed significantly higher calcium affinity (pKCa) than upon 
the addition of PLN in both experiments. (A) The addition of increasing lengths of random sequence RNA 
to the SERCA+PLN system restores SERCA’s calcium affinity, with the addition of 50mer RNA removing 
all inhibitory effect of PLN (no significant difference). (B) The addition of different types of random 
sequence oligonucleotide 20mers – peptide nucleic acid (PNA), morpholino nucleic acid, enantiomeric L-
DNA, 2’-O-methyl DNA, ssDNA, and phosphorothioate DNA (ptDNA) – increased SERCA calcium 
affinity to different extents, with phosphorothioate DNA yielding the greatest effect. XNA structures are 
shown in the Appendix (Figure A.7). Adapted from Soller et al.237 
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 Once the CM model has been established, the effects of different SPIDRs can be 
assayed by exposing CMs to the oligos using a transfection agent, such as Lipofectamine. 
SPIDRs are expected to increase SERCA activity and decrease the time required for the 
relaxation process, which is hypothesized to lead to an increased beat rate and amplitude 
while decreasing fall time. (Fall time measures the rate of relaxation and is the amount of 
time required for the amplitude to return from 90% to 10% after a beat.) One emerging 
strategy to track mechanical beating with high accuracy is a cellular impedance platform, 
which uses gold-plated electrodes built into the well to measure changing impedance across 
the cells in response to a very small alternating current.242-244 When relatively low 
frequency voltage is applied, current travels predominantly along the cell membranes 
(paracellular), and the impedance signal tracks changes in cell and junction morphology 
that occur during contraction.244  
 The main goal of my work was to lay the foundation for the project trajectory above 
by demonstrating reproducible CM generation and the suitability of our cells for impedance 
experiments. Herein, a procedure for culturing iPSCs for differentiation is developed, with 
a focus on optimizing cell passaging maximal cell coverage at the start of differentiation. 
The process of differentiation to CMs is optimized, including metabolic selection for 
improving CM purity. Finally, preliminary impedance measurements are shown, along 
with observations about replating cells and suggestions for future improvement.  
  
5.3 Methods 
 The optimization of iPSC growth and differentiation to CMs makes up the majority 
of the work in this chapter and involved numerous conditions tested across dozens of 
variables. For this reason, enumerating individual experimental conditions in this section 
is unfeasible. The methods below represent only the optimized protocol selected based on 
experimental results and practical considerations. Details on adjustments to this protocol 
and the conditions tested are specified in the results (section 5.4) with respect to their 
impact on the growth and differentiation process. 
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5.3.1 Materials 
 Cells. Cells from the iPSC line BXS0116 were obtained from American Type 
Culture Collection (ATCC, Manassas, VA). Cells from iPSC line SCVI-15 were obtained 
from the Stanford University Cardiovascular Institute (SCVI) Biobank (Stanford, CA).  
 Chemicals. Dimethylsulfoxide (DMSO) was obtained from ATCC (Manassas, 
VA). Growth factor reduced Matrigel basement membrane extract (BME) was obtained 
from Corning (Corning, NY). Essential 8 media (E8), DMEM:F12 media, 1× phosphate-
buffered saline minus Ca2+ and Mg2+ (PBS), Roswell Park Memorial Institute (RPMI) 1640 
media, RPMI 1640 media minus glucose, 50× B-27 supplement, and 50× B-27 supplement 
minus insulin were obtained from Gibco (Waltham, MA). WNT inhibitor Wnt-C59 was 
obtained from Santa Cruz Biotechnology (Dallas, TX). Rho-associated kinase (ROCK) 
inhibitor Y27632 and glycogen synthase kinase-3 (GSK3) inhibitor Chir99021 were 
obtained from Selleckchem (Houston, TX). EDTA solution was obtained from Invitrogen 
(Waltham, MA). mTeSR1 media was obtained from Stemcell technologies (Vancouver, 
Canada). Cultrex stem cell qualified Pathclear reduced growth factor BME was obtained 
from Trevigen (Gaithersburg, MD). Bambanker was obtained from Wako Chemicals 
(Richmond, VA).  
 All chemicals besides inhibitors (Y27632, Chir99021, Wnt-C59) were sterile upon 
receipt. Inhibitors were dissolved in DMSO to at least 1000× working concentration, 
passed through a 0.2 μm filter, and stored in sterilized containers. Stock Matrigel and 
Cultrex BME (12-18 mg/mL) were aliquoted upon arrival and stored at -80˚C. Stock and 
aliquots were thawed at 4˚C overnight before use. To avoid premature gelling, BME was 
kept on ice during use, plastic tubes and pipet tips were refrigerated at least 15 minutes 
prior to contact with BME, and all handling of BME was done as quickly as reasonably 
possible. 
5.3.2 Cell plate preparation 
 Matrigel was diluted 1:200 in ice cold DMEM:F12 and mixed by inversion. The 
mixture was added to each well – 2 mL/well for a 6 well plate (6WP), 1 mL/well for a 
24WP, or 200 μL/well for a 96WP or 96-well sensor plate – and the plate was incubated at 
37˚C for at least one hour but no more than three days prior to use. 
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5.3.3 iPSC growth and passaging 
 iPSCs frozen in liquid nitrogen vapor were thawed rapidly in a 37˚C water bath, 
mixed with 2 mL of mTeSR1 media, and centrifuged at 200×g for 5 minutes. The 
supernatant was aspirated and the cells were dispersed in 2 mL of mTeSR1 media with 
10 μM Y27632 in one well of a 6WP. Cells were changed to a 1:1 mixture of mTeSR1 and 
E8 after 24 hours, and to pure E8 after another 24 hours and every 1-2 days. 
 iPSCs were passaged at 65-80% confluency, approximately every 4 days. Cells 
were rinsed with PBS then incubated in 1 mL PBS with 0.5 mM EDTA at 37˚ for 6 minutes 
until cells were translucent white to the naked eye, then PBS:EDTA was gently removed. 
One mL of passage media, E8 with 10 μM Y27632, was pipetted directly onto the cells to 
dislodge them and triturated (pipetted up and down) 4-5 times to break up large clumps. 
Suspended cells were diluted in passage media to achieve a split ratio of approximatey 1:7 
and mixed gently. Media was removed from the coated plate (prepared above) and cell 
suspension was added to the new plate, 2 mL/well for 6WPs (for continued iPSC growth) 
or 1 mL/well for 24WPs (for differentiation to CMs). After ~24 hrs, media containing 
Y27632 was removed, cells were rinsed with PBS, and fresh E8 without Y27632 was 
added. Fresh media was supplied every 1-2 days, and within 24 hours prior to passaging 
where possible. 
5.3.4 Differentiation to CMs 
 Base media were prepared and used for up to 8 weeks: 1× B-27 minus insulin in 
RPMI 1640 (“M1”), 1× B-27 in RPMI 1640 minus glucose (“M2”), and 1× B-27 in RPMI 
1640 (“M3”).  
 iPSCs were grown in a 24WP for 4-5 days until most of the cells were highly 
compacted (see section 5.4.2) and cells were 90-95% confluent, defined as day 0 (D0). 
Cells were rinsed with PBS, then 1 mL of ice cold M1 with 8 μM Chir99021 and 1:200 
BME was added to each well. After 24 hours (D1), cells were rinsed with PBS and 1 mL 
of M1 was added to each well. On D3, cells were rinsed and 1 mL of M1 with 2 μM 
Wnt-C59 was added to each well. Cell media was replaced with M1 with 2 μM Wnt-C59 
every 2 days and cells were checked for evidence of spontaneous beating. 
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 Once beating was observed over at least 50% of the well surface, and the amount 
of beating cells in each well had stopped increasing (typically D10–D14), cells were rinsed 
twice with PBS and 1.3 mL of M2 were added to each well. After three days, cells were 
rinsed with PBS and 1 mL of M3 was added to each well. For wells that still contained 
≥25% non-beating cells, the M2 incubation process was repeated. Cells were maintained 
in 1 mL of M3, replaced every 1-2 days. 
5.3.5 Replating of CMs 
 A well containing beating CMs was rinsed with PBS and incubated with 1 mL of 
Accutase for 2-3 minutes at 37˚C until dead cells stuck in the Matrigel (see section 5.4.3) 
were loosened. The plate was swirled to suspend these cells and the liquid was aspirated. 
The well was incubated with 1 mL of fresh Accutase at 37˚C for 5-10 additional minutes 
until previously beating cells had been loosened. Cells were gently triturated with a P1000 
then added to a 15-mL centrifuge tube with 5 mL of M3. The tube was centrifuged at 200×g 
for 5 minutes, the supernatant was aspirated, and 200 μL of M3 was added per new well of 
a 96WP or sensor plate. Cells were gently triturated to break up the pellet and any large 
colonies remaining in suspension. Matrigel solution was removed from the new plate and 
200 μL of suspension was added to each well. 
 Newly replated cells were allowed to incubate undisturbed for 24 hours. M3 media 
was changed 24 hours after replating and every 1-2 days after. For each media change, half 
the media from a well (100 μL) was removed and replaced with fresh media, then the 
process was repeated. Added media was allowed to gently drip down the side of each well 
to avoid disturbing the cells. The impedance of replated cells was measured every 3-4 days. 
Cells with no beating after 21 days were considered to have failed the replating process.  
5.3.6 Microscopy and imaging 
 Cells were viewed on a Labomed TCM-400 inverted tissue culture microscope with 
phase contrast through a 4×, 10×, or 20× objective. Images were obtained with a 
Moticam-2 2.0 MP camera and Motic Images Plus 3.0. Brightness and contrast were 
adjusted in some images for ease of viewing. 
 91 
5.3.7 Impedance measurement 
 Impedance measurements were made on the Nanion CardioExcyte 96 system. The 
system used an Ibidi gas mixer and humidifying column set to 37˚C, 5% CO2, and 90% 
relative humidity. Once the correct conditions were reached, cells were allowed to incubate 
in the test chamber for 10 minutes prior to measurement. A 10kHz AC current provided 
1000 measurements per second for a 7-second sweep every 3 minutes. No pacing 
stimulation was used in order to obtain informative beat rate data. 
 
5.4 Results and Discussion 
 A number of sources served as good starting points for both iPSC growth and CM 
differentiation, including literature protocols,241, 245 protocols from ATCC246 and the SCVI 
Biobank,247, 248 and preliminary procedures used previously in the group.249 Optimization 
was largely broken into three parts. First, the iPSC culturing procedure was optimized to 
obtain a healthy monolayer across as much of the well as possible for efficient CM 
differentiation. Second, CM differentiation and metabolic selection were optimized 
primarily to maximize the number of beating CMs obtained, and secondarily to reduce the 
complexity and subjectivity of the differentiation procedure for future researchers in the 
group. Third, the process of replating CMs into the specialized 96-well electrode sensor 
plates was optimized with the primary goal that adhered cells resuming coordinated 
beating, and the secondary goal of maximizing impedance signal intensity and 
reproducibility. Preliminary impedance measurements are also shown. 
5.4.1 Stem cell growth 
 iPSC thawing. A number of sources suggest normal growth of iPSCs in E8 media 
but thawing of cells from cryostorage into mTeSR1 media. Thawing cells is a rare 
occurrence and uses little of the thawing media, which would lead to wasting most of the 
mTeSR1 due to its six month expiration. Given the expense and (at times) poor availability 
of mTeSR1, I took the opportunity to evaluate the importance of mTeSR1 immediately 
after thawing to see if the procedure could be streamlined by removing it. Stanford iPSCs 
at passage 6 were thawed as indicated in section 5.3.3 except for differences in the media: 
cells were plated into E8, fresh mTeSR1, or mTeSR1 significantly past its listed expiration 
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date (each time with 10 μM Y27632). At 24 hours, each mTeSR1 condition was changed 
to a 1:1 mixture of mTeSR1 and E8 while the E8 condition was changed to new E8. 
Following the media change, the mTeSR1 conditions showed good coverage of healthy 
looking cells while the E8 condition showed poor attachment efficiency. Several more days 
of growth confirmed a lack of adhered cells for the E8 attachment condition. Interestingly, 
the cells thawed in expired media were indistinguishable from those in fresh media, even 
after several passages. To date, cells have been thawed in mTeSR1 kept at 4˚C up to 18 
months past its expiration date and still displayed excellent morphology. This is important 
to know as obtaining new mTeSR1 is no longer a barrier to periodic iPSC thawing. 
 Optimizations to enhance the monolayer. Once cells were thawed and growing, 
one of the primary factors that seemed to affect differentiation efficiency was the 
establishment of a consistent, compacted monolayer of iPSCs, which in turn stemmed from 
homogenous distribution of seed colonies across the well during passaging. However, 
iPSCs are quite fastidious and do not tend to grow well from a single isolated cell. 
Therefore, the amount of homogenization during passaging was very particular: 
insufficiently homogenized cells led to adherence of large clumps of cells that caused 
uneven growth, while overly homogenized cells resulted in many single cells that didn’t 
tend to grow well. Overall, 3-4 full mixes with a 1000 μL pipet seemed to deliver optimal 
homogenization, but multiple other factors were discovered that impacted good monolayer 
formation. 
 Initially, the cell passaging schedule used in the group called for splitting cells once 
fully or nearly confluent based on other sources and past experience. However, 
experimentation with earlier splitting demonstrated that highly confluent cells develop 
some stronger intercellular interactions that require more pipetting to break up. As a result, 
cells split at 60-80% confluence (“early” split) yielded a more even distribution of 
appropriately sized seed colonies across the new well that those split at 80-95% confluence 
(“late” split) and had a lower incidence of cell clumps (Figure 5.2), which disrupt the 
monolayer and may begin unwanted differentiation. Split ratios ranging from 1:3 to 1:10 
are frequently quoted for iPSCs, though our iPSCs seemed to grow quite well, meaning 
that splitting less than about 1:5 resulted in cells ready to be split again almost immediately. 
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Contrary to some literature, we found that 
splitting 1:8 or harsher did not create wells 
seeded too sparsely to grow. However, 
because of the length of time until 
confluence in these situations, it was found 
that the well frequently became highly 
confluent in the center before there was 
much cell coverage on the sides, a problem 
for timing differentiation appropriately. A 
split ratio of about 1:7 was found to be 
ideal for creating even coverage in seeded 
wells, adjusting slightly higher or lower 
depending on confluence in the well being split. 
 The recency of the BME application was also found to be a factor. Plates to which 
Matrigel had been applied five days or more before seeding seemed to grow unevenly and 
also developed more stacked cells. This was believed to be due to uneven deterioration or 
“flow” of the BME over time which led to differences in adherence and/or rate of growth 
based on location. Therefore, coating wells with BME individually and within 24 hours of 
plating was found to be far superior to large batch coating. 
 In comparing the each cell line, iPSCs from ATCC were found to be more spindly 
and spread outward earlier than the rounder cells and colonies of Stanford iPSCs (Figure 
5.3). The cause is unknown, as the cell lines are largely similar in their source cell type and 
reprogramming  method, but this resulted in the ATCC cells more quickly spreading over 
the entire well surface in a web-like network, whereas the Stanford cells had a tendency to 
grow outward only after forming a dense colony at the center. Consequently, ATCC cells 
formed the homogenous monolayer ideal for differentiation whereas Stanford cells often 
became overcrowded at the center of the well before the edges were sufficiently confluent. 
Initial attempts were made to differentiate both cell lines, but the Stanford cells were 
phased out over time as the ATCC cells showed better differentiation results. 
 The findings regarding iPSC growth and passaging are summarize in Table 5.1. 
Figure 5.2: iPSC clumps (4×). iPSCs sometimes form 
small multilayer clumps consisting of dozens or 
hundreds of cells. These structures (circled) do not 
propagate outward as well as clean iPSC monolayers 




5.4.2 CM differentiation 
 Successfully differentiated CMs begin to contract spontaneously approximately 
7-12 days after the start of differentiation. Contraction typically occurs in isolated pockets 
at first, with small movements that can be difficult to see even at 4× objective 
magnification. Over the next several days, the number of beating cells gradually increases, 
and the size and frequency of the contractions generally grow as well. Luckily, this obvious 
phenotypic display makes positive identification of CM colonies very straightforward and 
circumvents the need for antibody labeling or morphology tracking. Still, iPSCs must go 
Thawing media 
E8 mTeSR1 (fresh) mTeSR1 (old) 
× + + 
Trituration (times 
pipetted) 
1 - 2 3 - 5 6 + 
– + × 
Confluence at 
passaging 
60 – 80% 80 – 95% 
+ – 
Split ratio 
1:3 1:5 1:7 1:10 




Table 5.1: Summary of the effects of thawing and splitting conditions on iPSC monolayer growth. For 
each variable investigated, the conditions tested are shown along with the effect on iPSC growth, where 
“+” indicates that cells established a homogenous monolayer, “–” indicates that cells grew unevenly or 
in multiple layers, and “×” indicates that cells died or adopted concerning morphologies. The shaded 
conditions indicate those chosen for future work. 
Figure 5.3: ATCC versus Stanford iPSC growth 24 hours after seeding (10×). (Left) ATCC iPSCs and 
colonies are more spindly, quickly spreading outward to form a web-like network. (Right) Stanford iPSC 




through a week of carefully timed steps before any beating can be seen, and issues at any 
point can lead to weak or non-existent beating with no obvious clue as to the specific cause. 
The differentiation procedure and metabolic CM selection were optimized in order to 
generate the largest number and highest purity of beating cells for impedance assays. 
Throughout this section, references to “failed” or “unsuccessful” differentiation indicate 
that cells did not display any significant beating after 14 days or that noticeable cell 
detachment was observed prior to 14 days that did not grow back. 
 Timing the start of differentiation. Many sources suggest beginning CM 
differentiation when iPSCs have reached 85-100% confluence but also admit that the 
timing should be optimized for each cell line. A complicating factor is that the well may 
be highly (or overly) confluent in some areas, usually the center, and relatively sparce in 
others. This makes quantitative estimates of confluence an unrepresentative or incomplete 
description of the cells’ status. Optimizations have already been shown to try to obtain 
consistent confluence across the well, but it is impossible to completely eliminate radial 
differences in confluence. Initially, experimental conditions were quantified by 
approximate confluence near the edges of the well (since the center was already fully 
confluent). The ends of the range displayed problematic signs: differentiation of wells not 
fully confluent at the center (est. 70-85% confluent at the edges) led to significant cell 
detachment, while wells that were confluent wall-to-wall developed some multilayer 
structures before differentiation and never successfully differentiated. However, there 
seemed to be no significant correlation with differentiation success over quite a wide range 
of confluence in the center of the range – conditions that appeared to be identical gave rise 
to completely different results from one time to the next. A number of different conditions 
did give rise to beating cells one time or another, but none more than half of the attempts. 
 Rather than focusing on confluence, the cells’ morphology was tracked in an 
attempt to obtain more reproducible differentiation. Work by Wakui et al.250 and by Healy 
and Ruban251 provided good reference images and descriptions of iPSCs at different stages 
of growth. Highlighted in this and other work is the importance of compaction, the process 
by which stem cells increase the level of physical and chemical interaction with one another 
in preparation for differentiation. iPSCs need to be sufficiently compacted in order to 
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efficiently relay the signals for directed differentiation, which explains why the 
insufficiently confluent cells did not differentiate well. On the other hand, once iPSC have 
become fully confluent and have remained compacted for more than a day or so, there is a 
drastically increased likelihood that the cells will begin to form multilayer structures and/or 
differentiate randomly. This premature differentiation toward a different cell type could 
explain why waiting for full confluence did not result in beating cells either. With this 
knowledge in hand, iPSC were grown until the main monolayer had a high degree of 
compaction, indicated by distinct nucleoli and minimal visible separation between cells 
(Figure 5.4), to begin differentiation. Due to variation in growth and seeding, the ideal level 
of iPSC compaction did not correspond to the same level of cell confluence each time, 
which is likely why trying to time differentiation by confluence alone was not reliable. 
 Beginning differentiation once the center was well compacted led to more reliable 
differentiation, with some level of beating achieved 70-80% of the time. While a large 






Figure 5.4: iPSC compaction at various stages (10×). 
(A) The center of the colony displays good cell 
compaction with minimal cell borders. Multiple large 
nucleoli are visible (inset, arrows), a sign of non-
differentiation. The edges of the colony show some 
light cell borders (circled) where cells are not yet 
compacted. (B) A large swath of homogenously 
compacted monolayer shows large, distinct nucleoli 
and no light borders. These cells are ideal for starting 
differentiation. (C) Light colored “cracking” along 
cell borders has become visible, a sign of 
overcompacted cells. Cardiac differentiation is 
possible at this point, but overcompacted iPSCs may 
differentiate along an unintended pathway instead. 
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differentiation timing by compaction and morphology was significantly more reliable than 
by confluence alone. If colonies became overcompacted (Figure 5.4C), attempts were still 
made to differentiate the cells, but these wells generally never exhibited a large number of 
beating cells. 
 Media supplement and inhibitor schedule. Initial attempts to differentiate iPSCs 
to CMs used the procedure laid out by Burridge et al.245 using chemically defined media 
in a 6WP. The advantages of a chemically defined media include better reproducibility 
compared to animal-derived components and improved cost efficiency and optimizability 
compared to commercial supplements. RPMI 1640 media supplemented with recombinant 
human albumin and L-ascorbic acid 2-phosphate (deemed CDM3) was used as the base 
media throughout. Canonical WNT signaling was activated at the start of differentiation 
(D0-D2) with Chir99021 and later subdued with Wnt-C59 (D2-D4). Significant changes 
in cell morphology occurred within the first 24-48 hours, including a multilayered 
architecture of varying thickness and density, the appearance of sections free of any cells, 
and cracking of the cell boundaries similar to Figure 5.4C. However, even in cases where 
most of the cells were retained and appeared healthy, fewer than 50% of attempted 
differentiations yielded any beating cells, and beating was typically limited to a few small 
colonies covering less than 5% of the well. Changes to concentrations of Chir99021 and 
Wnt-C59 were investigated (50%-150% of original concentrations), which impacted 
morphological changes somewhat but did not improve the proportion of beating cells. 
 In place of albumin and ascorbic acid phosphate, differentiation was attempted 
using the commercial supplement B-27 and substituting RPMI 1640 minus insulin, both of 
which feature in the work of Lian et al.241 This work and others also apply a different time 
course, using a WNT activator D0-D1, no WNT modulation D1-D3, and a WNT inhibitor 
from D3 until significant beating was observed. The B-27 supplemented media was tried 
in both time courses (Figure 5.5), and in both seemed to initiate a more aggressive change 
in morphology. Significant portions of the well (usually around the edge) were bare when 
viewing on D1 or D2 after differentiation (Figure 5.6), which resulted in significantly fewer 
adhered cells moving forward. Again, only about 50% of attempts gave rise to beating 
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cells, but many successful attempts saw 
significant beating across a much larger 
portion of the well (20-50%). There was no 
obvious difference between using the 
CDM3 timeline and the timeline from Lian 
et al., but the latter was implemented 
moving forward because it had been 
developed in conjunction with the media 
system being used. With the new timeline 
attempts were made to decrease the 
concentration of Chir99021 from 8 μΜ to 
6 μΜ or 4 μΜ. Doing so reduced the number of cells lost during differentiation but at the 
cost of less frequent and less extensive beating cells.  
 BME optimization. During these experiments and moving forward, differentiation 
was performed in 24WPs rather than 6WPs to allow a larger number of conditions and/or 
wells per condition to be tested and to facilitate easier quantification of cell adhesion and 
beating. In an attempt to decrease cell detachment without negatively affecting 
differentiation, the BME coating procedure was revisited. Some cells were grown on 
Cultrex BME with the same protein concentration and compared alongside cells grown on 
Matrigel as before, but no difference was observed. Additionally, cells were grown on 
100 μm
100 μm
Figure 5.6: Cell detachment during CM differentiation (4×). 24 hours after starting B-27 differentiation, 
noticeable gaps in the monolayer appeared. (Left) The center of the well often retained most of the cells with 
only a few gaps appearing (small gaps circled), likely due to cell rearrangement. (Right) Farther from the 
center of the well, cells were often absent from 50% or more of the surface due to significant cell detachment. 
Figure 5.5: Different timelines for WNT activation 
and inhibition during CM differentiation. Notably, 
the CDM3 method (Burridge et al.)245 applies two 
days of WNT activation while the B-27 method (Lian 
et al.)241 has only one day of activation and a two day 
gap. Additionally, the B-27 method continues to 
apply a WNT inhibitor until substantial beating is 
observed, whereas the CDM3 method ceases WNT 
inhibition after D4. 


























plates coated with Matrigel at various 
concentrations up to 225 μg/mL, and the 
percent of surface area with beating cells 
and the proportion of beating cells were each 
estimated by eye. There were minimal 
visible differences during iPSC growth, but 
beating was achieved in much higher rates 
within the sweet spot of 90-180 μg/mL 
(Figure 5.7). Coating used 90 μg/mL 
Matrigel moving forward.  
 Another condition tested was the matrix “sandwich” method introduced by Zhang 
et al.,252 whereby a new layer of BME is laid down on top of the cells at, or just before, the 
start of differentiation. While the authors’ primary intention with this process was to  
enhance CM differentiation by better simulating the cellular environment of the developing 
embryo, it was also believed that this might help our cells remain affixed to the surface 
better during differentiation, resulting in more cardiomyocytes for replating. To test this, 
the D0 media with Chir99021 was prepared ice cold with a small amount of Matrigel 
(50 μg/mL) and the media was changed normally. The resulting plates were only about 
50% full with cells by D2 but displayed beating across up to 80% of the cells by D12, a 
vast improvement over the previous method. 
 In an attempt to retain more cells, two test runs were performed adding the 
sandwich Matrigel in ice cold E8 to the cells 24 hours or 3 hours before switching the cells 
to differentiation media. The thought process was that this would provide extra stabilization 
to the cells before the destabilizing effect of the WNT activator was applied and prevent 
some cell loss. Interestingly, applying the sandwich layer 24 hours early, even in the 
absence of Chir99021, created a large number of gaps anyway that did not lead to 
improvement over simultaneous Matrigel and Chir99021 addition. Both of the conditions 
with early Matrigel addition led to a noticeable decrease in the number of beating cells by 
D14. This could be due to iPSCs under the influence of the Matrigel sandwich alone 















Figure 5.7: Effect of bottom Matrigel thickness on 
CM beating. CMs differentiated on a plate coated in  
90 μg/mL Matrigel displayed the greatest surface 
area with beating cells (solid) and the greatest 
percent of cells beating (hatched). No iPSCs adhered 
to uncoated wells, leading to no CM coverage. 
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differentiation. Another possibility is that Chir99021 added atop the already solidified 
Matrigel did not penetrate to the cells as well or did not affect the iPSCs in the same way 
in the presence of the new Matrigel layer. In light of these observations, the sandwich 
Matrigel and D0 differentiation media were applied simultaneously moving forward. 
 The findings regarding differentiation conditions are summarized in Table 5.2. 
5.4.3 Cell replating and preliminary impedance results 
 The end goal of the differentiation process was to obtain spontaneously beating 
CMs that could undergo impedance measurements to monitor contraction in response to 
SPIDR dosing. The CardioExcyte system makes impedance measurements using a custom 
disposable electrode-embedded 96-well sensor plate, meaning that beating CMs must be 
replated from a 24-well differentiation plate to the sensor plate before measurements can 
D0 timing by edge 
confluence 
70-85% 85-95% >95% 
× – – 
D0 timing by 
compaction 
Partly compacted Mostly compacted All compacted (some cracking) 






4 μM 8 μM 12 μM 
– + × 
[Wnt-C59] 
1 μM 2 μM 3 μM 
– + + 
Differentiation 
timeline 
CDM3 (2-day WNT activ.) B-27 (1-day WNT activ.) 
+ + 
BME type Matrigel Cultrex 
+ + 
Applied BME conc. 
(μg/mL) 
45 90 135 180 225 
– + + + – 
BME sandwich 
None Simultaneous 3 hrs before 24 hrs before 
– + – – 
Table 5.2: Summary of the effects of multiple variables on CM differentiation. For each variable 
investigated, the conditions tested are shown along with the effect on iPSC growth, where “+” indicates 
that beating cells were seen in large numbers or with high frequency, “–” indicates that cell beating was 
observed occasionally, and “×” indicates that cells adopted concerning morphologies or were never seen 
beating. The shaded conditions indicate those chosen for future work. 
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take place. Additionally, measurements are most precise when the CMs are high purity, 
covering a large portion of the surface area, and beating synchronously. 
 Metabolic selection. In order to improve CM purity, beating cells were subjected 
to a metabolic selection media without glucose. In this media, undifferentiated iPSCs are 
starved without their normal sugar source, but CMs are able to survive adequately by 
metabolizing the galactose present in B-27. Cells were generally grown in the selection 
media for 72 hours, returned to a glucose containing media for one day, then subjected to 
another 72 hours in the selection media. For many wells, there was a significant increase 
in the amount of beating observed, both in surface area and in magnitude of contraction, 
following metabolic selection. While it is possible that a large proportion of cell continued 
to differentiate in these cases (galactose is known to improve CM maturation253), the more 
likely explanation is that the presence of undifferentiated iPSCs amongst the CMs reduced 
CM mechanical and paracrine interactions, lessening or preventing beating.  
 Two problems were encountered during the selection. First, it was not uncommon 
for up to half of the cells to detach from the surface during metabolic selection, even those 
known to have contained beating sections previously. It was hypothesized that this was due 
to CMs being unable to continue growing in the absence of live neighbors, or due to dead 
iPSCs pulling attached CMs off the surface. In either of these cases, this occurrence would 
seem less likely in colonies with a high CM:iPSC ratio. This was confirmed by the 
observation that wells with a significant amount of beating prior to selection were more 
likely to have single cells or small colonies floating after selection. On the other hand, wells 
with fewer beating cells initially often had large sheets of cells floating following selection. 
The second issue was that many of the dead cells became trapped within the Matrigel. 
Though not easily distinguishable in still images, these cells were clearly isolated from 
other cells in the colony and were neither fixed to the surface nor completely free as though 
floating. Attempts were made to remove some of these cells during the replating process 
by performing two sequential rounds of cell detachment – a short incubation with accutase 
to detach and remove these weakly attached dead cells, and a longer incubation required to 
detach the larger beating colonies and transfer them to the sensor plates. 
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 Replating. Many procedures for replating of cardiomyocytes are designed for 
commercial CM systems and recommend a specific seeding density to obtain the 
appropriate culture. However, counting by hemacytometer requires that the suspension 
contain predominantly single cells. This makes sense for commercial CMs, which are 
easily mixed into single cell suspension, but CMs which have been differentiated using a 
Matrigel sandwich method are not easily separated. While dissociating cells from the 
surface using Accutase did not require significant pipetting, extensive not-so-gentle 
trituration with a P1000 was required even after extended incubations with high 
concentrations of Accutase or Accumax in order to break up large colonies. Multiple 
attempts to obtain a single-cell suspension for hemacytometer counting resulted in 
significant cellular debris and dead cells even as 100-cell clumps remained intact. Variation 
in Accutase concentration and incubation time did not noticeably ameliorate the process. 
 Instead, the process of cell counting was skipped in favor of replating based on the 
estimated confluence of beating cells. For example, with some experimentation, it was 
found that one well of a 24WP with 50% coverage of beating cells was appropriate for 
seeding 3-5 wells of a 96WP, depending on the desired apparent density. Unfortunately, 
the opacity and dimensions of the sensor plates prevented viewing the well contents 
through either an upright or inverted microscope, so cells were reseeded into a sensor plate 
and a standard 96WP under identical conditions in the hopes of obtaining impedance data 
and visual information for the same conditions.   
 Adjusted variables included Matrigel coating concentration of the sensor plate 
(1:400–1:100 dilution), dissociation enzyme used (Accutase or Accumax), incubation time 
before trituration (5-15 minutes), extent of trituration, and relative density seeded. Overall, 
replating success was found to be largely random and independent of most of the conditions 
investigated. Very few wells (<5%) gave rise to an impedance pattern visible above 
baseline noise within the 21 days checked, and each differed from other successes by 
multiple variables. Numerous possible causes were hypothesized that could yield no 
measurable impedance profile including: insufficient cells, due to poor adherence, 
improper seeding density, or cell death following replating; CMs that lived but did not 
resume beating, due to low density, low purity, or excessive separation or trauma during 
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replating; or CMs that resumed beating randomly rather than synchronously. In clear 
96WPs, sparse reseeding was less likely to ever resume beating, while denser reseeding 
had an increased likelihood of non-synchronous beating. Due to the inconsistency of wells 
replated under identical conditions, it was difficult to draw any link between impedance 
data and cell growth in clear 96WPs. More data, or a more quantitative procedure, will be 
required to reliably determine the ideal reseeding density.  
 Preliminary impedance measurements. Preliminary data249 from a previous 
group member using commercial cardiomyocytes demonstrated that dosing with ptDNA 
gave rise to a 17% increase in beat rate and 13% decrease in fall time according to 
impedance measurements. This is consistent with increased SERCA calcium affinity in the 
presence of oligos, which is hypothesized to increase the rate of calcium reuptake into the 
SR. Before oligo dosing experiments could be performed with our differentiated CMs, the 
level of baseline consistency had to be established. Ideally, CMs would have a consistent 
beat rate and fall time over tens of minutes (for data averaging), over several days (for 
longitudinal experiments), and between wells (for parallel assays). 
 Only one well (Figure 5.8) gave quantifiable patterns on multiple days. The beat 
rate over 48 minutes (17 measurements) was found to be 60±2 min-1 with no apparent 
systematic change over the period. While the uncertainty was about double that observed 
in the commercial CMs, the sub-4% RSD was still substantially lower than the 17% change 
in beat rate observed previously, confirming that these changes would be visible over the 






































Figure 5.8: Sample impedance measurement data for differentiated cardiomyocytes. (Left) A 
representative impedance trace shows the consistent beat rate and amplitude during the sweep. (Right) The 
average beat rate and fall time for each sweep were plotted over time. The beat rate displayed good 
consistency (±3.7% RSD) but the variation in the fall time was evident (±15% RSD) likely due to the low 
impedance amplitude. 
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baseline noise in our differentiated CM system. A single sweep 48 hours later showed a 
beat rate of 59, suggesting long term consistency in beat rate, but more data is needed 
confirm this. Unfortunately, the fall time varied much more from one sweep to the next, 
yielding a RSD of 15%. This RSD is higher than the change in fall time observed in the 
commercial CM system, meaning that measuring a more consistent fall time is necessary 
before changes in fall time between conditions become detectable. The high RSD in the 
fall time likely stems from low absolute impedance changes. In order to obtain a stronger 
impedance fluctuation, future experiments will aim to use a greater seeding density. 
 The beat rate uncertainty for one well over time (±2 min-1) was found to be much 
smaller than the differences between wells, which varied roughly from 40-90 min-1 even 
among the small number of wells with measurable impedance profiles. While the exact 
uncertainty could not be calculated, it seems unlikely that comparison between wells will 
be more reliable than long term comparison of one well over time. 
 
5.5 Conclusions 
 Numerous variables were optimized in order to obtain a reliable procedure for the 
thawing, growth, and passaging of iPSCs. Cells grew to sufficient confluence for passaging 
in roughly four days, leading to a reliable supply of iPSCs with which to attempt 
differentiation. Timing the start of differentiation based on colony morphology and level 
of compaction was found to be more reliable than based on confluence alone, which is not 
noted in many literature protocols. Relatively pure beating CMs were obtained with better 
than 50% frequency through appropriately timed Matrigel application, WNT activation by 
Chir99021, WNT inhibition with Wnt-C59, and metabolic selection in the absence of 
glucose. 
 Replating beating CMs onto a CardioExcyte sensor plate for impedance 
measurement proved unreliable due to difficulties obtaining a monodisperse cell 
suspension for counting and predictable reseeding. Future work will focus on a wider 
variety of cell detachment strategies in order to obtain a procedure that is reproducible 
enough for more fine-tuned optimization. Preliminary impedance measurements showed 
that replated CMs that did resume synchronous beating could be detected well enough to 
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generate a signal quantifiable above baseline noise. Measurement of beat rate showed a 
high degree of consistency over one hour (±2 min-1), and possibly over several days, that 
would allow quantification of beat rate by longitudinal SPIDR dosing assays. The high 
degree of uncertainty observed in the measurement of fall time would likely obscure small 
changes due to SPIDR application, but it is expected that improved replating strategies and 




























 In summary, this dissertation centered on highlighting and improving microfluidic 
methods of aptamer selection, particularly CE-SELEX, in addition to expanding the scope 
of protein targets and biological applications for oligonucleotide affinity reagents.  
 Chapter 2 reviewed the wide variety of microfluidic techniques for selection and 
characterization of aptamers, focusing on the tremendous enhancement of efficiency and 
automatability offered by all microfluidic techniques. Specifically, selection techniques 
based on electrophoresis (CE and μFFE), magnetic and non-magnetic microbeads, and sol-
gel encapsulation were covered in depth, including recent developments and example 
aptamers selected. Several prototypes of increasingly comprehensive integrated 
microfluidic SELEX systems, incorporating elements of negative selection, amplification, 
and/or purification into the same system, were enumerated. Finally, the capabilities of 
DNA microarrays as both characterization technique and selection tool, which will only 
improve with increased scale and decreased cost, were discussed at length. 
 Chapter 3 developed a strategy for CE-SELEX against untruncated LDL receptor 
by stabilizing the transmembrane region in surfactant micelles during selection. To our 
knowledge, this type of selection against an intact membrane-bound protein has not been 
documented in the literature to date, and the mechanisms developed here are applicable to 
a wide variety of membrane protein targets. Selection at physiological temperatures and 
increased (but still sub-physiological) NaCl concentrations were tolerated, but even trace 
glycerol was found to be detrimental and removed prior to separation. Three to four rounds 
of selection resulted in approximately a five-fold increase in affinity of the DNA pool, and 
two of the six aptamer sequences synthesized for characterization displayed a Kd below 20 
nM. Further tests are needed to confirm Kd values as well as to characterize binding and 
possible endocytosis in LDLR-expressing cells. 
 Chapter 4 explored anti-leptin aptamers for use in a proposed real-time microfluidic 
leptin quantification assay for cultured 3T3-L1 adipocyte-like cells based on fluorescent 
aptamer detection by μFFE-LIF. Two literature aptamers against human leptin (Lep2 and 
Lep3) were evaluated in their ability to bind mouse leptin, but both were found to have a 
Kd > 1 μM, significantly worse affinity than against human leptin. Next, CE-SELEX was 
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performed against mouse leptin in a Ringer’s-based buffer (to simulate the proposed assay). 
The random library displayed multiple early features that made it difficult to establish a 
late collection window. Affinity measurements by FP and CE were somewhat inconclusive 
but suggested an unsuccessful selection with no measurable increase in affinity. A method 
of mathematically approximating the complex peak time was developed based on literature 
analyses of ssDNA diffusion, and the complex peak was found to be later than expected 
and outside the collection window used. 
 Chapter 5 looked at SPIDRs, sequence-independent aptamer-like oligonucleotide 
affinity reagents that have been found to bind to proteins controlling the calcium cycling 
process in heart cells. Previous work had established a functional effect of binding on 
calcium affinity, and this chapter aimed to optimize a differentiated cardiomyocyte system 
to evaluate the physiological effects of SPIDRs on contraction by cell impedance assays. 
The process of iPSC culture and passaging were optimized, and a method of timing the 
start of differentiation based on morphology and compaction was found to be superior to 
evaluating confluence alone. Beating cardiomyocytes were obtained with better than 50% 
frequency through optimization of Matrigel application and WNT pathway modulation, 
but replating CMs into sensor plates for impedance measurement was found to be 
unreliable, partly due to difficulty obtaining a monodisperse suspension, and optimization 
was impossible because of the highly random outcomes of replating. With a small number 
of successfully replated wells, a high degree of beat rate consistency was established over 
one hour and possibly over several days, but all fall time measurements and cross-well beat 
rate measurements were found to be too inconsistent for precise comparison without 
improved replating strategies. 
 
6.2 Future directions 
6.2.1 Improvement of electrophoretic SELEX 
 CE-SELEX is a highly flexible technique because changing the collection window 
timing allows the stringency to be adjusted with ease. Unfortunately, as demonstrated in 
Chapter 4, incorrect collection window timing can lead to unsuccessful selection, so careful 
thought is required in determining the collection window. One potential solution is better 
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purification of the DNA library to remove the disruptive early peaks that pressure an early 
collection window. Because the sequences and structures in the pool are so diverse, though, 
there is some worry that purification techniques might unintentionally cause systematic 
bias by removing certain DNA structures, sequences high or low in particular nucleotides, 
or the like. If any of these groups were more likely to exhibit binding, their removal from 
the library could dramatically reduce the efficiency of the selection. In order to determine 
whether this type of biasing occurs and has an impact on selection, a comparison of 
different pre-SELEX library purification methods (such as liquid chromatography, size 
exclusion, or CE) should be carried out in parallel against the same target to evaluate their 
impact on the speed of convergence, the prevalence of high affinity aptamers, or magnitude 
of aptamer affinity obtained. While a small bias against some types of sequences is 
inevitable during purification, it is likely that the removal of early DNA peaks would allow 
a much higher efficiency separation step, improving the method overall. 
 Alternatively or additionally, the precision of the calculational model developed in 
Chapter 4 could be improved dramatically through incorporation of more experimental 
data from specifically designed experiments. The version shown here included a number 
of approximations and assumptions, but an improved version would allow much more 
precise calculation of the complex peak location for optimal timing of the collection 
window and higher efficiency separation. Experiments would aim to evaluate the 
electrophoretic mobility of aptamer library designs common in SELEX as well as mobility 
changes resulting from complexation with different sized protein or adjustments to the 
chemical environment. This work would benefit the CE-SELEX community greatly since 
most physical chemistry literature in this area does not focus on short (<100 base) oligos, 
ssDNA, or oligonucleotide-protein complex behavior. 
 In the long term, 3D printed μFFE devices represent a major step forward as a 
potential cost-effective, highly accessible microfluidic SELEX platform. Such a device 
would be ideal for application-focus groups interested in selecting their own aptamers but 
lacking the experience of many method-focused SELEX groups. Significant headway has 
already been made in this lab toward 3D printed ABS μFFE devices that are considerably 
faster and cheaper to produce than the original etched glass versions.218 While μFFE-
 110 
SELEX has been demonstrated before on glass devices,108 new attempts using a 3D printed 
device are warranted to confirm sufficient resolution and performance as a low-cost 
disposable SELEX device.  
6.2.2 Testing of aptamer and SPIDR biological applications 
 In Chapter 3, multiple aptamers were obtained that display significant affinity for 
micelle-solubilized recombinant LDLR. While this is a significant achievement for CE-
SELEX, the aptamers themselves ultimately mean very little if they do not display affinity 
towards wild-type LDLR in a physiological system. Future experiments are planned to 
evaluate the binding, and hopefully internalization, of these LDLR aptamers in HepG2 
cells, a human hepatocarcinoma line known to overexpress multiple metabolically-
significant receptors including LDLR. Internalization could be confirmed visually using 
confocal fluorescence microscopy or functionally using an aptamer-siRNA hybrid to 
trigger a phenotypic change. More quantitative experiments would require the use of flow 
cytometry to evaluate binding or internalization over a large population of cells. 
Commercially available fluorescent LDL and previously selected LDLR aptamers254 could 
serve as effective positive controls for these experiments. 
 For SPIDRs, now that the iPSC-derived CM system is more reliable, extensive 
investigation of their physiological effects can take place. Similarly to previous 
experiments with recombinant protein, the effects of different oligo lengths and different 
XNA backbones will be investigated, this time observing their impact on beat rate, beat 
amplitude, and fall time. Once this relationship has been established more confidently and 
quantitatively, experiments with increasing biological complexity, and with more of an eye 
to therapeutic potential, can take place. Eventually, it will be important to evaluate SPIDRs 
in an environment with external pacing cues, such as a small or medium animal, which has 
complexities of the tissue and organ level absent in culture. It would also be beneficial to 
evaluate specific PLN mutants linked to CVD, which are available as iPSCs from SCVI 
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Aptamer Count Sequence (random region) 
A1 740   CTCATACGTTTAACTTGATTCTGCTAATTTAAGACTCTGG 
A3 448   TTGCATGGATTGAGTTTCATTACGTTATACATGGTCATTG 
A4 359   ACATCATGGGTTATATGCACACAGGTTTAACATCGTGTAC 
A5 124   ATCACTCTGCATGTCAAATAGAAACGACAAAGAATCGTGA 
A9 68   ATTGAGATAGTTTGTGAAGACTGGTCTAGCAATCATGTAA 
A10 62   AGGAGTACACAAGCATAAGTTAATCAGGGTTTCTGTCTCA 
A11 61   AGTATTCAGAGTCCAAATAGAGCAATGGTTAAGACAATCA 
A12 58   TGTTAAATATCGCTAGCTGAGTATTACTTGTAGGTCTTGA 
A13 53   CCCATCACTAGTGTCACCATGCAAGCGTCTATCCATTGCC 
A14 48   ATCACTATCGAAAGATTCTGATCGTAAGTAGTTTTGAACG 
A17 39   TCTTCATCGTAAGATTCAACGTCGATTTGATAGAGCGTAT 
A19 36   CGGATATGCATTCCTCATCTCCCCAATCCGTCCCAAGCCT 
A25 25   GTTTGAGTCAAACTTGTATCGGATCGACAATATCCACGTG 
A31 23   TTCATACGTTTAACTTGATTCTGCTAATTTAAGACTCTGG 
A32 22   TCGTTTATATTGACGAAGTTGATCGACAGTATTTCAACAG 
A33 22   TACCCTGTATGTAAGCCATAAACCTTGTGATAGTTATTTG 
A35 20   TCTTGTTATCACTGTTCTATCCATTAGACTTATGAATGTA 
A37 20   CTCATACGTTTAACTTGATTCTGCTAATTTAAGACTCTGA 
A38 20   CTCATACGTTTAACCTGATTCTGCTAATTTAAGACTCTGG 
A41 19   CTCATACGTTTAACTTGATTCCGCTAATTTAAGACTCTGG 
A42 17   CTCATACGTTTAACTTGATTCTGCTAATCTAAGACTCTGG 
A46 16   CCCACTCCTCACCTTGCACACCCAGCTTGGGCTTGCTGTC 
A47 16   CTCATACGTCTAACTTGATTCTGCTAATTTAAGACTCTGG 
A49 15   TCACGCAGATTGCTAATATTACCTACCACTGTTTACTACC 
A50 15   CTCATACGTTTAACTTGACTCTGCTAATTTAAGACTCTGG 
A55 13   AGATTGGTATGGTTGCACAAGAATAGCATCCATTGAAAGC 
A58 13   CTCATACGTTTAACTCGATTCTGCTAATTTAAGACTCTGG 
A61 13   CGGATATCCTGTTGGATGGGAATACTATGGTGAGTGGAGC 
A62 12   CTCATACGTTTAACTTGATTCTGCTAATTTAAGACTCCGG 
A63 12   CTCATACGTTTAACTTGATTCTGCTAACTTAAGACTCTGG 
A65 12   CTCATACGTTTAACTTGATTCTGCTAATTTAGGACTCTGG 
A68 11   GCATCATGGGTTATATGCACACAGGTTTAACATCGTGTAC 
A70 11   AGGATGTTTATTCCGTTTGTTTAAATATGCCTCCAACACA 
A71 11   TCATATCTCTTCGCTCACTATTCGCTTATTCCTACCTCTT 
A73 11   CTCATACGTTTAACTTGATTCTGCTGATTTAAGACTCTGG 
A75 11   CTCATACGTTTATCTTGATTCTGCTAATTTAAGACTCTGG 
A76 11   TGCAGAGATCTAAGTCCTACATTTGTACTGTTCCGACTAT 
A77 11   TTGCATGGATTGAGTTTCATTACGTTATACGTGGTCATTG 
A79 10   TTGCATGGATTGAGTCTCATTACGTTATACATGGTCATTG 
A80 10   CTCATACGTTTAACTTGATTCTGCTAGTTTAAGACTCTGG 
A81 10   TCGCATGGATTGAGTTTCATTACGTTATACATGGTCATTG 
A85 10   CTCATACGCTTAACTTGATTCTGCTAATTTAAGACTCTGG 
 
Table A.1: Ranked list of LDLR aptamer sequences with read count ≥10. For each aptamer, the full 
sequence is: AGCAGCACAGAGGTCAGATG–[Random region]–TTCACGGTAGCACGCATAGG. 
Missing sequences (such as A2) were removed due to primer sequences within the random region. 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A.1: FP fraction bound plots for LDLR aptamers. Y-values indicate uncorrected (non-normalized) 
fraction bound calculated from Equation 1.10. Error bars indicate standard deviation of all replicate 
measurements of each sample. The red line shows the hyperboloid fit obtained (if it converged), even if 
the results were questionable due to low absolute binding (Bmax<0.3) or poor fit (R2<0.5). The Kd is 



































































































Figure A.2: FP fraction bound plots for LDLR negative control aptamer and starting library. Y-values 
indicate uncorrected (non-normalized) fraction bound calculated from Equation 1.10. Error bars indicate 
standard deviation of all replicate measurements of each sample. The red line shows the hyperboloid fit 
obtained (if it converged). Three separate assays of the library were performed and averaged to obtain the 



















































































































































Figure A.3: CE fraction bound plots for LDLR aptamers. Y-values indicate uncorrected (non-normalized) 
fraction bound calculated from Equations 1.11 or 1.13. Error bars indicate standard deviation of all replicate 
measurements of each sample. The red line shows the hyperboloid fit obtained, even if the  results were 
rejected due to low absolute binding (Bmax<0.3) or poor fit (R2<0.5) in Table 3.3. The Kd is reported 
± standard error calculated from the fit. The A1 plot shows data for the ratiometric calculation (Equations 




























































Figure A.4: CE fraction bound plots for LDLR negative control aptamer and starting library. Y-values 
indicate uncorrected (non-normalized) fraction bound calculated from Equation 1.11. Error bars indicate 
standard deviation of all replicate measurements of each sample. The red line shows the hyperboloid fit 
obtained, even if the  results were rejected due to low absolute binding (Bmax<0.3) or poor fit (R2<0.5) in 







































































































Figure A.5: DNA binding plots against leptin for multiple SELEX pools, collected by FP. Plots are 
shown for the starting library and for rounds 2 to 4 (R2-R4). Y-values indicate uncorrected (non-
normalized) fraction bound calculated from Equation 1.10. Each plot is highly random with no clear 
trend, indicating no visible affinity of the aptamer pool for leptin. This supports the hypothesis that 
binding complexes were excluded during the first round, leading to unsuccessful selection. 





































































Figure A.6: DNA binding plots against leptin for multiple SELEX pools, collected by CE. Plots are 
shown for the starting library and for round  4 (R4). Y-values indicate the mean and standard deviation 
for triplicate measurements calculated by Equation 1.11 using free DNA peak height. No clear trend 
emerged for either plot, indicating no visible affinity of the aptamer pool for leptin. This supports the 







more efficiently than the random mixture of 20-nucleotide RNA sequences 
(Figure 3-3E). Both miR-1 and miR-21 remove all PLN mediated inhibition. The 
resulting pKCa is not statistically dif ferent than SERCA alone (Figure 3-3E). This 
suggests that miRNAs may have a secondary structure that relieves inhibition 
more effectively than random sequence RNA.  
3.3.3 Oligonucleotide analogs (XNAs) bind phospholamban with 
low nanomolar dissociation constants  
We analyzed several modified oligonucleotide analogs to determine the 
Figure 3-4  Chemical structures of oligonucleotide analogs (XNAs). Modified XNAs were 
chosen for their different chemical properties and nuclease resistance. From top to bottom, left 
to right, the modifications are as follows: D-DNA (naturally occurring DNA bases and 
backbone), RNA (naturally occurring RNA bases and backbone), phosphorothioate (PT DNA, 
replacement of one of the non-bridging o gen  i h a lf r), 2 -O-methyl RNA (addition of a 
OCH3 group to carbon 2), L-DNA (the enantiomer of natural DNA), peptide nucleic acids (PNA, 
neutral peptide backbone with DNA bases), and morpholino (neutral backbone). 
Figure A.7: Backbone structures of DNA, RNA, and XNAs. In each structure, B indicates the location of 
the nucleobase. From top to bottom, left to right, the nucleic acids are: deoxyribonucleic acid (DNA); 
ribonucleic acid (RNA); phosphorothioate (ptDNA); 2’-O-methyl RNA (2’-O-Me); enantiomeric DNA 
(L-DNA); peptide nucleic acid (PNA); and morpholino DNA. Adapted from Soller et al.237 
